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Résumé 	  
En 2015, la récidive tumorale et les métastases du cancer du sein demeurent une 
cause importante de décès à travers le monde. Toutefois, ces cancers sont souvent 
hétérogènes car en dépit d’un phénotype similaire, l’évolution clinique et la réponse au 
traitement peuvent varier considérablement. Il y a donc un intérêt évident à identifier et à 
caractériser de nouveaux biomarqueurs pour permettre classer les tumeurs mammaires 
dans des sous-groupes plus homogènes. Notre hypothèse est que chaque cancer 
mammaire possède des caractéristiques distinctes au plan des altérations du génome et 
des profils d’expression géniques et que ces changements se traduisent cliniquement par 
une prédisposition à former des métastases ou à répondre ou non à la chimiothérapie et 
aux thérapies ciblées. Dans le cadre de nos travaux, nous nous sommes intéressés aux 
sous-types agressifs de tumeurs mammaires et notamment les cancers de type triple 
négatif. Nous avons aussi tenté d’identifier des marqueurs capables de distinguer l’une de 
l’autre les tumeurs de type luminal A et luminal B. 
Pour ce faire, nous avons d’abord utilisé une stratégie in silico à partir de données 
publiques (micro-puces d’ADN et séquençage de l’ARN). Nous avons ensuite construit 
sept micro-matrices tissulaires (TMA) provenant de tissus mammaires normaux et 
tumoraux fixés à la formaline et enrobés en paraffine. Ces outils nous ont permis 
d’évaluer par immunohistochimie  les niveaux d’expression différentielle des marqueurs 
suivants : ANXA1, MMP-9, DP103 et MCM2. Ceux-ci ont été comparés aux marqueurs 
usuels du cancer du sein (ER, PR, HER2, CK5/6 et FOXA1) et corrélés aux données 
cliniques (survie globale et métastase). 
Nos résultats indiquent que ces nouveaux marqueurs jouent un rôle important 
dans l’évolution clinique défavorable des tumeurs de haut grade. Dans un premier article 
nous avons montré que l’expression d’ANXA1 est dérégulée dans les cancers de type 
triple-négatif et aussi, dans une certaine mesure, dans les tumeurs HER2+. Nous croyons 
qu’ANXA1 permet de mieux comprendre le processus d’hétérogénéité tumorale et 
facilite l’identification des tumeurs de haut grade. Nous proposons également qu’ 
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d’ANXA1 stimule la transition épithélio-mésenchymateuse (EMT) et la formation des 
métastases. 
Dans un second temps, nous avons montré que les niveaux d’expression de MMP-
9 reflètent la différenciation cellulaire et corrèlent avec les sous-types de cancers 
mammaires ayant un mauvais pronostic. Nous estimons que MMP-9 permet de mieux 
comprendre et d’identifier les tumeurs mammaires à haut risque. De fait, la surexpression 
de MMP-9 est associée à une augmentation des métastases, une récidive précoce et une 
diminution de la survie globale. 
Dans le cadre d’un troisième article, nous avons montré que la surexpression du 
marqueur de prolifération MCM2 s’observe dans les cancers triple-négatifs, HER2+ et 
Luminal B par comparaison aux cancers luminal A (p< 0.0001). Nos résultats suggèrent 
qu’en utilisant un seuil de 40% de noyaux marqués, nous pourrions distinguer l’une de 
l’autre les tumeurs de type luminal A et luminal B. Cela dit, avant de pouvoir envisager 
l’utilisation de ce marqueur en clinique, une étude de validation sur une nouvelle cohorte 
de patientes s’impose. 
En somme, les résultats de nos travaux suggèrent qu’ANXA1, MMP-9 et MCM2 
sont des marqueurs intéressants pour mieux comprendre les mécanismes 
physiopathologiques impliqués dans la progression tumorale et le développement des 
métastases. À terme, ces nouveaux marqueurs pourraient être utilisés seuls ou en 
combinaison avec d’autres gènes candidats pour permettre le développement de 
trousses  « multigènes » ou d’essais protéomiques multiplex pour prédire l’évolution 
clinique des cancers mammaires.  
 
Mots-­‐clés:	   Cancer du sein humain, biomarqueur, l'analyse silico, matrices tissulaires, 
ANXA1, MMP-9, MCM2, Ki-67 
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Summary  
 
In 2015, breast cancer remains a leading cause of death among women worldwide 
due to relapse and metastases. However, mammary tumors are known to be 
heterogeneous in terms of their clinical course and response to treatment, despite a 
seemingly similar phenotype. There is therefore an obvious need to identify and 
characterize new biomarkers of progression in breast cancers so that each tumor can be 
properly classified. Our hypothesis is that each breast cancer has its own set of genomic 
abnormalities or altered pattern of gene expression that can explain the aggressiveness of 
each tumor, its ability to metastasize and its response to chemotherapeutic agents or other 
forms of targeted therapies. In this study, our aim is to identify and characterize new 
biomarkers with prognostic value in aggressive subsets of breast cancer focusing 
primarily on triple-negative tumors and luminal B breast cancer.  
To achieve those aims, we conducted an in silico search from public databases of 
DNA microchip and RNA sequencing data. We next constructed seven tissue microarrays 
(TMA) using paraffin blocks from human breast cancer along with normal breast to 
examine the differential expression of new putative markers: ANXA1, MMP-9, DP103 
and MCM2. Expression levels measured by immunohistochemistry were then compared 
to other conventional markers of breast cancer (ER, PR, HER2, Ki-67, CK 5/6, FOXA1) 
and correlated with clinical data (overall survival and metastasis). 
By comparing the relative expression of these markers in human breast tumors we 
were able to pinpoint the important role of ANXA1, MMP-9, DP103, and MCM2 in 
aggressive tumor subtypes recognized for their poor clinical course. Firstly, we have 
shown that ANXA1 expression is severely deregulated in high-grade breast cancers 
including triple-negative and, to some extent, HER2-positive breast cancers. In addition, 
our results also indicated a possible role of ANXA1 in regulating EMT and breast cancer 
cell metastasis. 
Secondly, expression of MMP-9 was found to mirror the degree of tumor 
differentiation and to correlate with breast cancers of unfavorable outcome. This implies 
that MMP-9 can help better characterize the biology of breast carcinoma and to identify 
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subgroups of high-risk breast tumors. In fact, we found that high levels of MMP-9 in 
tumors were associated with increased metastatic dissemination, early relapse and 
reduced survival.  
Thirdly, we demonstrated that MCM2 is overexpressed in triple-negative, HER2 
positive and luminal B breast cancer in comparison to luminal A breast cancer (p-value < 
0.0001). Our findings support the notion that MCM2 can be used to distinguish luminal A 
from luminal B breast cancer based on a 40% index cut-point. However, an independent 
validation cohort is needed to confirm the clinical utility of MCM2. 
Lastly, our results suggest that ANXA1, MMP-9 and MCM2 are valuable 
genes/proteins candidate that can help better understand the mechanisms involved in 
tumor progression and metastasis. One may also envisage their use, alone or in 
combination with other genes, in the development of a multi-gene panel or multiplex 
proteomic assay to predict clinical outcome and guide therapeutic decisions.  
 	  
Keywords: Human breast cancer, biomarker, in silico analysis, tissue microarray, 
ANXA1, MMP-9, MCM2, Ki-67 
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CHAPTER I 
Introduction 
1. Hallmarks of cancer 
During the last decade, bio-medical research has focused on better understanding 
the molecular events that play a role in the initiation and progression of cancer. In 2000, 
Hanahan and Weinberg proposed six hallmarks of cancer in an effort to didactically 
pinpoint the most salient features of cancer [5]. The hallmarks of cancer are mechanistic 
alterations in the cell concurring to bring about transformation of normal cells into 
malignant cells. These hallmarks include: 1) self-sufficiency in growth signals; 2) 
resistance to antigrowth signals; 3) escape of apoptosis; 4) limitless replicative potential; 
5) sustained angiogenesis; 6) tissue invasion and metastasis [5]. In 2011, following new 
advances in cancer research, Hanahan and Weinberg have proposed two more additional 
hallmarks: reprogramming of energy metabolism and evasion of immune destruction. 
They also added two enabling characteristics: genome instability and tumor-promoting 
inflammation (Figure 1.1) [6].    
1) Self-sufficiency in growth signals: Normal cells are critically dependent on growth 
signals to leave G naught and enter an actively proliferating stage. In contrast, cancer 
cells seem to acquire sustained proliferative capacity through different mechanisms 
including: autonomous growth factors production by tumor cells, paracrine 
interactions with surrounding stromal cells, up-regulation of receptors present at the 
cell surface and structural alterations of the receptor such as receptor truncation 
leading to unregulated cell proliferation. In addition, constitutive activation of the 
signaling molecules downstream to the receptors as well as interference with normal 
mechanisms that attenuate proliferation may also stimulate cancer cell proliferation. 
2) Insensitivity to antigrowth signals: To maintain normal cellular quiescence and 
tissue homeostasis, many anti-proliferative signals are required. Signals associated 
with the cell cycle clock and soluble growth inhibitors like transforming growth 
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factor-β (TGF-β) are thought to be important in this regard. Many cancer cells are 
able to inhibit these anti-proliferative signals to induce uncontrolled proliferation. 
3) Evading apoptosis: Signals that induce apoptosis in normal cells can be generated 
from the cell surface receptors that bind survival and death factors  (e.g. FAS ligand 
and its receptor CD95) and monitor the extracellular environment. Alternatively, pro-
apoptotic signals may emerge from inside the cell via DNA damage, lack of sufficient 
survival signals and hypoxia. It is now believed that all cancer cells harbor alterations 
that enable them to escape apoptosis in response to anti-apoptotic regulators and 
survival factors or, alternatively, decrease production of pro-apoptotic proteins. 
4) Limitless replicative potential: Cancer cells have the ability to replicate indefinitely 
and escape senescence. There are different mechanisms that help cancer cell 
becoming immortal including genetic and epigenetic changes that disable the cell 
cycle checkpoint control or alter the maintenance of telomeres at length that prevents 
senescence either through up-regulation of telomerase activity or by recombination-
based lengthening of telomeres. 
5) Sustained angiogenesis: Cancer cell require abundant supply of oxygen and nutrients 
to grow and expand their tissue mass. By the same token, they also need to get rid of 
their waste products. These crucial requirements of cancer cells are met by 
stimulating sustained formation of new blood vessels that subsequently help maintain 
tumor growth. Mechanisms that foster increased angiogenic ability of malignant cells 
include either an increase in pro-angiogenic factors such as vascular endothelial 
growth factor (VEGF) or a loss of anti-angiogenic factors such as endostatin. 
Recently, pericytes and bone marrow derived stromal cells have been shown to be 
important components of the tumor microenvironment that have the ability to 
stimulate cancer related angiogenesis. 
6) Tissue invasion and metastasis: During the development of a malignant tumor, 
some pioneering cancer cells escape their primary location to invade the adjacent 
tissue and travel to distant sites in order to develop new colonies of cancer cells. 
Invasion and metastasis are complex multi-step processes that involve many cellular 
changes such as alteration in cell-cell adhesion molecules (E-cadherin and integrin)  
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Figure 1.1: Hallmarks and enabling characteristics of cancer. 
This illustration includes the eight hallmarks and two enabling characteristics that 
have been proposed by Hanahan and Weinberg. The hallmarks include: self-
sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, 
limitless replicative potential, sustained angiogenesis, tissue invasion and metastasis, 
reprogram energy metabolism and evading immune destruction [5, 6]. 
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and increased production of extracellular proteases (matrix metalloproteinases 
(MMPs)). 
7) Reprogramming of energy metabolism: Under normal conditions, cells use oxygen 
for energy production. This process is known as aerobic respiration. However, normal 
cells can switch to anaerobic respiration when oxygen becomes deficient. In both 
cases, energy is obtained from breaking down glucose to produce adenosine 
triphosphate (ATP) that serves as a primary source of energy in the cell [7]. 
Modifying or reprogramming energy metabolism is an adaptive mechanism of cancer 
cells to satisfy their energetic needs and fulfill important cell processes such as cell 
growth and division. Increased glucose transport to cancer cells through up-regulation 
of glucose transporters is one strategy used by cancer cells to increase their energy 
production.   
8) Evading immune destruction: There is an increasing body of evidence to suggest 
that the immune system acts as a barrier against tumor development and progression. 
Cancer cells are able to evade immune recognition by the cells of the immune system 
or by recruiting immune-suppressive inflammatory cells as T-regulatory cells.  
 
Genomic instability and inflammation are considered to be two enabling 
characteristics that contribute to the occurrence of the above-mentioned hallmarks of 
cancer [6]. On the one hand, multistep carcinogenesis is depending on the stepwise 
accumulation of mutations. Indeed, breakdown of one or more components of the 
genomic maintenance machinery involved in the detection and repair of DNA damages, 
is one of the principal inducers of genomic instability in cancer cells. On the other hand, 
inflammatory cells can also contribute to initiation of multiple hallmarks of cancer in 
several important ways like supplying bioactive molecules to the tumor 
microenvironment such as growth factors, survival factors and pro-angiogenic factors. Of 
note, inflammatory cells may deliver mutagenic chemicals such as reactive oxygen 
species in the vicinity of cancer cells therefore contributing to genetic progression 
towards a more malignant phenotype.  
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2. Normal breast tissue 
The breasts or mammary glands are paired organs present in both sexes that 
become fully functional only in nursing females.  Mammary glands reach their full 
development only during the end of pregnancy [8]. Mammary glands are composed of a 
complex assembly of tissues overlying the chest pectoral muscles [9]. Histologically, one 
recognizes two main components: glandular tissue and scaffolding stroma. The 
supporting stromal tissue is made up of mesenchymal-derived cells such as fibroblasts, 
adipocytes, immune cells, and extracellular matrix [10].  
The glandular component of each breast consists of a dichotomously branching 
ductal–lobular system. Each lobule is made up of acini that form the functional secretory 
units of the mammary gland, also known as terminal duct lobular units (TDLUs) [11]. In 
turn, lobules drain into a complex intertwined network of collecting ducts. Normally, 
mammary ducts and lobules are lined with two cell types: an inner secretory or luminal 
cells layer and an outer or basal cell layer. The inner luminal cells participate in the 
production and secretion of milk whereas the outer contractile myoepithelial cell layer 
facilitates excretion of colostrum and milk into the ducts during lactation [12]. The basal 
layer includes terminally differentiated myoepithelial cells, mammary stem cells and their 
progenitors (Figure 1.2) [13, 14]. Moreover, myoepithelial cells are responsible for 
creating and maintaining the surrounding basement membrane, which is formed of 
extremely dense layer of collagen IV, laminin and proteoglycans. It is responsible of 
separating the basal cell layer from the surrounding stroma [15]. 
Paracrine interactions that occur between myoepithelial and luminal epithelial 
cells are thought to be important in maintaining several important functions including 
regulation of cell cycle progression, establishment of epithelial cell polarity, and 
inhibition of cell migration and invasion [16]. Until recently, it was believed that the 
great majority of human breast cancers arise from luminal epithelial cells [17]. However, 
recent molecular studies have raised the possibility that different subtypes of breast 
cancers may originate from different cellular types such as luminal, myoepithelial and 
stem cells [18].  
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Figure 1.2: Structure of normal breast 
A) Diagram depicting the structure of the normal breast. The glandular portion of the 
breast is composed of a complex branching ductal–lobular system. Each lobule is made 
up of acini that form the functional terminal duct lobular units (TDLUs). Normal ducts 
and lobules are lined by an inner secretory luminal cell layer and by an outer layer of 
basal cells comprising differentiated myoepithelial cells, mammary stem cells and allied 
progenitors. B) Normal breast lobule stained with H&E showing both glandular tissue 
and supporting stroma. The inset depicts a normal breast duct lined with an inner luminal 
cell layer and outer myoepithelial cell layer (Magnification: 20X, inset: 63X). 
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3. Breast cancer 
3.1 Incidence and heterogeneity of breast cancer 
Breast cancer is the second most common cancer in women after lung cancer [19]. 
It is estimated that about 1.7 million new female breast cancer cases are diagnosed every 
year [20]. According to the 2015 report of the American Cancer Society, 231,840 new 
cases of invasive breast cancer are diagnosed among women in the United States. An 
estimated 40,290 breast cancer deaths in women are expected during the same year [21]. 
This high mortality rate stems mainly from metastasis due to spread of cancer cells to 
distant sites such as liver, lungs, bones and brain [22].  
Breast cancer is a complex and heterogeneous disease. Not surprisingly, risk 
factors, clinical presentation, pathological features, molecular characteristics and 
response to treatment vary a great deal from one tumor to the other [23]. The 
classification of breast cancer which is currently based on clinical and pathological 
features attempts to classify breast cancer into distinct categories with different prognosis 
and clinical outcome [24]. Unfortunately, tumors with similar histological features may 
display divergent clinical behaviors [25]. Recent advances in cancer research based on 
DNA microarray, functional genomics and gene expression profiling have made 
important headways in understanding the heterogeneity and complexity of breast cancer 
[26]. The current molecular classification suggest that breast cancers can be divided into 
five distinct subtypes; luminal A, luminal B, HER2-positive, basal-like and normal 
breast-like breast cancer. This approach has allowed the development of prognostic and 
predictive gene expression signatures and identified new therapeutic targets [27]. 
3.2 Histological classification of breast cancer 
3.2.1	  Histological	  subtypes	  	  
The traditional histological classification of breast cancer takes advantage of 
morphological changes to divide tumors into categories with different prognosis and 
clinical behavior [24]. Breast cancers are roughly divided into in situ carcinoma or 
invasive breast cancer. Ductal carcinoma in situ (DCIS) and lobular carcinoma in situ
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(LCIS) are considered to be non-invasive or pre-invasive breast cancers involving 
abnormally proliferating epithelial cells whose expansion in the TDLUs is limited by the 
basement membrane of the breast ductal or lobular system [28, 29] (Figure 1.3A).  
Invasive breast carcinoma results from the spread of cancer cells beyond the 
basement membrane. In turn, invasive breast cancer can be further classified into ductal 
carcinoma, no special type (IDC-NST) when it fails to exhibit specific tumor 
characteristics that allow inclusion into specific histological types such as lobular, 
tubular, papillary, medullary and mucinous breast cancers (Figure 1.3B-F) [30]. 
According to the 2012 edition of the World Health Organization (WHO), IDC-NST is 
considered to be the most common type of breast cancer comprising 40%-75% of all 
breast cancers leaving only 20%-25% of breast cancers to other special types [31]. 
Evidently, this histological classification has important limitations since there is an 
important variability in the outcome of patients belonging to the same histological 
subtype of breast cancer. Furthermore, left alone (i.e. without additional markers) this 
classification is not able to guide treatment of breast cancer patients [30]. 
 
Figure 1.3: Different histological subtypes of breast cancer 
A) Ductal carcinoma in situ, B) invasive ductal carcinoma, C) Invasive lobular 
carcinoma, D) Colloid carcinoma, E) Medullary carcinoma, F) Tubular carcinoma 
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3.2.2	  Histological	  grades	  	  
Histological grade of tumors is based on three parameters: degree of 
differentiation (i.e. extent of tubule formation), proliferation rate (i.e. mitotic index) and 
nuclear polymorphism (Table 1.1) [24]. Breast cancer patients are ascribed to one of the 
three different histological grades (Grade I, II & III). Grade I tumors (well differentiated) 
demonstrate conspicuous tubule formation (> 70%), low mitotic count and only a mild 
degree of nuclear polymorphism. Grade II tumors (moderately differentiated) have a 
lower degree of tubule formation (10-70%), intermediate mitotic count and higher degree 
of nuclear polymorphism. Grade III tumor (poorly differentiated) shows no or very little 
tubule formation (< 10%), frequent mitoses and a marked degree of cellular 
polymorphism (Figure 1.4A-C).  
Histological grading of breast cancer is a relatively simple and cost-effective 
method. Genome-wide microarray-based expression profiling studies have provided 
further evidence that the biological features captured by the histological grade are 
important to determine tumor behavior [32]. Interestingly, the breast cancer grading 
system has been incorporated into the criteria used by the adjuvant! Online predictive 
tool and the 2013 St-Gallen’s expert consensus guidelines for adjuvant chemotherapy of 
breast cancer [33, 34].  
 
 3.3 Molecular classification of breast cancer 
The rapidly expanding amount of molecular data has led to a better understanding 
of the heterogeneity of breast cancers and allowed to propose new etiologic pathways 
leading to breast cancer development [35]. In 2000, gene expression profiling was first 
developed by the Stanford group in an attempt to classify breast cancer into molecularly 
distinct groups. Using complementary DNA (cDNA) from 65 samples of breast cancer 
they sought to determine the levels of expression of 8,102 human genes. Unsupervised 
hierarchical clustering on these genes revealed “molecular portraits” that give indications 
about similarities and differences among tumors, and, in many cases, pointed to 
biological hypotheses [36]. This seminal study was followed by many different attempts  
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Table 1.1: Parameters of histological grading of invasive breast carcinoma [24]. 
 
Score 1 2 3 
Tubular score  > 70% 10-70% < 10% 
Mitotic count/10HPF 0-9 10-19 > 20 
Nuclear score Small, regular, 
uniform 
Moderate size & 
Variation 
Large & marked 
nuclear variation 
Total score: range 3-9 
Grade I: total score is 3-5 (Well differentiated) 
Grade II: total score is 6-7 (Moderately differentiated) 
Grade III: total score is 8,9 (Poorly differentiated) 
 
 
 
Figure 1.4: Different histological grades of breast cancer 
A) Grade I tumors (well differentiated) demonstrate conspicuous tubule formation (> 
70%), low mitotic count and only a mild degree of nuclear polymorphism. B) Grade II 
tumors (moderately differentiated) have a lower degree of tubule formation (10-70%), 
intermediate mitotic count and higher degree of nuclear polymorphism. C) Grade III 
tumor (poorly differentiated) shows no or very little tubule formation (< 10%), frequent 
mitoses and a marked degree of cellular polymorphism 
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by the same group or by other groups to analyze larger number of patients and validate 
the reproducibility of these molecular subtypes.  Additionally, they also thought fit to 
further correlate subtypes with clinical outcome in these patients [3, 37-40]. This 
classification of breast cancer provided, to some extent, explanations on how two tumors 
with identical clinical and pathological features could behave differently. 
The main molecular, intrinsic, subtypes comprised: estrogen receptor positive 
(ER-positive) breast cancer (luminal A and luminal B) and estrogen receptor negative 
(ER-negative) breast cancer (HER2-enriched, basal-like and normal breast-like breast 
cancer). Interferon-rich, apocrine and claudin-low molecular subtypes were added at a 
later date into the ER-negative molecular breast cancer subtypes (Table 1.2) [1-4]. In 
addition, Sorlie et al. proposed an additional subset of luminal breast cancer called 
luminal C which could be distinguished from luminal A and B subtypes by over 
expression of a novel set of genes shared with basal-like and HER2-enriched subtypes 
but whose function is currently unknown [37]. However, further studies failed to 
reproduce the luminal C subtype and, therefore the luminal classification now comprises 
only luminal A and B subtypes [41]. 
3.3.1	  ER-­‐positive	  breast	  cancer:	  Luminal	  breast	  cancers	  	  	  
Luminal tumors are the most common molecular subtype of breast cancer and 
account for approximately 75% of breast cancers [42]. Luminal breast cancer are known 
to express gene cluster characteristic of luminal epithelial cells such as Estrogen receptor 
(ER), Progesterone receptor (PR), cytokeratin 8 and 18 (CK8 and 18), GATA3, FOXA1, 
XBP1 and MYB [36, 43]. In addition, depending on the expression levels of 
proliferation-related genes and, to a lesser extent, the expression levels of ER and ER-
related genes, hormone responsive breast cancer (luminal breast cancer) can be further 
classified into either luminal A or luminal B breast cancers [23].  
Luminal A breast cancer, which is the less aggressive subtype, express the highest 
level of ER-related genes and the lowest level of proliferation-related genes. In addition, 
this type of tumor is usually of low histological grade and is associated with a good 
prognosis [41, 44, 45]. Endocrine therapy alone is the mainstay of systemic therapy 
recommended for luminal A breast cancer. Generally, agents such as selective estrogen
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 receptor modulators (SERMs) like tamoxifen, pure selective regulators of ER like 
fulvestrant and third-generation aromatase inhibitors (anastrozole, letrozole, or 
exemestane) are recommended [46].  
In contrast, luminal B is a more aggressive breast cancer subtype.  As expected, it 
is associated with a lower level of expression of ER and ER-related genes, weak or low 
levels of progesterone receptor expression and increased expression of proliferation-
related genes [47]. In addition, activation of the growth factor receptor signaling 
pathways such as IGF-1R and PI3K/AKT/mTOR is commonplace in this subtype of 
breast cancer [48]. In contrast to luminal A subtype, luminal B breast cancer is associated 
with a higher histological grade, sustained proliferation rates, and an overall worse 
prognosis [49]. Interestingly, the overall survival of untreated luminal B breast cancer is 
similar to that of HER2-enriched and basal-like subtypes [41]. As a result, treatment of 
luminal B breast cancer generally combines both endocrine therapy and chemotherapy. 
According to the 2013 St. Gallen’s recommendations, addition of chemotherapy is 
considered only in patients with intermediate or high risk for recurrence [33]. Although 
as many as 30% of luminal B breast cancers overexpress HER2 (luminal B/HER2-
positive), these tumors maintain the same profile of gene expression that is observed in 
luminal B/HER2-negative subtype. However, luminal B/HER2-positive tumors require a 
distinct therapeutic approach, with addition of HER2-targeted therapy such as 
trastuzumab to chemotherapy [50].  
3.3.2	  ER-­‐negative	  breast	  cancer	  	  
HER2-enriched breast cancer 
HER2 belongs to the receptor tyrosine kinase family that comprises EGFR 
(ErbB1, HER1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4). The HER2 gene is 
located on chromosome 17 and found to be amplified in several types of cancers 
including ovary, endometrium, bladder, lung, colon, and head and neck [51]. Activation 
of HER2 brings about different cellular responses such as cytoskeletal rearrangement, 
abrogation of apoptosis and increased cell proliferation [52]. Both HER2 gene 
amplification and activating somatic mutations are associated with HER2-enriched breast 
cancer [53, 54]. 
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The HER2-enriched subtype of breast cancer comprises approximately of 15-20% 
of all breast cancers. It is characterized by elevated expression of HER2 gene and other 
genes associated with the HER2 pathway or genes located in the vicinity of the HER2 
locus on chromosome 17. It entails overexpression of proliferation related genes and a 
lower expression of luminal associated genes [55]. In addition, 75% of HER2-positive 
tumors display a high histological grade and more than 40% harbor TP53 mutations [56].  
Generally, HER2-positive breast cancers have a poor prognosis. However, in the 
last decade, the use of anti-HER2 therapy such as trastuzumab has improved the survival 
of HER2-positive patients both in metastatic disease and in early breast cancer [57, 58]. 
Interestingly, some tumors lose HER2 expression upon treatment with trastuzumab 
resulting in a significantly worse relapse-free survival than those with tumors that 
retained HER2 amplification [59]. Clinical trials combining drugs that inhibit HER2 
signaling pathway at different levels showed promising results in terms of response rate 
and tolerability [60, 61].  
 
Basal-like breast cancer 
The basal-like breast cancer represents 10-20% of all breast carcinomas [55]. The 
incidence of this subtype of breast cancer is highest among premenopausal African-
American women. It is characterized by larger tumor size, higher histological grade and 
regional lymph node involvement [62, 63]. Overall, women with basal-like breast cancers 
have a worse prognosis and shorter relapse-free life expectancy than women with other 
types of breast cancer [64]. In addition, basal-like breast cancer is associated with higher 
rates of metastasis to the brain and lungs [65, 66]. 
Based on gene expression profiling, the term basal-like breast cancer was coined 
due to the expression of genes that are normally expressed in normal basal and/or 
myoepithelial cells. The gene expression cluster characteristic of basal cells includes 
keratin 5, keratin 17, integrin b4, laminin, vimentin, epidermal growth factor receptor 
(EGFR) and markers of proliferation [36, 67]. In the clinics, immunohistochemistry 
(IHC) has been used as a surrogate of gene expression profiling to identify this subtype of 
breast cancer since it is not only easier but also readily applicable to formalin-fixed, 
paraffin-embedded (FFPE) samples [68].  
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There are many ways to define basal-like breast cancer using IHC staining; most 
commonly one looks at the ‘triple-negative phenotype’, which is characterized by a lack 
of ER, PR and HER2 expression [22]. Other authors maintain that the basal cytokeratin 
profile should also be present including expression of basal cytokeratin 5, 14 and/or 17 
[69]. Lastly, it has been proposed that the combined expression of five markers best 
define this subtype of breast cancer; this panel includes negative expression of ER, PR 
and HER2 and positive expression of CK5/6 and/or EGFR [70]. Of note, one third of 
triple-negative tumors have a non-basal genomic profile; these tumors generally have an 
improved prognosis [22]. 
When basal-like breast cancers are considered, the overall mutation rate is much 
higher than for luminal A tumors [43]. Accordingly, basal-like breast cancers exhibit 
numerous genetic alterations including looses of TP53, RB1 and BRCA1 or amplification 
of CCNE1 and MYC [71]. It has been reported that close to 20% of basal-like breast 
cancer harbor either germ line or somatic mutations in BRCA1 or BRCA2 genes [43, 72]. 
In addition, basal-like breast cancers are generally highly proliferative tumors due to 
defective TP53 and/or retinoblastoma (RB1) proteins [73, 74].   
To date, there is no targeted therapy available for treatment of basal breast 
cancers. Because basal-like breast cancer fail to express either hormonal receptors or 
HER2, one does not expect clinical response to any known endocrine or targeted therapy 
such as tamoxifen, aromatase inhibitors or trastuzumab [75]. According to several 
clinical trials, basal-like breast cancers are more likely to respond to anthracycline or 
platinium-based neoadjuvant chemotherapy protocols than any other subtypes of breast 
cancer. However, despite initial good clinical response to chemotherapy, basal-like breast 
cancer have a poor prognosis due to higher rate of relapse [76]. Recently, new regimens 
of therapies have been developed to specifically target Poly (ADP-ribose) polymerase 1 
(PARP1), EGFR, mitogen-activated protein kinase (MAPK) and the AKT pathways [22, 
77]. So far, none of these therapies have yet reached approval by the U.S. Food and Drug 
Administration (FDA) [77]. 
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Normal-like breast cancer 
Normal-like breast cancer subtype is thought to represent about 5-10% of all 
breast carcinomas [55]. Perou et al. have clustered the normal-like breast cancers with 
both normal breast tissues and fibroadenomas. The gene expression pattern in these 
tumors comprises elevated levels of genes expressed in basal epithelial cells and adipose 
cells, and low levels of expression in genes characteristic of luminal epithelial cells [36]. 
Most tumors lack expression of ER, PR and HER2, and, accordingly, these tumors should 
be classified as triple negative. However, since they lack the expression of CK5 and 
EGFR they are not considered to belong to the basal-like breast cancers subtype [55]. Of 
note, normal-like tumors showed the lowest degree of expression of proliferation related 
genes [78].  
Previous studies have raised important doubts about the existence of this 
molecular subtype [3, 25, 79]. Indeed, these tumors may simply correspond to technical 
artifacts resulting from a high degree of contamination of frozen samples with normal 
breast tissue and stromal cells [25, 79]. Given that no case of normal-breast like tumors 
could be detected when neoplastic cells were isolated by micro-dissection, there are 
reasons to question the validity of this molecular subtype [80]. 
 
Interferon-rich subtype 
The interferon-rich subtype of breast cancer is an ER-negative subgroup that has 
been described for the first time by Hu and colleagues [3]. This subtype is characterized 
by enhanced expression of either interferon-regulated genes such as STAT1 or some 
other immune response related genes [3]. The IFN gene cluster has been linked to lymph 
node metastasis and poor prognosis [3, 81]. Interferon-rich breast cancers are highly 
proliferative when compared to luminal A tumors [82]. In addition, survival rates are 
comparable to that of luminal B tumors.  The prognosis in these tumors is somewhat 
better than for all other ER-negative breast cancers [82, 83]. 
 
Molecular apocrine subtype 
The molecular apocrine group of breast cancer combines the concomitant loss of 
ER expression with up-regulation of androgen signaling and expression of apocrine 
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histological characteristics. These tumors share some common features with HER2-
positive subtype of breast cancer [2, 84]. Banneau et al. suggested that the development 
of apocrine breast cancers is due to loss of PTEN at the early stages of tumor 
development [1]. Cells with apocrine features in the mammary gland originate from 
metaplastic changes of normal ductal cells leading to morphological changes akin to 
those seen in apocrine glands of the axilla and perineum [85]. The molecular apocrine 
tumors are considered to be aggressive and have a poor clinical outcome [86]. Indeed, 
poor prognostic factors such as high histological grades, increased proliferation rate, 
lymphovascular invasion and lymph node involvement all accompany apocrine cancers 
[87].  
 
Claudin-low molecular subtype 
In 2007, claudin-low molecular subtypes was first identified and characterized by 
Herschkowitz and his colleagues using 13 different murine models and comparing the 
results to that of human breast cancer [88]. They demonstrated that this molecular 
subtypes is characterized by a lower expression of genes involved in tight-junctions and 
cell-cell adhesion molecules, including claudins 3, 4, 7, occludin, and E-cadherin. These 
tumors display low levels of luminal related genes, inconsistent basal gene expression, 
and a high expression of lymphocyte and endothelial cell markers [88]. Furthermore, 
there is now compelling evidence to suggest that claudin-low tumors are enriched in cells 
undergoing epithelial-to-mesenchymal transition (EMT) and showing immune system 
responses and stem cell-associated features [4, 89].  
It has been estimated that approximately 75-80% of these tumors are triple-
negative (ER-/PR-/HER2-), while the remaining 15-25% express hormone receptors [90]. 
Clinically, this molecular subtype of breast cancer appears to be a strong predictor of 
relapse and poor prognosis [91, 92]. The response rate of claudin-low tumors to standard 
preoperative neoadjuvant chemotherapy is intermediate between that of basal-like and 
luminal tumors [4]. 
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3.4 Immunohistochemical markers as surrogate for molecular 
subtyping and its pitfalls 
There is no doubt that gene expression profiling resulted in a substantial advance 
in our understanding of breast cancer heterogeneity. It also paved the way to molecular 
classifications of breast cancer with delineation of clinically relevant subtypes. However, 
there are important limitations that need to be resolved before considering gene 
expression profiling ready for prime time clinical usage. The reliability and the 
reproducibility of this technique is questionable as different studies revealed large 
variations in the expression profiles between cDNA microarrays, difficulties in 
distinguishing between two similar genes and their spliced variants and inconsistent 
sequence fidelity of spotted microarrays with only 62%-80% of genes immobilized on the 
microarray matching the correct sequence of the clones [93-97]. Notably, using different 
commercially available microarray platforms with identical RNA preparations one 
observes considerable divergence in the gene expression measurements across different 
platforms [98]. There are also complexity issues surrounding microarray analysis such as 
the unyielding nature of data generated by bioinformatics analysis and the cryptic 
methods used for interpretation [97]. Finally, the high cost of this analysis in comparison 
to already available pathological approaches is another important issue [99]. 
Due to the above shortcomings, efforts have been made to compare and contrast 
the results collected from gene expression profiling of breast tissue with currently 
existing IHC-based assays using different prognostic and predictive biomarkers [100-
102]. IHC is a widely available and relatively inexpensive technique to measure 
biomarker expression on fresh and FFPE tissues [103-105]. New tools such as automated 
IHC, whole slide cell scanning and advances in digital pathology softwares to assist IHC 
scoring are now becoming widely available [106]. Taken together, these factors along 
with the availability of tissue microarray (TMA) allow using high throughput approach to 
be used simultaneously on a large number of tissue samples [107]. Importantly, because 
IHC maintains tissue architecture, one can evaluate tumor and stromal cells separately 
which is not yet possible with gene expression profiling [99]. To be fair, many difficulties 
and limitations are also associated with IHC. These include pre-analytical and analytical 
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factors including specimen fixation, tissue processing, antigen retrieval and the use of 
revealing reagents. Other analytical and post-analytical issues should also be considered 
in the selection of antibodies, sensitivity of reagents, choice of antibody type and clone 
and interpretation of the results [108, 109]. Standardization of various aspects of IHC 
techniques needs to be resolved before producing sound clinical results. 
It has been suggested that IHC can be used clinically to define biologically 
relevant breast cancer subgroups comparable to those identified by gene expression 
profiling. Nielsen et al. have demonstrated that a panel of four antibodies (ER, HER1, 
HER2, and cytokeratin 5/6) can identify basal-like tumors [110]. Others have defined 
basal-like breast cancer using a panel of five biomarkers (ER, PR, HER2, EGFR, 
cytokeratin 5/6) that presumably allow predicting more accurately breast cancer survival 
[70]. In 2011, the 12th St. Gallen’s international breast cancer expert panel approved a 
new classification of patients for therapeutic purposes. It has been suggested that using 
ER, PR, HER could distinguish molecular subtypes and adding Ki-67 with 14% threshold 
could help separate luminal A from luminal B subtypes [111].  However, both Guiu et al. 
and Lips et al. claimed that using Ki-67 with a 14% index has no predictive or prognostic 
value in luminal breast cancer and rather recommended the use of IHC for ER and HER2 
alone for the detection of clinically relevant subtypes of breast cancer [112, 113].  Newer 
recommendations presented at the 13th St Gallen’s international breast cancer expert 
panel in 2013 proposed to change the Ki-67 index from 14% to 20% to better distinguish 
luminal A from luminal B breast cancer [45].  
 
4. Cancer biomarkers 
According to the American Cancer Society, a tumor marker is defined as a 
molecule or process that refers to the presence of cancer [114]. Tumor markers are often 
produced by cancer cells themselves or by other tissues in response to the presence of 
cancer cells or other associated conditions such as inflammation. Tumor biomarker 
detection can rely on non-invasive approaches when it is used on body fluids such as 
blood and urine. Alternatively, tumor markers can be detected on a biopsy of a solid 
tumor. 
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An ideal tumor marker should clearly distinguish normal and cancer cells, be easy 
to use, reproducible, reliable, sensitive (low false negative rates), specific (low false 
positive rate) and cost effective. Unfortunately, biomarkers with ideal sensitivity and 
specificity profiles are difficult to find [115]. Davis et al. rightly emphasized that 
lowering medical cost together with better patient care should be the main objectives of a 
new biomarker [116].  
 
4.1 Biomarkers: from discovery to clinics 
The essential steps leading to the development of a new biomarker include the 
following; biomarker discovery, validation and qualification. Two general approaches 
have been proposed for biomarker discovery. The first one is a stepwise, hypothesis-
driven approach that assesses molecules believed to be potential biomarkers [117]. The 
other is a discovery-based approach, looking at gene-expression patterns or mass-
spectroscopic peaks that could identify new candidate genes, proteins or expression 
signatures [118]. 
A biomarker should pass through two distinct exhaustive processes from 
discovery to the point of use that include the analytical validation method and the clinical 
qualification processes [119]. 
  
A) Biomarker validation: this step consists of evaluating the assay, its performance 
characteristics, and the optimal condition to be used in order to generate reproducible 
and accurate results [120]. The validation process should be tailored to meet the 
intended use of the biomarker, also known as a “fit-for-purpose” approach [121]. 
Pepe et al. has enumerated the following steps in the process of biomarker validation 
[122]:  
1. Preclinical exploratory studies: to recognize and prioritize potentially useful 
biomarkers. 
2. Clinical assay development and validation:  to assess the ability of a biomarker to 
distinguish subjects with cancer from normal individuals. 
	  	  	  
	  	  
21	  
3. Retrospective longitudinal studies:  to study if a biomarker can detect cancer at an 
early stage before it becomes clinically detectable. 
4. Prospective screening studies: to assess biomarker accuracy by determining its 
detection rate and false referral rate. 
5. Cancer control studies:  to assess if a biomarker reduces the burden of cancer on the 
population. 
 
B) Biomarker qualification: 
Validated biomarkers could be qualified for clinical use by different approaches [123, 
124]:  
1. Passive approach: This approach is based on what is already published in the 
literature to accept a biomarker for clinical use. However, this process is time 
consuming, inefficient and unreliable for biomarker qualification. 
2. Active approach:  In this approach, qualification depends on a comprehensive process 
that provides clearly defined and precise roles to help the development of new 
biomarkers. A FDA biomarker qualification pilot study is an example [125].  
 
4.2 Classifications of tumor biomarkers: 
Tumor biomarkers can be classified in many ways such as the nature of the 
biomolecules under scrutiny (e.g. DNA, RNA and Proteins biomarkers), tissue 
distribution (e.g. blood, urine or tissue biomarkers) and potential clinical application (e.g. 
risk detector, diagnostic, prognostic and predictive biomarkers). 
4.2.1	  Classifications	  of	  tumor	  biomarkers	  according	  to	  their	  potential	  use	  	  
Risk detection biomarker 
These markers are used to determine whose patient is at risk of developing certain 
type of cancers [126]. BRCA1 and BRCA2 are good examples of risk detectors that can 
be applied to high-risk group such as those with a strong family history of breast or 
ovarian cancer [127]. 
 
	  	  	  
	  	  
22	  
Screening biomarker 
These biomarkers should be able to detect early stages of tumor development 
before the onset of clinical manifestations. The WHO has proposed specific criteria to 
consider a specific biomarker to be a good screening test. These criteria include the 
following: the screened tumor should occur with a high incidence or be associated with a 
significant mortality rate, the progression of the tumor should be fully characterized, 
facilities for early diagnosis and treatment especially for those at an early stage of the 
disease should be available, the test should be acceptable to the population, cost-effective 
and endowed with a high sensitivity and a high specificity [128]. Notably, the potential 
benefit of a tumor screening strategy should outweigh the potential harms that could 
result from the intervention to prove the disease. 
After approval by the FDA in 1986, Prostate specific antigen (PSA) became the 
most widely used biomarker for prostate cancer screening [129]. However, patients with 
high level of PSA should not be considered to suffer from prostatic cancer but instead 
should be investigated further. CA-125 is another screening biomarker that has been 
recommended by American Congress of Obstetricians and Gynecologists for women with 
average risk of developing ovarian cancer [130]. However, one must bear in mind that 
benign conditions such as leiomyoma, endometriosis and inflammatory conditions in the 
abdomen such as peritonitis can cause elevated level of CA-125, implying that this test is 
not specific for ovarian cancer [131]. 
 
Diagnostic biomarker 
Diagnostic biomarkers are useful to help detecting certain types of cancers. They 
may also help in establishing a differential diagnosis during the course of the evaluation 
of a tissue mass (cancer or benign condition), or in determining the likely site of origin of 
a tumor (primary or metastasis) [126].  These biomarkers should have high sensitivity 
and specificity in order to decrease the likelihood of falsely positive (positive results in 
the absence of the disease) and falsely negative (missed diagnosis of real disease) results 
[132]. Examples of the most common diagnostic markers include serum level of alpha 
fetoprotein (AFP) for liver cancer [133] carcino-embryonic antigen (CEA), neuron-
specific enolase (NSE) or cytokeratin 19 (CK19) in lung cancer [134].  
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Prognostic biomarker 
Prognostic biomarker help providing information about the behavior of a tumor, 
regardless of the type of treatment envisaged: aggressiveness, probability of relapse, and 
risk of developing metastases [126, 135]. Such markers could help deciding the need for 
further treatment. For example, high level of human kallikreins; KLK4 and KLK5 are 
associated with aggressive forms of ovarian cancers [136]. Another example is the lack of 
ER, PR and HER2 in breast cancer suggesting the presence of an aggressive form of 
breast cancer and a higher risk of developing metastases [64]. HCG and AFP are also 
considered prognostic markers and have been recommended by The American Society of 
Clinical Oncology (ASCO) to monitor for recurrence in patients treated for advanced 
seminoma [137].  
 
Predictive biomarker 
Predictive biomarkers can predict the response of a tumor to a given therapy 
before the initiation of treatment or predict which therapy is likely to be effective [126].  
For instance, ER-positive breast cancers may benefit from anti-estrogen such as 
Tamoxifen or aromatase inhibitors [138]. Breast cancer patients with HER2 gene 
amplification should receive trastuzumab (Herceptin®), a monoclonal antibody that binds 
to the HER2 receptor [45]. In addition, it has been reported that Ki-67 is a good 
predictive marker to guide the use of adjuvant therapy in hormone receptors positive 
breast cancer [139]. Colorectal cancers with activating mutation of KRAS that predicts 
resistance to EGFR-specific targeted therapy with cetuximab and panitumumab is another 
example [140]. 
4.2.2	  Classifications	  of	  tumor	  biomarkers	  according	  to	  the	  biomolecules	  	  
1) Genetic biomarker (DNA biomarker) 
Genetic biomarkers include any of the following alterations of DNA: single 
nucleotide polymorphisms (SNP), loss of hetrozygosity (LOH), copy number variation 
(CNV) of genes and structural variations in chromosomes such as insertion, deletion, 
translocation, duplication and inversion [141]. For instance, germ line mutation of 
BRCA1 and BRCA2 genes could be considered as risk detectors as they help identifying 
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individuals with high risk of developing breast and ovarian cancer [127]. Another 
example concerns HER2 gene amplification in breast cancer that is considered to be a 
marker of poor prognosis and an indicator of a higher risk of developing brain metastasis 
[142]. Moreover, HER2 overexpression can help predict the clinical benefit to anti-HER2 
targeting therapy (Trastuzumab), increased sensitivity to chemotherapy regimens 
containing taxanes and anthracyclines, and resistance to tamoxifen [143, 144]. 
Furthermore, somatic mutations of mitochondrial DNA such as ATPase6 gene alterations 
have been recently suggested to be potential biomarkers of breast cancer [145, 146]. 
 
2) Epigenetic biomarker 
Epigenetics describes heritable changes in cellular phenotype due to changes in 
the regulation of gene activity and expression that are independent of alteration in the 
DNA sequence [147]. Some epigenetic changes are used as tumor markers such as 
aberrant DNA methylation and elevation of global histone deacetylation [148, 149]. 
Interestingly, epigenetic modifications that occur in the tumor tissues can also be detected 
in some biological fluids such as urine and serum implying that it could be useful as non-
invasive screening tools [150].  
Previous studies have reported the usefulness of DNA methylation as epigenetic 
marker in breast cancer. For example, methylation analysis of a panel of genes consisting 
of APC, GSTP1, RAR-β and RASSF1A was shown to help in the detection of breast 
cancer [151]. It has also been shown that epigenetic silencing of the Breast Cancer 
Metastasis Suppressor 1 (BMRS1) gene due to methylation of its promoter helps 
predicting an adverse prognosis in breast cancer [152]. Other studies have reported the 
use of DNA methylation as a marker to help monitor efficacy of breast cancer treatment 
such as neoadjuvant chemotherapy and tamoxifen [153, 154]. 
 
3) Expression biomarkers (RNA biomarkers) 
Detection of differentially expressed genes is an interesting approach to new 
cancer biomarkers discovery [155]. For example, gene expression profiling signatures are 
able to predict the clinical outcome in breast cancer patients [156]. Recently, microarray 
gene expression profiling and real time-PCR have been used successfully in detecting 
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molecular subtypes of breast cancer.  We also witnessed the development of multigene 
diagnostic tests to predict breast cancer recurrence (Oncotype DX or 21 gene assay) or 
(PAM50 or 50 genes assay) and metastasis (Mammaprint or 70 gene assay) [99, 157].  
MicroRNAs (miRNAs) are short, non-coding RNAs that play an essential role in 
the regulation of gene expression through pairing to specific mRNA targets leading to 
their degradation and/or translational inhibition [158]. Although the notion of using 
miRNA as tumor biomarker has not yet been introduced in clinical practice, many reports 
have indicated specific patterns of miRNA expression in certain types of cancer. Indeed, 
it has been shown that the expression of MiR-210 is a strong potential prognostic marker 
in breast cancer [159, 160]. A recent study has reported the use of a four-microRNA 
signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers 
[161]. Furthermore, miRNA can also predict the response to different types of cancer 
treatment such as elevated levels of miR-125b in breast cancer can predict resistance to 
taxol-based regimens [162].  
 
4) Protein biomarker 
The proteome of cancer cells suffers from many aberrations that result from the 
translation of accumulated gene defects in the DNA. Proteome is also responsible for 
determining cancer phenotypes and regulating tumor behavior [163]. Since proteins are 
the main components of signaling pathways in both normal and cancer cells, they are 
potentially valuable biomarker molecules [164]. Despite the large number of putative 
biomarkers, there is some merit to recall that the only FDA-approved biomarkers in 
clinical use are proteins [165].  
Although there are thousands of protein tumor biomarkers identified by proteomic 
studies, only a few of them have been found to be clinically useful mainly because of 
insufficient validation studies [164]. The latest guidelines of the ASCO in 2007 and the 
National Academy of Clinical Biochemistry Laboratory Medicine Practice in 2008 
recommended the use of ER, PR and HER2 protein expression in invasive breast cancer 
to predict response to therapies such as hormonal therapy and Trastuzumab [166, 167].  
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4.3 Problems associated with biomarkers 
Despite the presence of thousands of publications about potential biomarkers 
including their applications and usefulness, only a handful of them have become 
clinically approved test. This state of affair plainly indicates that the transfer of 
biomarkers from the bench to clinical application is a lengthy process filled with lots of 
pitfalls and limitations [115]. The position of the biomarker in the spectrum between 
research tool and clinical end point depends on the accuracy and strength of experimental 
demonstration required to achieve method validation [168]. Of note, most of the potential 
biomarkers to date fail to show adequate sensitivity and specificity to allow them to be 
used as clinical tests [169]. Some of the potential limitations in the processes of 
biomarker research are outlined below. 
 
4.3.1	  Specimens’	  problems:	  	  
1. Lack of standardization of sample collection: inconsistency in storage conditions, 
sample handling and who decide to include a given sample in the study can all affect 
the levels of biomarker detected or lead to false detection due to artifacts present in 
the samples [169, 170]. Another set of variables such as the type of fixative, time of 
hot and cold ischemia, time of fixation, inclusion method, time of paraffin-
embedding, thickness of the sections, storage of unstained slides and the methods for 
antigen retrieval are all major sources of variability when comparing the results of 
different studies [118]. Stringent quality control during specimen collection, storage 
and handling is crucial for successful biomarker identification. In addition, specialists 
such pathologists should pay careful attention to select the right samples and 
appropriate controls. In particular, care must be to obtain the right quantity (enough 
tissue) and quality (for example; containing cancer cells not only stroma) of tissue for 
biobanking [171]. Interestingly Moore and his colleagues reported that using high 
quality controls during tissue collection is a way to improve the overall quality of the 
specimens, storage and handling [172]. 
2. Insufficient number of samples to be included in a study are major problems in the 
process of biomarker identification [173]. Zolg reported that to confirm the results 
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obtained from a small number of sample, second and third discovery rounds are 
required to complement the results of the first round [174]. However, to overcome the 
problem of sample insufficiency Poste G. suggested using hundreds or even 
thousands of matched diseased and control samples to satisfy regulatory requirements 
and to demonstrate the clinical usefulness of the tested biomarkers [175].  
3. Unbalanced grouping: using samples from patients and controls belonging to different 
groups such as different race or ages can greatly affect the outcome of a study [169]. 
To overcome this limitation, people should be matched for as many variables as 
possible. However, at least their age, sex, race, ethnicity and lifestyle such as alcohol 
consumption and smoking should be matched [115, 175]. 
4. Difference on how the patients/samples are assessed, who assessed these 
patients/samples and how these assessments are reported can also be critical. Detailed 
history and information about each patient/sample such as the type and grade of 
cancer are crucial for a good study design. This detailed data will aid in improving 
samples stratification (e.g. patients with same grade of cancer are in the same group) 
that could help in detecting biomarkers especially in slowly progressive diseases 
[115]. In addition, using universal-standardized reporting methods is essential to help 
comparing different biomarker trails [115]. 
5. Single analysis of the samples included in biomarker identification studies could 
affect the final results. Elias and his coworkers study on large scale proteomic 
analysis demonstrated that reliable results could be obtained only by analyzing 
samples multiple times [176]. Furthermore, Drucker & Krapfenbauer suggested that 
samples should be analyzed in triplicates and, one should improve validity of 
measurements by calculating the mean and standard deviation [115]. 
6. Another point to consider is the use of tumor cell lines types [177, 178]. Using cell 
lines may be easier to handle and more accessible as surrogates for patients’ tissues. 
However, there are many disadvantages associated with cell lines including genotypic 
and phenotypic drift away from the originating tumor during culture work, intra and 
inter-laboratory cell line heterogeneity and cell line cross-contamination with other 
cell lines used in the laboratory [179]. Although using replicates (3-10) of each cell 
line to create a comprehensive biomarker profile is a good approach, it leads to an 
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increase in the cost of the study [180, 181]. It is highly recommended that scientists 
ensure that the proprieties of each cell lines they use during the course of their 
investigations match those of equivalent cell types in vivo [175]. 
4.3.2	  Personnel	  and	  instrumental	  problems	  	  	  
 Physical conditions in the laboratory and inadequate instrumentation, failure to 
calibrate and validate instruments, variations both within and between equipment can all 
be limiting factors that affect the final outcome of biomarker studies. For example, it has 
been reported that proteome analysis using different analytical approaches resulted in a 
discordant number of proteins detected by each method [182, 183]. Moreover, inadequate 
training of technicians, biochemists and bioinformatics specialists dealing with clinical 
specimens, faulty pieces of equipment and improper data algorithms can all lead to 
flawed results. This is especially true of new technological advances being used in 
biomarker research, where highly trained personnel need to interpret complex set of data 
[184]. To overcome these limitations, FDA and NIH have set up recommendations to 
oversee the quality of techniques used in biomarker research [115]. Moreover, FDA has 
suggested that central reference laboratories be selected to conduct testing of new 
biomarkers for one or two years prior to its release to the market [185].  
4.3.3	  Data	  analysis	  and	  interpretation	  	  
Lack of standardization in conducting analytical methods and interpreting data are 
important issues to be taken into account in the field of biomarker research. Most 
published studies have categorized biomarkers with reference to positive/negative cut-off 
points. However, this oversimplification probably reduces the value of any given 
biomarker, as it does not reflect the complexity of many biological phenomenon [118]. 
For example, although classification of ER-positive breast cancers into two distinct 
groups; luminal A and luminal B based on proliferation-related genes has been accepted 
in breast cancer research [23, 80], contrasting views have emerged suggesting that ER-
positive breast cancers may form a continuum of tumors with both good and bad 
prognosis at each end of the spectrum [186-188]. 
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Appropriate statistical methods are required throughout the entire biomarker 
development pathway [189]. Lee et al. stated that using quantitative analytical methods 
that are capable of generating reliable data constitute solid ground for statistical 
assessment of the predictive value of biomarkers [168]. In addition, criteria on how to 
develop high-quality data project should be established to help comparing outcomes of 
biomarker research between different research labs or clinical trial studies [115]. Poste G. 
has suggested a stringent approach to overcome problems related to data analysis 
including defining intended algorithms for statistical and computational analysis, 
handling indeterminate results and outliers to resolve clinical false-positive results, 
estimating clinical sensitivity and specificity with 95% confidence intervals and assessing 
positive and negative biomarker predictive power [190]. 
 
5. Biomarkers in breast cancer 
5.1 Established biomarkers in breast cancer  
5.1.1	  Estrogen	  receptor	  (ER)	  	  
Estrogen receptor (ER) is a member of the nuclear hormone receptor superfamily 
located in the cytoplasm and translocate to the nucleus upon activation [191]. ER has two 
distinct isoforms; ERα and ERβ that are encoded by different genes ESR1 and ESR2 
respectively. Each gene is located on different chromosome (locus 6q and locus 14q, 
respectively) [192]. Both isoforms show considerable sequence homology, each 
consisting of six domains as depicted in figure 1.5A [193]. Their tissue distribution is 
quite different as ERα is expressed in uterus, testis, pituitary, ovary, kidney, epididymis, 
and adrenal gland while ERβ is found in prostate, ovary, lung, bladder, brain, uterus, and 
testis [194]. Normal breast tissue showed scattered ER-α staining in the ductal epithelium 
and only occasional nuclear staining for ER-β [195]. ERα and ERβ have different 
transcriptional activities and opposing actions on cellular processes such as proliferation, 
apoptosis and migration [193, 196]. However, in the following section we will focus only 
of ERα (ER). 
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ER can exert both genomic and non-genomic effects (Figure 1.5B) [197, 198]. 
Genomic effects happen through interaction between ER and DNA inside the nucleus, 
either in a ligand-dependent or ligand-independent fashion. In the presence of a ligand 
such as estrogen, the receptor forms a complex at the ligand-binding site of ER [199]. 
This complex then migrates to the nucleus where it forms dimer with other ER or, 
alternatively with direct DNA-binding transcription factors (TFs). Dimers attach 
themselves to DNA directly at the estrogen responsive element (ERE) or indirectly 
through tethering interaction with other transcription factor such as activator protein 1 
(AP-1) or specificity protein 1 (Sp-1) [198]. At these sites, ER recruits co-activators and 
co-repressors that lead to modulation of gene transcription through the recruitment of co-
regulatory proteins such as histone acetyltransferase (HAT) and ubiquitin ligase (UL). 
However, ER can also be activated in a ligand-independent manner through activation of 
ERK and AKT serine/threonine kinases by different growth factors [197, 199]. In that 
case, the activated kinases phosphorylate ER leading to its activation, dimerization, 
binding to DNA and subsequent gene regulation [197, 199]. On the other hand, non-
genomic effects occur when the ligand-ER complex, present in the cytoplasm or 
associated with the plasma membrane activates protein kinase cascades (e.g. SRC, PI3K 
and G proteins (GPs)), phosphatases or increase ion fluxes across membranes. These 
effects result in rapid physiological responses independent of gene regulation [199-201]. 
ER is one of the few biomarkers currently in use in the clinical management of 
breast cancer patients. In normal breast tissue, only 4-15% of epithelial cells express ER 
[202]. Low expression of ER was reported in normal breast tissue of women at low risk 
of developing breast cancer [203]. In contrast, overexpression of ER has been observed in 
normal breast tissue of breast cancer patients [204]. Taken together, the above mentioned 
data support the notion that ER can be considered a risk factor detector as its 
overexpression in normal breast tissue augment the risk of breast cancer development 
[205]. Furthermore, ER has a prognostic value as most of ER-positive breast cancers fare 
better than ER-negative tumors [206]. However, not all ER-positive tumors have a good 
prognosis as untreated luminal B breast cancer, which is ER-positive, has an unfavorable 
prognosis similar to that of HER2-positive and basal-like subtypes of breast cancer [41].  
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Figure 1.5: Structure and different mechanisms of action of ER 
A) ER has the following structural domains: DNA binding domain (DBD), a flexible 
hinge region that is immediately adjacent to the DNA binding domain, a ligand-binding 
domain (LBD), two activating function (AF) domains (AF-1 is located on the N-terminal 
domain and AF-2 which is ligand-dependent). B) Genomic and non-genomic actions of 
ER: I. Genomic effects happen through interaction between ER and DNA inside the 
nucleus, either in a ligand-dependent (A) or ligand-independent fashion (B). In the 
presence of a ligand such as estrogen, the receptor forms a complex at the ligand-binding 
site of ER. This complex then migrates to the nucleus where it forms dimer with other ER 
or, alternatively with direct DNA-binding transcription factors (TFs). Dimers attach 
themselves to DNA directly at the estrogen responsive element (ERE) or indirectly 
through tethering interaction with other transcription factor such as activator protein 1 
(AP-1) or specificity protein 1 (Sp-1). At these sites, ER recruits co-activators and co-
repressors that lead to modulation of gene transcription through the recruitment of co-
regulatory proteins. However, ER can also be activated in a ligand-independent manner 
(B) through activation of ERK and AKT serine/threonine kinases by different growth 
factors. II. Non-genomic effects occur when the ligand-ER complex, present in the 
cytoplasm or associated with the plasma membrane activates protein kinase cascades 
(e.g. SRC, PI3K and G proteins (GPs)), phosphatases or increase ion fluxes across 
membranes. These effects result in rapid physiological responses independent of gene 
regulation [193, 197, 198] 
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ER has also a predictive value in breast cancer. Indeed, assessing ER status allows 
one to predict response to hormonal therapy depending on the level of its expression. 
Quantitative assessment of ER expression using IHC staining is routinely performed on 
all breast cancer patients [207]. Allred score stratifies breast cancer patients into two 
groups according to the probability of responding to hormonal therapy [208]. It is 
composed of the sum of the proportion (scale of 0-5) and average intensity (scale of 0-3) 
scores of positive tumor cells resulting in a total score (TS) ranging from 0 to 8 which 
reflects the staining signal of ER [209]. Tumors with total scores   ≥  3 (corresponding to 
1% to 10% of weakly positive cells) are considered to be positive. This cutoff point was 
detected based on the analysis of disease-free survival (DFS) in a study involving patients 
receiving any adjuvant endocrine therapy [210]. Tumors with high expression of ER 
respond better to hormonal therapy while those with low ER status generally benefit from 
chemotherapy [138, 211].  
De novo and acquired resistance to hormonal therapy has been reported in a 
subgroup of ER-positive breast cancer [212]. Mechanisms involved in resistance to 
hormone therapy include loss or modification in the ER expression, cross talk between 
ER and growth factors such as EGFR and HER2, loss of PTEN, constitutive activation of 
the PI3K/Akt pathway, altered expression of specific microRNAs and genetic 
polymorphisms involved in tamoxifen metabolic activity [213-216]. Consequently, new 
treatment strategies are being developed to reverse hormonal resistance and/or amplify 
the sensitivity of breast cancer cells including the addition of anti-HER2 (Trastuzumab) 
or chemotherapy to anti-estrogen agents [213, 217]. 
 
5.1.2	  Progesterone	  receptor	  (PR)	  	  
Progesterone receptor (PR) is another member of nuclear steroid receptor 
superfamily that rapidly shuttles between the cytoplasm and the nucleus [218]. It 
comprises three isoforms, PR-A, PR-B and PR-C with different molecular weight: 94 
KDa, 116 KDa and 60 KDa respectively [219, 220]. All isoforms are translated from the 
PGR gene, which is located on chromosome 11q22 [221]. PRs are composed of the  
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Figure 1.6: Structure and mechanism of action of PR 
A) This diagram shows the structural domain of the three isoforms of PR, which include 
PR-A, PR-B and PR-C. PR-A is composed of: DNA binding domain (DBD), a flexible 
hinge region that assist in DNA binding, a ligand-binding domain (LBD), and multiple 
activating function (AF) domains required for transcriptional activity. PR-B contains 
additional unique B-upstream segment (BUS) absent in PR-A. As for PR-C, it has no 
BUS domain and part of the DBD. B) Genomic and non-genomic actions of PR. In the 
absence of ligand (progesterone), PR forms a multi-protein complex with chaperon 
proteins such as heat shock proteins (HSP70 and HSP90) and FKBP52. In the cytoplasm, 
binding of progesterone to PR stimulates its dissociation from chaperon proteins followed 
by homo-/hetero-dimerization of PR. These dimers translocate to the nucleus where they 
bind to the DNA through progesterone receptor element (PRE), AP-1 or SP-1 to induce 
recruitment of co-regulators (genomic action). However, PR dimers, present in the 
cytoplasm or associated with the membrane can activate mitogenic protein kinases such 
as Src and MAPK (non-genomic action) [218, 220, 222, 223] 
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following structural domains: DNA binding domain (DBD), a flexible hinge region that 
assist in DNA binding, a ligand-binding domain (LBD), and multiple activating function 
(AF) domains required for transcriptional activity. PR-B contains additional unique B-
upstream segment (BUS) absent in PR-A (Figure 1.6A) [218, 222]. As for PR-C, it is 
transcriptionally inactive due to the lack of BUS and part of the DBD [220]. 
PR plays an essential role in normal human female reproductive tissues such as 
uterus and mammary gland and in non-reproductive tissues such as bone, brain and 
cardiovascular system [223-226]. It has been reported that PR-A and PR-B are equally 
expressed in most human target cells suggesting involvement of alternative mechanisms 
to explain the diversity of progesterone actions [227]. Progesterone receptor shares 
common features with ER. In that it also functions through genomic and non-genomic 
signaling pathways (Figure 1.6B) [222, 223]. In the absence of ligand (progesterone), PR 
forms a multi-protein complex with chaperon proteins such as heat shock proteins 
(HSP70 and HSP90) and FKBP52 [222]. In the cytoplasm, binding of progesterone to PR 
stimulates its dissociation from chaperon proteins followed by homo-/hetero-dimerization 
of PR. These dimers translocate to the nucleus where they bind to the DNA through 
progesterone receptor element (PRE), AP-1 or SP-1 to induce recruitment of co-
regulators (genomic action) [219]. However, PR dimers, present in the cytoplasm or 
associated with the membrane can activate mitogenic protein kinases such as Src and 
MAPK (non-genomic action) [218]. 
Like ER, quantitative assessment of PR expression using IHC staining is routinely 
performed in all breast cancer patients. [209]. PR, together with ER, is a significant 
prognostic factor in early breast cancer as it helps assessing the risk of early relapse in 
patients receiving endocrine therapy [228, 229]. It is also an independent prognostic and 
predictive marker among ER-positive breast cancer patients [230, 231]. Furthermore, 
Bardou et al. demonstrated that PR status provides additional value to ER in predicting 
the benefit of endocrine treatment among patients with primary breast cancer [230]. 
Another interesting study claims that PR is a stronger predictor than ER regarding the 
response to adjuvant tamoxifen in premenopausal breast cancer patients [232].  
Not all ER-positive breast cancers are found to express PR, as there are ER+/PR- 
and ER-/PR+ phenotypes. Loss of PR expression often identifies luminal B breast 
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cancers that are associated with a worse overall prognosis and a higher risk of relapse 
among ER-positive patients [233]. Also, it was reported that ER+/PR-, ER-/PR+, or ER-
/PR- breast tumors have a lower response to tamoxifen and a relatively higher risk of 
death when compared to ER+/PR+ tumors [234, 235]. This being said, Hefti et al. used 
gene expression microarray-based analysis of 4000 breast cancer patients to show that 
ER-/PR+ phenotype is very rare and not a reproducible subtype [236].  
 
5.1.3	  HER2	  (ERBB2)	  	  
HER2 belongs to the HER family of trans-membrane receptor tyrosine kinase that 
includes the following four members; EGFR (ErbB1, HER1), ErbB2 (HER2), ErbB3 
(HER3) and ErbB4 (HER4). The name ERBB is derived from the name of erythroblastic 
leukemia viral oncogene [237]. All the HER family members share the same structural 
domains: an extracellular domain, a trans-membrane domain, an intracellular domain and 
a C-terminal tail [238]. The HER2 gene is located on the long arm of chromosome 17 and 
has been found to be amplified in several cancers including breast, ovary, endometrium, 
bladder, lung, colon, and head and neck [51].  
The HER2 receptor is present at the cell surface as monomer [239]. Attachment of 
ligands to HER2 receptor stimulates homo-dimerization with other HER2 receptors or 
hetero-dimerization with other members of the HER family or other membrane receptors 
such as insulin-like growth factor receptor 1 (IGF-1) [240]. The dimerization step leads to 
phosphorylation of tyrosine residues in the cytoplasmic domain, which then activates 
multiple signaling pathways such as RAS/RAF/MAPK, PI3K/AKT, and PLC/PKC. 
Activation of these signaling pathways drives a number of different cellular responses 
such as cell proliferation, differentiation, cell survival and cytoskeletal rearrangement 
[51, 52]. 
The last 2014 recommendations of The ASCO/ CAP (College of American 
Pathologist) stated that HER2 status should be determined in all patients with invasive 
breast cancer [241]. HER2 status can be assessed using either IHC and/or fluorescent in 
situ hybridization (FISH). The scoring of HER2 expression levels by IHC is based on 
both the pattern and intensity of cell membrane staining. IHC scores are used to measure 
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HER2 expression. Results are reported as 0-1+ (negative), 2+ (equivocal) or 3+ (positive) 
(Figure 1.7). According to the last recommendations, if the IHC results are equivocal, 
reflex test should be done using an alternative assay such as FISH.  It is also 
recommended to repeat the test if the results are discordant with other pathologic findings 
(e.g. 3+ tubular of classical lobular carcinoma) [241].  
FISH assay assess the HER2-to-CEP17 ratio and gene copy number (dual-probe 
ISH). Amplification in a dual-probe ISH assay is defined by examining first the 
HER2/CEP17 ratio followed by the average HER2 copy number. The interpretation of 
HER2 FISH scores can be one of the following: positive HER2 amplification when 
HER2/CEP17 ratio ≥ 2.0 with average HER2 copy number ≥ or < 4.0 signal/cell. Also, 
HER2 is considered positive when HER2/CEP17 ratio < 2.0 with average HER2 copy 
number ≥ 6.0 signal/cell. HER2 FISH score is considered to be negative when 
HER2/CEP17 ratio < 2.0 with average HER2 copy number < 4.0 signal/cell and 
equivocal when HER2/CEP17 ratio < 2.0 with average HER2 copy number ≥ 4.0 and < 
6.0 signal/cell. “Indeterminate for HER2” is a new category of interpretation that 
indicates the occurrence of technical issues that interfere with accurate interpretation of 
one or both tests (IHC and FISH).  Other in situ hybridization techniques “the bright field 
ISH” can be used to assess HER2 gene status using a regular light microscope [241]. Of 
note, HER2 overexpression is not limited to HER2-positive breast cancer as some of 
luminal breast cancers can also be positive for HER2 [242]. 
 
 
Figure 1.7: IHC scoring of HER2 expression. A) HER2 score = 1+ (negative), B) 
HER2 score = 2+ (equivocal), C) HER2 score = 3+ (positive) 
	  	  	  
	  	  
39	  
Amplification of the HER2 gene has been shown to have a great prognostic value 
in breast cancer. Its overexpression is associated with aggressive breast tumors, a high 
rate of recurrence, early relapse and increased mortality [243, 244]. The association of 
HER2 overexpression with shorter disease free and overall survival is independent of 
other clinical variable such as age, stage and tumor grade [245, 246]. However, HER2 
overexpression is significantly correlated with older age > 50 years, high tumor stage and 
high histological grade of breast cancer [247]. On the other hand, HER2 status is 
predictive of response to endocrine therapy, adjuvant chemotherapy and HER2-targeted 
therapy. Enhanced HER2 expression predicts tamoxifen resistance in estrogen receptor 
positive primary and metastatic breast cancer [248-251]. Furthermore, HER2 status can 
also predict resistance or sensitivity to different chemotherapeutic agents such as 
anthracycline, docetaxel and taxane chemotherapy [252-254]. Lastly, overexpression of 
the HER2 gene identifies primary and metastatic breast cancer patients who will benefit 
from HER2-targeted therapy such as trastuzumab (Herceptin ®) and tyrosine kinase 
inhibitors such as lapatinib [57, 58]. Results coming from different studies demonstrated 
the fundamental role of HER2-targeted therapies in improving clinical outcomes and 
increasing the number of pathological complete response rates [255, 256].  
5.2 Multigene expression assays available in clinical setting   
Multigene assays have been introduced with the hope of providing better 
indicators than conventional clinico-pathologic parameters in terms of classification, 
prognosis and prediction of breast cancer [99]. In addition, it has been demonstrated that 
using these assays one could modify the treatment strategy in 25-30% of breast cancer 
patients [257]. Although these assays use different techniques and different combination 
of gene sets (Table 1.3), none of them could reach 100% sensitivity and specificity [258].  
5.2.1	  Oncotype	  Dx™	  (21-­‐gene	  assay)	  	  
Oncotype Dx™ is a reverse transcriptase–polymerase chain reaction (RT-PCR) assay that 
measures the expression of 21 genes, 16 cancer related genes and 5 reference genes (table 
1.4) in RNA extracted from FFPE tissues [166]. In 2004, Paik and coworkers validated 
the capability of Oncotype DX™ assay to predict the likelihood of distant recurrence in 
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tamoxifen-treated patients with node-negative and estrogen receptor positive breast 
cancer (prognostic significance) [259]. Other key studies have shown that Oncotype 
Dx™ helps predicting the likelihood of 10-year survival (distant relapse free survival 
DRFS) for breast cancer patients and the magnitude of benefits from adjuvant 
chemotherapy (predictive significance) [260, 261]. Moreover, promising results have 
been reported in different studies when the Oncotype DX™ assay has been tested in 
estrogen receptor positive, lymph node-positive breast cancer patients [262-264] 
Oncotype Dx™ calculates recurrence scores (RS) ranging from 0-100 to 
categorize breast cancer patients (hormone receptor positive, lymph node negative) into 
three different groups; low-risk (RS < 18), intermediate-risk (RS =18-31) and high-risk 
(RS ≥ 31) of distant recurrence (Table 1.5). Paik et al. reported distant recurrence rates of 
6.8%, 14.3%, and 30.5% in the different risk groups [259]. Likewise, a significant 
association has been found between RS and the risk for local recurrence in patients with 
node-negative, ER-positive breast cancer [265]. Furthermore, patients with high RS 
derive a larger benefit from chemotherapy when compared to those with low RS [261]. 
However, the extent of benefits in patients with intermediate score remains uncertain 
[261]. The TAILORx trail (Trial Assigning Individualized Options for Treatment (Rx)) 
was launched in 2006 to assess the ability of RS to guide therapeutic decisions in breast 
cancer patients with intermediate score [266]. 
Oncotype DX™ is performed only in the USA by Genomic Health test center, 
which is Clinical Laboratory Improvement Amendments (CLIA)-certified and CAP-
accredited centralized laboratory [267]. Interestingly, this assay has been incorporated 
into the ASCO, the National Comprehensive Cancer Network (NCCN) and St Gallen 
clinical practice guidelines [45, 166, 268]. Overall, oncotype Dx™ assay has many 
advantages as it enables more individualized treatment decisions in estrogen receptor-
positive breast cancer patients, lowers both adverse effects and costs associated with 
chemotherapy over-treatment and identifies patients who may not have been offered 
chemotherapy based on traditional clinical and pathological measures alone [269]. 
However, there are important limitations associated with the use of Oncotype Dx™ 
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including its high cost (4,175.00$ per assay), criteria of inclusion (ER-positive, lymph 
node-negative) and lack of cross-validation by other independent laboratories [270]. 
 
Table 1.3: Multigene expression assays available in clinical settings. 
 
 Oncotype Dx MammaPrint PAM50 (Prosigna) 
No. of genes 
analyzed 
21 genes 
(16 cancer related 
genes + 5 reference 
genes) 
70 genes 50 genes+ 5 reference genes 
Tissue 
requirement 
FFPE tissue Fresh tissue FFPE tissue 
Technique qRT-PCR Microarray-based  
gene expression profiling 
qRT-PCR/Nanostring 
nCounter 
Target 
patients 
ER-positive, lymph 
node negative 
patients 
Patients with stage 1 or 2 
invasive breast cancer,  
<61 years old, with a node 
negative tumor less than 
5mm3 
In USA, ER-positive, lymph 
node-negative, Stage I or II 
breast cancer 
OR 
ER-positive, lymph node-
positive (1-3 positive 
nodes), Stage II breast 
cancer [271].  
Score • Recurrence 
score (RS)(0-
100) 
• Predict the risk 
of 10-years 
distance 
recurrence 
Low-risk (RS < 
18),  
Intermediate-risk 
(RS =18-31), 
High-risk (RS ≥ 
31)  
Predict the risk of 10-year 
distant metastasis-free 
survival rates 
 
Low risk (good prognosis),  
High risk (bad prognosis) 
• Risk of recurrence 
(ROR) 
• Predict late distant 
recurrence in the first 5 
years  
Low risk (ROR < 29), 
 Moderate risk (ROR = 29-
53), High risk (ROR ≥ 53) 
 
• Identify different 
molecular subtypes of 
breast cancer 
Performance 
site 
Central 
Genomic Health 
test center, USA 
Central 
Agendia, Amsterdam, the 
Netherlands 
Not central 
The most known is 
ARUP Laboratories 
Guideline NCCN/ASCO, St 
Gallen clinical 
practice guidelines 
St Gallen clinical practice 
guidelines,  
FDA cleared 
Received the CE mark, 
FDA cleared 
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Table 1.4: Panel of genes in Oncotype Dx™ assay (21-gene assay) [166].    
 
Groups of 
genes 
Gene name Gene description 
Estrogen-
related 
genes 
ER 
PR 
Bcl2 
SCUBE2 
Estrogen receptor 
Progesterone receptor 
B-Cell CLL/Lymphoma 2 
Signal Peptide, CUB and epidermal growth 
factor-Like Domain-Containing Protein 2 
HER2-
related 
genes 
HER2 
GRB7 
Human epidermal growth factor receptor 2 
Growth factor receptor-bound protein 7 
Proliferation 
genes 
MKI67 
STK15 (Aurora A 
kinase) 
BIRC5 (Survivin) 
CCNB1 (Cyclin B1) 
MYBL2 
Marker of proliferation Ki-67 
STK15: Serine/Threonine-Protein Kinase 15 
Baculoviral inhibitor of apoptosis repeat-
containing 5 
G2/mitotic-specific cyclin-B1 
V-Myb Avian Myeloblastosis Viral Oncogene 
Homolog-Like 2 
Invasion 
genes 
MMP11 
(Stromolysin) 
CTSL2 
Matrix metalloproteinase 11 
Cathepsin L2 
Macrophage 
genes 
CD68 Cluster of differentiation 68 
Others GSTM1 
BAG1 
Glutathione S-transferase Mu 1 
BCL2-associated athanogene 
Reference 
genes 
ACTB 
GAPDH 
RPLPO 
GUS 
TFRC 
β-actin 
Glyceraldehyde 3-phosphate dehydrogenase 
Large ribosomal protein 
β-glucuronidase 
Transferrin receptor protein 1 
 
Table 1.5: Oncotype Dx™ recurrence score 
 
Recurrence score 
(RS) 
Risk of 
recurrence 
Benefit from 
chemotherapy 
Likelihood of 10-
year DRFS 
<18 Low Minimal or no benefit High 
18-30 Intermediate  Uncertain Intermediate 
≥30 High High Low 
DRFS: distant relapse free survival 
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5.2.2	  MammaPrint	  (70-­‐gene	  assay)	  	  
MammaPrint is a microarray-based gene expression assay of RNA extracted from 
fresh breast cancer tissue performed by Agendia, which is a central laboratory in 
Amsterdam, the Netherlands [166]. This assay studies the expression of 70 genes that are 
associated with different hallmarks of cancer such as genes regulating cell cycle, cell 
growth, proliferation, invasion and metastasis, adaptation to unfamiliar 
microenvironment as well as angiogenesis (Appendix I) [156, 272]. MammaPrint is 
currently recommended for patients with stage 1 or 2 invasive breast cancer, < 61 years 
old, with a node negative tumor less than 5mm3 [270]. It is a prognostic tool that 
categorizes early-stage breast cancer patients as low risk (good prognosis) or high risk 
(bad prognosis) groups that correspond to 10-year distant metastasis-free survival rates of 
> 90% or < 90%, respectively [273]. Only patients with high risk of metastasis need 
supplementary chemotherapy in contrast to those with low risk of recurrence who can 
forego adjuvant chemotherapy with its associated toxicity (Predictive significance) [274].  
Microarray In Node-Negative and 1 to 3 positive lymph node Disease may Avoid 
Chemotherapy (MINDACT) trail evaluates the ability of MammaPrint to select the right 
breast cancer patients for treatment with chemotherapy in addition to surgery and 
hormonal therapy. In 2007, MammaPrint has received clearance for use by the FDA. In 
addition, this assay is included in the clinical practice guidelines of St. Gallen for 
assessing risk of distant relapse and the benefit of adjuvant chemotherapy [45]. However, 
both the ASCO the European Society for Medical Oncology (ESMO) reported that the 
final results from the MINDACT trial, which will not be available for several years, are 
crucial to prove the MammaPrint as an important prognostic and predictive tool in breast 
cancer treatment [166, 275]. As for Oncotype Dx™, MammaPrint is costly (4,200$ in the 
USA). In addition, the requirement of relatively large amount of fresh tissue that has to 
be snap-frozen in liquid nitrogen within one hour after surgery is another challenging 
point for MammaPrint assay [166]. 
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5.2.3	  PAM50	  (50-­‐gene	  assay,	  Prediction	  Analysis	  of	  Microarray	  50)	  	  
The PAM50 Breast Cancer Intrinsic Classifier™ is an RT-PCR assay that studies 
the expression of 50 classifier genes and five control genes to identify different molecular 
subtypes of breast cancer; luminal A, luminal B, HER2-enriched and basal-like 
(Appendix II) [276]. The normal-like molecular subtype is not reported in the 
commercial PAM50 assay as research microarray studies reported that this subtype is due 
to cancer specimens containing too much normal breast tissue [157, 277]. Furthermore, 
PAM50 calculates the risk of recurrence (ROR) by weighing the molecular subtype in 
combination with clinical variables such as tumor size, grade, histological subtypes, ER 
status and node status. Patients were categorized based on ROR into three groups; low 
risk (ROR < 29), moderate risk (ROR = 29-53) and high risk (ROR ≥ 53) [40]. This assay 
uses RNA extracted from FFPE tissues. 
PAM50 has been extensively studied in different research settings. Kelly and his 
colleagues have evaluated the performance of Oncotype DX and PAM50 among patients 
with early-stage ER-positive breast cancer. They reported a good agreement between the 
Oncotype DX and PAM50 assays for high (i.e., luminal B and RS ≥ 31) and low (i.e., 
luminal A and RS <18) prognostic risk assignment. In addition, about half of the 
intermediate RS group was reclassified as low risk by the PAM50 that could forgo some 
patients from receiving chemotherapy [277]. Other studies confirmed that PAM50 assay 
gives more prognostic information than standard methods such as clinical factors (tumor 
size, nodal status, histologic grade, patient’s age) and IHC study of ER, PR, HER2 and 
Ki-67 biomarkers in tamoxifen-treated estrogen receptor-positive breast cancer [157].  
PAM50 assay is highly predictive of neoadjuvant response when considering all 
breast cancer patients including those with ER-negative disease [40]. Prat et al. 
demonstrated that PAM50-ROR was consistently found to be independent predictors of 
relapse and its combination with OncotypeDX, Mammaprint and SET (index of 
sensitivity to endocrine therapy) will significantly increase the performance of prediction 
[278]. Interestingly, the PAM50 based-Prosigna breast cancer prognostic gene signature 
assay received the CE mark in 2012, which indicates European approval followed by the 
U.S. FDA clearance in 2013 [279].  
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5.3 Proliferative biomarkers in breast cancer 
Uncontrolled cell proliferation is one of the hallmarks of cancer [6]. There is now 
growing evidence that the degree of proliferative capacity of breast cancer impacts on its 
aggressiveness, prognosis and clinical behavior [280-282]. Various approaches have been 
developed to assess proliferation in breast cancer such as DNA microarray, mitotic score, 
and immunohistochemistry of proliferation-associated antigen such as Ki-67, cyclin A, 
MCMs and topoisomerase IIα [112, 281, 283]. However, to date, mitotic score remains 
the only proliferative marker incorporated in routine clinical practice [284]. In the 
following section, we will focus on mitotic score and two IHC proliferative markers Ki-
67 and MCM2. 
5.3.1	  Mitotic	  score	  	  
Mitotic count is one of the three components of breast tumors grading system 
[285]. Counting mitotic figures is the simplest and the most conventional approach in 
assessing proliferative capacity of breast cancer cells [286]. Mitotic count can be 
achieved by calculating the number of mitotic figures in 10 consecutive high power fields 
(x400) in routine H&E stained slides [287]. Mitotic counting has been described as a 
powerful, easy to perform, cheap, reliable and reproducible proliferation marker that can 
be applied to all cases of breast cancer [288, 289]. In 2013, the 13th St Gallen 
International Breast Cancer Conference Expert Panel included histological grading as one 
of the factors to determine inclusion of chemotherapy in treatment of luminal A breast 
cancer [45]. 
Different studies have reported the importance of the mitotic count in weighing 
the prognosis of breast cancers [287, 290-292]. It has been reported that a low mitotic 
index in the primary breast tumor is associated with better prognosis and less aggressive 
biological behavior than tumors with high mitotic index [293, 294]. Moreover, a high 
mitotic count in the primary breast tumors is correlated to a higher incidence to develop 
metastases [295]. Evaluating proliferative activity by counting mitotic figures in lymph 
node metastases of breast cancer patients also provides some prognostic values as it can 
predict the clinical course of distant metastasis and the clinical outcome of those patients 
[296-298]. In addition, Penault-llorca et al. demonstrated variation in the mitotic index 
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before and after neoadjuvant chemotherapy that bears on the prognosis [299]. Besides, 
high mitotic index is predictive to pathologic complete response to neoadjuvant 
chemotherapy, meaning that patients whose tumors have high mitotic count respond 
better to neoadjuvant treatment than those patients whose tumor have low mitotic count 
[300, 301].  
5.3.2	  Ki-­‐67	  	  
Ki-67, a nuclear non-histone protein was originally described by Gerdes and his 
colleagues in the 1980s. It was characterized using a monoclonal antibody directed 
against a Hodgkin’s lymphoma derived cell line. This antibody was coined after the city 
of Kiel in Germany where the clone was raised while the suffix 67 refers to the clone 
number on the 96-well plate [302, 303]. The expression of Ki-67 in all proliferating cells 
and its absence in quiescent cells raised great interest on its potential role as a marker of 
cell proliferation [304]. However, afterwards other studies demonstrated that proliferating 
cells that pass from G0 to G1 phase of the cell cycle do not express Ki-67 and that the 
onset of Ki-67 expression in those cells occurs only in the late G1 phase [305, 306]. In 
addition, there is alteration of Ki-67 concentration during the different phases of the cell 
cycle with the highest concentration found during the G2 and S phases and the nadir 
during anaphase and telophase of the cell cycle. Low levels of Ki-67 could also be 
detected in G1 phase of the cell cycle [307-309]. 
Taken together, it seems that Ki-67 plays a crucial role during cell division but its 
exact function inside the cell is currently unknown [281]. Notably, despite the fact that 
Ki-67 depleted cells and their cognate nuclei are smaller than their normal counterpart, 
these cells maintain a normal cell-cycle profile [310]. In addition, there is evidence that 
Ki-67 might be involved in other non cell cycle related processes such as ribosomal 
biosynthesis [311, 312]. Trihia et al. demonstrated that Ki-67 allows estimation of the 
growth fraction of breast cancer cells [286]. Furthermore, it has been reported that Ki-67 
is more accurate than mitotic score in assessing tumor cell proliferation and predicting 
prognosis of breast cancer patients [313].  
Many studies have looked into the prognostic significance of Ki-67 expression in 
breast carcinomas [286, 314-316]. High Ki-67 expression in breast cancer is associated 
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with ER negativity, HER2 positivity and high histological grade [317]. It has been 
reported that elevated expression levels of Ki-67 in early breast cancer is a strong 
predictor of a higher risk of relapse and reduced disease-free survival [314, 318]. 
Moreover, Ki-67 overexpression is more likely to be associated with axillary nodal 
metastasis in high-grade breast carcinoma [319]. Interestingly, most axillary lymph node 
metastases display higher levels of Ki-67 expression than that of the primary breast tumor 
suggesting that metastatic cells have a higher proliferating potential and more aggressive 
behavior than the primary breast cancer cells [320].  
On the other hand, Ki-67 is a predictive marker of response to endocrine therapy 
as high levels of Ki-67 expression identify patients that particularly benefits from 
hormonal therapy [316]. In addition, high Ki-67 index is a predictive factor of pathologic 
complete response to neoadjuvant chemotherapy in patients with locally advanced breast 
cancers [299, 321]. 
Another important issue that has been thoroughly studied is the prognostic value 
of endocrine and chemotherapy induced variation in Ki-67 expression level. Breast 
tumors with decreased Ki-67 expression following endocrine or chemotherapy were more 
likely to achieve complete pathological response [322, 323]. Ki-67 index of ≥ 15% after 
preoperative chemotherapy is a significant poor prognostic indictor in breast cancer 
patients as it is associated with a worse disease-free survival and a higher incidence of 
recurrence compared to other patients [324]. Data from the IMPAKT study have shown 
that elevated levels of Ki-67 two weeks after the onset of endocrine therapy was 
predictive of a worse recurrence-free survival [325]. Dowsett and his colleagues 
demonstrated that combining Ki-67 measurements in breast cancer patients before and 
after endocrine therapy could improve the prediction of recurrence-free survival [326]. 
Luminal breast cancer (ER+/HER2-) can be classified into luminal A and luminal 
B breast cancer based on 14% Ki-67 index [50]. However, the IMPAKT 2012 working 
group stated that there was not enough evidence to support a Ki-67 labeling index of 14% 
to identify clinically relevant subtypes of breast cancer [112]. Furthermore, further 
studies suggested different Ki-67 cutoff points such as 10%, 14% and 20% to distinguish 
luminal A from luminal B breast cancer [45, 50, 282, 327-329]. In 2013, the 13th St 
Gallen International Breast Cancer Conference Expert Panel adopted a new approach to 
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the classification of breast cancer patients for therapeutic purposes and recommended to 
use a 20% Ki-67 index to discriminate between luminal A and luminal B breast cancers 
[45]. 
So far, Ki-67 has failed to impose itself as an accepted breast cancer biomarker 
because of marked heterogeneity, poorly standardized staining and scoring conditions, 
lack of reproducibility and the difficulty to establish an appropriate cutoff point [45, 50, 
282, 327-329]. Due to the above limitations, neither the ASCO nor The NCCN 
recommended to use Ki-67 as a routine breast cancer biomarker [281, 330]. Surely, there 
is much more research to be done to propose the use of Ki-67 as a standard proliferative 
marker in clinical laboratories. 
5.3.3	  MCM2	  	  
MCM2 is one of the highly conserved family members of minichromosome 
maintenance (MCMs) proteins that function together as a complex in the cell [331]. 
MCM2-7 heterohexameric ring complex plays a crucial role in initiation of DNA 
replication and unwinding of the DNA due to its replicative helicase activity [332, 333]. 
It is one of the vital mechanisms that ensure single replication of the DNA per cell cycle 
[334]. During G1 phase of the cell cycle, pre-replication complex (pre-RC) is assembled 
by interaction of the following proteins at the replication origins: origin recognition 
complex (ORC), CDC6, CDT1 and MCM heterohexameric ring complex. During S 
phase, MCM complex unwind the double stranded DNA to allow initiation of replication 
then move out of the replicated DNA while remaining attached to un-replicated DNA. 
MCMs dissociate from the ORC and remain in the nuclear matrix during G2 and early 
mitosis until a new round of replication starts again (Figure 1.8). If the cells decide to exit 
the cell cycle and enter G0, MCMs are displaced from chromatin and degraded, as this 
complex is no longer required [311, 334]. Of note, there is a growing body of evidence to 
suggest that MCM proteins exert important roles in chromosomal dynamics and integrity, 
genomic stability and DNA repair [335, 336]. 
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Figure 1.8: Role of MCMs complex in precise DNA replication 
During G1 phase of the cell cycle, pre-replication complex (pre-RC) is assembled by 
interaction of the following proteins at the replication origins: origin recognition complex 
(ORC), CDC6, CDT1 and MCM heterohexameric ring complex. During S phase, MCM 
complex unwind the double stranded DNA to allow initiation of replication then move 
out of the replicated DNA while remaining attached to un-replicated DNA. MCMs 
dissociate from the ORC and remain in the nuclear matrix during G2 and early mitosis 
until a new round of replication starts again [311, 334] 
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Considering the above-mentioned functions of MCMs, MCM2 has been 
considered a potential prognostic biomarker in different types of cancer such as colon, 
prostate, lung, lymphoma and breast [337-340]. Overexpression of MCM2 is 
significantly associated with poor outcomes in diffuse large B cell lymphoma and in non-
small cell lung cancer [340, 341]. In addition, MCM2 is an independent predictor of 
recurrence in prostate cancer and hepatocellular carcinoma [342]. It is also one of the 
candidate genes identified by Cunha et al. to control local aggressiveness and metastatic 
behavior in soft tissue tumors [343]. Furthermore, Gonzalez and his colleagues showed 
that MCM2 is a strong independent prognostic marker in breast cancer as it is 
significantly associated with poor survival and development of regional and distant 
metastases. These authors indicated that high expression of MCM2 is associated with 
tumor size, higher mitotic index and a higher histologic grade of breast cancer [344]. 
MCM2 can also be predictive; for instance it may help to determine which 
cervical tumors are likely to respond to radiation therapy [345]. Loddo et al. provided 
evidence that MCM2 has a predictive value in breast cancer, as tumors with elevated 
levels of MCM2 are more likely to benefit from chemotherapy [346]. The fact that 
MCM2 is present in all proliferating cells and at all stages of the cell cycle together with 
its absence in non-proliferating cells support the notion that MCM2 is an ideal 
proliferative biomarker [347]. Many studies have reported its role as proliferative marker 
in numerous malignant tumors such as prostate, thyroid and colorectal carcinoma [348-
350]. In addition, there was a positive correlation between MCM2 and other proliferative 
markers such as Ki-67 and PCNA in colorectal carcinoma and in ductal breast carcinoma 
[349, 351]. Finally, MCMs together with other members of Pre-RC could be attractive 
targets to design new cancer therapies [311]. 
5.4 Other emerging biomarkers in breast cancer 
5.4.1	  Annexin	  A1	  (ANXA1)	  	  
Annexin A1, is a 37KDa protein that belongs to the superfamily of calcium-
dependent phospholipid-binding proteins that share a peculiar protein core domain [352]. 
Human annexin A1 is translated from the ANXA1 gene, which is located on chromosome 
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9q21 [353]. ANXA1 is known to be present in the cytoplasm, membrane and nucleus. 
However, its subcellular localization is critically dependent on certain stimuli; for 
example, ANXA1 translocate to the membrane and exported to the extracellular surface 
of the cell membrane in response to glucocorticoids [354]. In contrast, epidermal growth 
factor (EGF) stimulation and stress induce its translocation to the nuclei [355, 356]. 
Interestingly, nuclear localization of ANXA1 has been reported to correlate with 
advanced gastric carcinoma and with peritoneal dissemination [357].    
ANXA1 is thought to function as an anti-inflammatory molecule [358]. However, 
there is growing evidence that it participates to other critical cellular processes implicated 
in development and progress of cancers such as cell proliferation, differentiation and 
apoptosis [359-361]. It has been reported that ANXA1 regulates the epithelial cell 
migration in some malignancy [362]. Furthermore, loss of ANXA1 has been associated 
with an increased susceptibility to DNA damage and mutations [363]. Several studies 
have confirmed a deregulated ANXA1 expression in a variety of tumors. Overexpression 
of ANXA1 has been reported in gastric, hepatic and pancreatic carcinomas [364-366]. On 
the other hand, decreased expression of ANXA1 has been described in other types of 
cancers as in prostate and thyroid carcinomas [367, 368].  
More specifically, differential expression of ANXA1 in normal and malignant 
mammary cells has been reported in different studies. However, the results of these 
studies are somewhat controversial and confusing with regards to two important issues. 
The first one is the level of ANXA1 expression in breast cancer tissue when compared to 
normal breast tissue as some of these studies reported increased expression of ANXA1 in 
breast cancer [369, 370], while others showed the opposite [371-373]. The second issue is 
the role of ANXA1 in progression and metastasis of breast cancer cells. Several studies 
have claimed that ANXA1 increases the metastatic potential of tumors [374, 375]. In 
contrast, others studies reported that ANXA1 attenuates epithelial-mesenchymal 
transition and reduces metastatic potential in breast cancer [376].   
ANXA1 has also been demonstrated as a potential prognostic biomarker in 
different types of cancer such as lung, breast, gastric, colon and nasopharyngeal 
carcinoma [366, 377-379]. Increased expression of serum ANXA1 was significantly 
correlated with pathological grade and clinical stage of lung cancer patients [377]. 
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Moreover, up-regulated ANXA1 expression is significantly associated with invasion, 
lymph node metastasis and poor prognosis of gastric and colon cancer patients [366]. 
Also, elevated levels of ANXA1 has been reported to be a promising marker to predict 
the recurrence of bladder cancer [378]. In addition, high expression of ANXA1 was 
associated with unfavorable disease characteristics in invasive breast carcinoma such as 
high histological grade [375, 379]. Lastly, a panel of four genes that includes ANXA1, 
PRKCA, DUSP2 and SERPINA3 has recently been suggested to be a reliable predictive 
tool for the identification of breast cancer response to neoadjuvant chemotherapy [380].  
5.4.2	  MMP-­‐9	  	  
Matrix metalloproteinase-9 (MMP-9) is a zinc-dependent peptidase that belongs 
to the gelatinase subfamily of MMPs. It is excreted as an inactive pro-enzyme that 
undergoes activation upon cleavage by different types of extracellular proteases [381]. 
MMP-9 is regulated through interactions with growth factors and cytokines and 
activation of intracellular signaling pathways [382]. In transgenic mice, MMP-9 
expression is elevated in osteoclasts and migrating keratinocytes [383]. Interestingly, in 
many normal human tissues and human tissue cell lines (epithelial, connective tissue, and 
muscle origin) MMP-9 in not expressed [384, 385]. According to several studies, MMP-9 
is produced in many stromal cells such as fibroblasts, macrophages, granulocytes and 
lymphocytes adjacent to the tumor cells [386].  
MMP-9 acts mainly to degrade gelatin present in the ECM and collagen type IV 
of the basement membrane implying an important physiological role in tissue remodeling 
embryonic implantation and wound healing [387, 388]. In addition, MMP-9 allows 
implantation primary tumors and contributes to early stages of tumor growth, cell 
proliferation and angiogenesis [389-391]. MMP-9 also contributes to cancer 
dissemination and invasiveness as it affects tumor cellular adhesion, remodeling of the 
ECM and cleavage of membrane-bound growth factors. Because MMP-9 allows the 
establishment of pre-metastatic niches, it paves the way to tumor cell dissemination and 
facilitates the growth of metastatic cells in the distant organs [387, 391-394]. 
MMP-9 is also a promising prognostic biomarker in various types of cancer 
including cervical, colorectal and ovarian neoplasms for elevated serum and urine levels 
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of MMP-9 are associated with invasion, metastasis and a poor prognosis [395-400]. In 
addition, MMP-9 has been described as a poor prognostic factor in breast cancer patients 
being associated with higher TNM stage, lymph node involvement and a high propensity 
to distant metastasis [401, 402]. Elevated levels of MMP-9 are correlated with triple 
negative and HER2-positive subtypes of breast cancers that are known to have high 
metastatic potentialities [403, 404]. Moreover, high level of MMP-9 is significantly 
correlated with shorter time to relapse and a lower survival rate in breast cancer patients 
[405]. Of note, MMP-9 can also be envisaged as a potential predictive marker for 
adjuvant systemic therapy in breast cancer patients [406]. Lastly, it is interesting to note 
that elevated serum level of MMP-9 before the initiation of neoadjuvant chemotherapy 
for locally advanced breast cancer has been correlated with improved clinical response 
[407]. 
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6. Objectives of this work 
There are many evidences that each breast cancer has its own set of genomic 
abnormalities or altered pattern of gene expression that can explain the aggressiveness of 
each tumor, its ability to metastasize and its response to chemotherapeutic agents or other 
forms of targeted therapies. In this study, our general objective is to identify and 
characterize new biomarkers with prognostic value in aggressive subsets of breast cancer 
focusing primarily on triple-negative tumors and luminal B breast cancer. In this thesis, 
we studied two biomarkers, ANXA1 and MMP-9 as potential prognostic biomarkers for 
triple-negative breast cancer and MCM2 as a potential proliferative biomarker that can 
distinguish between luminal A and luminal B breast cancer. 
 
I. Novel biomarkers in triple-negative molecular subtypes of breast cancer 
A) ANXA1: our aim was to investigate the differential expression of ANXA1 among 
various histological grades and molecular subtypes of breast cancers and in particular 
triple negative tumors. Also, we sought to study the putative role of ANXA1 in EMT 
by comparing its expression with a panel of EMT markers. 
 
B) MMP-9: The aim of this study was to assess the potential clinical usefulness of 
MMP-9 as a prognostic biomarker of breast cancer. We also wanted to study the 
expression of MMP-9 in different histological grades and molecular subtypes of 
breast cancer. 
 
II. Novel biomarkers to distinguish luminal A from luminal B molecular subtypes 
of breast cancer 
MCM2: The main aim of this study is to determine if MCM2 can be an alternative to 
Ki-67 for measuring breast cancer cell proliferation. We studied the expression of 
MCM2 in comparison to Ki-67 as they relate to breast cancers of different 
histological grades and molecular subtypes focusing primarily on ER-positive 
tumors.	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Abstract 
 
Context: Breast cancer is a heterogeneous disease comprising a diversity of tumor 
subtypes. All of them differ from each other resulting in a wide array of clinical pictures, 
risks of recurrence and response to treatment. In recent years, tumor biomarkers have 
changed the way breast cancers are diagnosed and treated. 
 
Objectives: In this paper, we have sought to investigate the differential expression of 
ANXA1, a multifunctional calcium-binding protein, among various molecular subtypes 
of breast cancers and in particular triple-negative tumors.  
 
Design: ANXA1 was first studied using in silico analysis on available DNA microarray 
and RNA sequencing data of human breast tissues. Next we ascertained ANXA1 
expression on cell lines and breast carcinoma tissue microarrays along with cognate 
normal breast tissue.  
 
Results: Whereas ANXA1 expression is normally restricted to the normal myoepithelial 
cell layer it becomes ectopically and aberrantly expressed in tumor cells of a significant 
minority of aggressive breast cancers. Specifically, we found that ANXA1 expression is 
severely deregulated in high-grade breast cancers that comprise clinically aggressive 
tumors such as triple-negative and, to some extent, HER2-positive breast cancers. 
 
Conclusion: Our results indicate that ANXA1 is a valuable breast cancer biomarker that 
can help to segregate and dissect out subsets of high histological grade breast cancers 
paving the way to a better understanding of breast cancer progression and metastasis. 
 
 
Keywords: ANXA1; Multifunctional calcium binding protein; Breast cancer 
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Introduction 
 
Breast cancer is a heterogeneous disease characterized by a wide range of 
pathological features, diverse clinical behavior and variable response to treatment based 
on a complex interplay between characteristics of the tumor and the host [23]. In 2013, 
approximately 1 in 8 (12%) women in the USA will develop invasive breast cancer. 
Breast cancer is the second cause of death after lung cancer among American women. 
The American Cancer Society's estimated 39,620 deaths from breast cancer patients to 
occur this year [408]. The high mortality rate from breast cancer results mainly from 
metastasis due to spread of cancer cells to distant organs such as the liver, lungs, brain 
and bones [22]. In selective subtypes of breast cancer, therapies targeting specific 
signaling pathways are well known and many of them are now widely used in the clinics 
[409]. For instance, hormonal therapy (Tamoxifen and aromatase inhibitors) can inhibit 
the effect of estrogen or decrease estrogen levels in patients with hormonally responsive 
tumors. In HER2-positive patients, Trastuzumab can prolong survival and lower the risk 
of relapse. Unfortunately, patients whose tumor fail to express hormonal receptors or lack 
HER2 overexpression will not benefit from those types of treatment and hence must rely 
mainly on chemotherapy. There is now a large body of evidence to suggest that cancer 
treatment must be tailored to individual tumor characteristics [410]. Despite the success 
of current therapies, we still need to uncover unique genetic alterations or tumor 
characteristics that might be translated into prognostic & predictive biomarkers or 
pharmacologically amenable targets.  
Annexin A1 (ANXA1), the first characterized member of the annexin 
superfamily, is a calcium and phosopholipid binding protein known to mediate the anti-
inflammatory actions of glucocorticoids [352]. However, it possesses many other 
functions that impact on key cellular processes such as proliferation, differentiation, 
cytoskeletal organization, cell migration and apoptosis [359, 360, 362, 375]. Expression 
of ANXA1 has been associated with the development and progression of different types 
of cancer. On the one hand, ANXA1 has been shown to be down-regulated in esophageal 
cancer, head and neck cancer, and prostate cancer [367, 411, 412]. On the other, ANXA1 
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was found to be up-regulated in other types of malignancies such as pancreatic cancer, 
hepatocellular carcinoma and stomach cancer [364, 365, 413].   
We became interested in the status of ANXA1 gene expression in breast 
carcinomas following the seminal work by Perou et al. on the molecular classes of breast 
cancer [36]. Although the authors did not expand specifically on the putative role of 
ANXA1 in breast cancer, molecular profiling of tumors clearly indicated that ANXA1 
was related to the basal-like subtype of breast cancer. Upon carefully reviewing the 
literature we found that the status of ANXA1 expression and its role in initiation and 
progression of breast cancer was still an unresolved issue. It was reported that a lower 
expression of ANXA1 was significantly associated with advanced stage of breast cancer 
and poor overall survival when compared to patients with high ANXA1 expression [371]. 
Likewise, it has also been shown that expression of ANXA1 is down-regulated in 
metastatic tumors suggesting that ANXA1 functions as an epithelial-mesenchymal 
transition (EMT) /metastatic suppressor [376]. These observations are hard to reconcile 
though with the findings by Yi & Schnitzer [414] who reported that ANXA1 null mice 
had impaired tumor growth and a lower propensity to develop metastasis. Furthermore, it 
was reported by others that ANXA1 promotes metastasis formation of basal-like breast 
cancer through its regulation of TGF-β [375]. Indeed, Yom et al. demonstrated that high 
ANXA1 expression was significantly correlated with unfavorable prognostic factors such 
as hormone receptor negativity, HER2 overexpression and triple-negative breast cancer 
[379]. 
In this study, we investigated ANXA1 expression using in silico analysis on 
available DNA microarray and RNA sequencing data of both normal human breast tissue 
and in a variety of human breast cancers. We also carried out immunohistochemical 
analyses on a large number of normal breast tissue and breast carcinoma using cell 
microarrays (CMA) and tissue microarrays (TMA). This allowed us to compare ANXA1 
expression at the protein level with that of other available breast biomarkers. Here, we 
show that ANXA1 is differentially expressed in normal human breast tissue and in breast 
tumors. Moreover, we found that ANXA1 expression is severely deregulated in high-
grade breast cancers that comprise clinically aggressive tumors such as triple-negative 
and to some extent HER2-positive breast cancers. Our results suggest that ANXA1 is a 
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valuable breast cancer biomarker whose deregulated pattern of expression may help to 
segregate subsets of high histological grade breast cancers such as triple-negative 
category and HER2-positive breast tumors into clinically meaningful categories. 
 
Material and methods 
In silico Analysis 
The web application bc-GenExMiner [415] was used for correlation analysis of 
ANXA1 gene expression on a dataset comprising over 3400 microarrays. The "aov" and 
"TukeyHSD" functions were carried out to compare the mRNA levels within each breast 
cancer molecular subtypes for the ANOVA and Tukey multiple comparisons of means. 
The ANOVA was applied to check for an overall difference of expression level between 
molecular subtypes. The Tukey multiple comparisons of means were used to test for a 
significant difference between two subtypes (e.g. luminal A vs. basal). For both tests, a p-
value < 0.05 was considered significant. The mRNA levels of ANXA1, Vimentin (VIM), 
ESR1 and FOXA1 were compared using publically available microarrays and mRNA 
sequencing breast cancer patients datasets. The former included 51 breast cancer cell 
lines [416] and 247 patients [417]. The mRNA sequencing dataset from the Cancer 
Genome Atlas Network [43] included 844 patients.  Moreover, MiSTIC dataset was also 
used to correlate ANXA1 with a different set of genes in normal breast tissue (102 cases) 
and breast cancer (756 patients) based on RNA-sequencing data derived from The Cancer 
Genome Atlas (TCGA). Pearson correlation coefficient between set of genes was 
calculated with the "cor.test" function of the R language and environment for statistical 
computing (http://www.R-project.org/). 
 
Cell Culture  
All cell lines were purchased from the American Type Culture Collection 
(ATCC). MCF10F and MDA-MB-231 cells were maintained at 37°C in Dulbecco's 
modified Eagle's medium Nutrient Mixture F-12 (DMEM/F12) (Wisent) supplemented 
with 10% fetal bovine serum (FBS) (Sigma), 0.5 µg/ml hydrocortisone, 10 ng/ml EGF, 
10 µg/ml insulin, 1% penicillin-streptomycin and 100 ng/ml choleratoxin (Wisent). 184-
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B5 cell line was maintained in the same medium except that 1 ng/ml of choleratoxin was 
used instead of 100 ng/ml. MCF-7 cell line was maintained in Dulbecco's modified 
Eagle's medium Nutrient Mixture (DMEM) supplemented with 10% FBS and 1% 
penicillin-streptomycin. ZR-75-1 cell line was maintained in RPMI with 10% FBS and 
1% penicillin-streptomycin. MDA-MB-361 was maintained in L15 + 2mM Glutamine + 
15% FBS. MDA-MB-468 was maintained in Ham's-F12 medium (1:1 mixture) 
supplemented with 2 mM L-glutamine and 5% FBS. 
 
Preparation of Paraffin-Embedded Cell Pellets  
All cell lines were maintained in culture until they reached 80% confluence. Petri 
dishes were then washed with PBS followed by trypsinization of the cell layer until they 
completely detached from the bottom of the dish, then media specific for each cell line 
was added to inactivate trypsin. Cells and media were collected in 15 ml tube and 
centrifuged at 1000 rpm for 5 minutes. The supernatant was aspirated and the pellets 
were resuspended in 10% neutral buffered formalin and kept at 4 °C for 24 hours to allow 
proper fixation.  After 24 hours, the cells were centrifuged at 1,800 rpm for 10 minutes 
and the supernatant was aspirated and the pellets resuspended in melted HistoGel 
(thermoscientific). Cell pellets were maintained in HistoGel at 4 °C for 20 minutes until 
the gel solidified. Pellets were then removed from the eppendorf tubes and placed in 
embedding cassettes for further fixation in 10% neutral buffered formalin. Cell pellets 
were next processed in SAKURA Tissue-Tek VIP (Vacuum infiltration processor) then 
embedded in paraffin blocks. 3 µm section from each block was prepared and stained 
with Haematoxylin and Eosin (H&E) to evaluate the relative position of each cell cluster 
in each block and to determine cellularity. 
 
Cell Microarray (CMA) Construction 
CMA was prepared as follows: two punches (2mm) from each cell line were 
plucked and inserted into recipient blocks according to the intended design of the map 
using a Manual Tissue Arrayer I (Beecher Instruments). Blocks were next inverted and 
incubated overnight in the oven over a glass slide. The blocks were allowed to cool off 
until they could be detached from the glass slide. 3 µm sections were prepared from the 
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CMA and stained with H&E or submitted to automated immunohistochemical (IHC) 
reactions.  
 
Patient Samples and Tissue Microarray (TMA) Construction 
This study was conducted on 300 archived formalin-fixed, paraffin-embedded 
(FFPE) samples containing both normal and tumor tissues obtained from female patients. 
All samples were obtained from Centre Hospitalier de l’Université de Montréal (CHUM) 
after obtaining the approval of the research ethical committee (SL 05.019). The collected 
blocks contained both invasive and in situ carcinoma of the breast obtained at surgery 
(lumpectomy or mastectomy). Normal breast tissues were obtained from healthy women 
undergoing plastic surgery (Table 2.1). A number of extraneous tissues such as colon, 
thyroid and placenta were included in each TMA to serve as external controls. 
To construct TMAs, 4 µm sections from each paraffin donor block were stained 
with H&E. These sections were microscopically examined by two independent 
pathologists to select the most representative fields. Areas from each corresponding 
paraffin blocks were plucked in duplicate or triplicate and 1 mm core punches realigned 
into recipient blocks using a Manual Tissue Arrayer I (Beecher Instruments). Tissue 
sections from each TMA were prepared and one slide from each block was stained with 
H&E to review the diagnoses and histological grades on all tissue samples. 
 
Histological Grading of Breast Cancer 
Modified Scarff-Bloom-Richardson-Ellis-Elston grading system (SBR-EE) [418] 
was used to score invasive breast cancers. The patients were classified into one of three 
different histological grades (Grade I, II & III). Briefly, tumor grade is determined based 
on three parameters: - extent of tubule formation, mitotic rate and nuclear size. Each of 
these features is assigned a score ranging from 1-3. Next, the scores for each criterion are 
added together with a cumulative figure ranging from 3 to 9. Grade I tumors are well 
differentiated (low grade) with a total score of 3 to 5. Grade II tumors are moderately 
differentiated (intermediate grade) with a total score of 6 to 7. Grade III are poorly 
differentiated (high grade) with a total score of 8 to 9.  
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Table 2.1: Clinico-pathological data of tissues used in TMAs 
 
Variables No. of cores % 
Organs used in TMA 643 
Colon 4 0.7 
Lymph node 26 4.0 
Mammary gland 596 92.7 
Rectum 11 1.7 
Thyroid 6 0.9 
Grade 570 
I 54 9.5 
II 116 20.3 
III 400 70.2 
Molecular subtypes 488 
Luminal A 143 29.3 
Luminal B 54 11.1 
HER2-positive 68 13.9 
Triple-negative 223 45.7 
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Immunohistochemistry 
Immunohistochemistry was carried out according to manufacturer 
recommendations on an automated immunostainer (Discovery XT system, Ventana 
Medical Systems, Tucson, AZ). Antigen retrieval was performed with proprietary 
reagents followed by incubation with the primary antibody. Antibodies used are listed in 
table (2.2). Sections were then incubated with a specific secondary biotinylated antibody 
for 32 minutes. Streptavidin horseradish peroxidase, and 3,3-diaminobenzidine were used 
according to the manufacturer’s instructions (DABmap detection kit, Ventana Medical 
Systems). Finally, sections were counterstained with Gill hematoxylin and sodium 
bicarbonate. For ANXA1, MDA-MB-231 cell line and thyroid carcinomas were used as 
positive controls while MCF-7 and ZR-75-1 cell lines served as negative controls. Each 
section was scanned at a high resolution (40X) using the Nanozoomer Digital Pathology 
equipment (Hamamatsu, Bridgewater, NJ).  
The scoring system used for each antibody is listed in table (2.3) [364, 419, 420].  
IHC staining for ER, PR, HER2 and Ki-67 were used as surrogate markers to classify 
breast cancer tumors into luminal A, luminal B, HER2-positive and triple-negative breast 
cancer. Luminal A was defined by being (ER positive, PR positive, HER2 negative and 
Ki-67 < 14%) and luminal B was defined by being (ER, PR and HER2-positive) or (ER 
positive, PR positive, HER2 negative and Ki-67 ≥ 14%). Triple-negative breast cancers 
were samples that lack expression of ER, PR and HER2. Samples with HER2-positive 
while ER and PR are negative were considered as HER2-positive subtype [421].  
 
Immunofluorescence and Confocal Microscopy 
Direct immunofluorescence staining was carried out using Ventana automated 
immunostainer. Dylights 550 and 650 fluorophores from Thermo Scientific Pierce 
protein biology products were used to label primary antibodies against p63 (p63 Ab-1; 
IgG clone 4A4, Thermo-scientific) and ANXA1 (ANXA1; IgG1 clone29/Annexin I, BD 
transduction laboratory). The slides were incubated with the labeled antibodies for six 
hours. The slides were next washed and DAPI was applied. Sections were cover slipped 
and kept at -20 °C. 
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Table 2.2: Antibodies used for immunohistochemistry 
 
Antibody Clone Dilution Provider Retrieval 
method 
Positive score 
ER SP1 RTU Ventana HIER pH 6 Allred score ≥ 3 
PR 1E2 RTU Ventana HIER pH 6 Allred score ≥ 3 
HER2 4B5 RTU Ventana HIER pH 6 3+ 
Ki-67 SP6 1/100 BioCare  HIER pH 6 >14% 
ANXA1 Clone29 1/500 BD HIER pH 9 0-4 low expression 
6-12 high expression 
FOXA1 Polyclonal 1/500 Abcam HIER pH 6 0-4 low expression 
6-12 high expression 
VIM  3B4 1/100 Dako HIER pH 6 0-4 low expression 
5-12 high expression 
ER, Estrogen receptor, PR, Progesterone receptor; HER2, Human epidermal growth 
factor receptor 2; ANXA1, Annexin A1, FOXA1, Forkhead box protein A1; VIM, 
Vimentin; RTU, ready-to-use; HIER, Heat-induced epitope retrieval. 
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Fluorescent images were captured using Zeiss LSM 510 laser scanning confocal 
microscope equipped with 63x oil immersion objective lens. META detector was used 
for spectral separation of fluorochromes with overlapping spectra. Images were cropped, 
resized, and brightness and contrast over the whole image adjusted where necessary, 
using AxioVision and ImageJ softwares. 
 
Statistical Analyses 
All statistical analyses were carried out using different packages of language R. 
The distribution of ANXA1 in different histological grades and molecular subtypes is 
shown using box plots and bar charts. Non-parametric tests are used due to the nature of 
ordinal and categorical data. The overall relationship between ANXA1 scores and other 
characteristics (i.e. histological grades, and molecular subtypes) was evaluated by chi-
square test. Correlation analysis for immunohistochemical expression levels was carried 
out using the Spearman’s rho correlation coefficient. Statistical significance was 
considered, with a p-value < 0.05.  
 
Results  
 
ANXA1 is Highly Expressed in Basal-Like Breast Cancer in silico Analysis. 
Comparison of mRNA levels within breast cancer molecular subtypes using the 
bc-GenExMiner database comprising over 3400 microarrays and the mRNA sequencing 
dataset from the Cancer Genome Atlas (TCGA) dataset that included 844 patients were 
carried out. In patient microarray data sets, 59% of the basal-like and 70% of normal-like 
breast cancer subtypes show high level of ANXA1 expression. In contrast, 21% of 
luminal A and only 7% of luminal B subtypes demonstrate high expression of ANXA1. 
For the HER2-positive subtype, the percentage of patients with high or low expression of 
ANXA1 is nearly identical (32% vs. 29%, Figure 2.1A). Similarly, in the patient 
sequenced transcriptomes, ANXA1 mRNA levels were found to be significantly 
overexpressed in the basal-like subtype when compared to both luminal A (p-value 
<0.001) and B subtypes (p-value <0.001) (Figure 2.1B).  
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ANXA1 is Overexpressed in Triple-Negative Breast Cancer Cell Lines. 
To validate the results obtained from our in silico analysis, ANXA1 expression 
was studied in a panel of human breast cancer cell lines with varying degree of 
expression of ER, PR and HER2 (Table 2.4). ANXA1 expression was detected in all 
basal-like cell lines 184-B5, MCF10F, MDA-MB-468 and MDB-MB-231 [422]. Intense 
membrane staining was present in all triple-negative cell lines. However, cytoplasmic and 
nuclear staining intensity somewhat varied in these cell lines (Figure 2.2A-D). In sharp 
contrast, ANXA1 was absent from MCF7, ZR-75-1 and MDA-MB-361 cell lines (Figure 
2.2A-F) which are all considered to belong to the luminal subtype categories [422, 423]. 
Taken together, our findings in breast cancer cell lines support our in silico analysis 
showing higher expression of ANXA1 in triple-negative breast cancer. 
 
ANXA1 is Strictly Confined to Myoepithelial cells in Both Normal Breast Tissue and 
In situ Breast Cancers. 
In normal breast tissue and in situ carcinoma, we found ANXA1 to be strongly 
expressed in myoepithelial cells and in a few adjacent stromal cells (Figure 2.3A&B). 
Myoepithelial cell identity was confirmed by their typical localization around the luminal 
cells, their characteristic flattened morphology and more directly by the co-expression of 
ANXA1 with the specific myoepithelial cell marker p63 using confocal microscopy. 
ANXA1 and p63 were co-localized in the very same myoepithelial cells either in normal 
mammary gland or in ductal carcinoma in situ (Figure 2.3C&D).  
 
ANXA1 is Overexpressed in Subsets of Triple-Negative and HER2-Positive Breast 
Cancers 
Variation in the levels of ANXA1 expression according to molecular subtypes of 
breast cancer was assessed. All samples collected from patients with luminal A and 
luminal B breast cancer lacked detectable expression of ANXA1 (Figure 2.4A&B). In  	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Figure 2.1: In silico analyses of ANXA1 expression in PAM50 molecular subtypes of 
breast cancer using A. The bc-GenExMiner database comprising over 3400 microarrays, 
B. TCGA mRNA sequencing dataset including 844 patients showing that ANXA1 is 
highly expressed in basal-like subtype. *** p-value < 0.001, Tukey's test.  
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Table 2.4: Expression of ER, PR, HER2 and ANXA1 in different types of breast 
cancer cell lines [422, 423]. 
 
Cell Lines ER PR HER2 Molecular Subtypes ANXA1 
184B5 - - - Basal + 
MDA-MB-468 - - - Basal  + 
MCF10F - - - Basal + 
MDAMB231 - - - Basal  + 
ZR-75-1 + + - Luminal  - 
MDA-MB-361 + - + Luminal  _ 
MCF7 + + - Luminal  - 
ER, Estrogen receptor, PR, progesterone receptor; HER2, Human epidermal growth 
factor receptor 2; ANXA1, Annexin A1. 	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Figure 2.2. Expression of ANXA1 in different types of breast cancer cell lines. Strong 
ANXA1 expression in basal-like breast cancer cell lines (A-C). Lack of ANXA1 
expression in luminal breast cancer cell lines (D-F). Magnification: 40X (A-F) 
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Figure 2.3. Expression of ANXA1 in normal breast tissue and in situ carcinoma using 
immunohistochemistry (A&B) and direct immunofluorescence (C&D). ANXA1 
expression is restricted to myoepithelial cells and a few adjacent stromal cells. For figure 
2.3 C&D, the green color mark ANXA1 and the purple mark the P63 Magnification: 20X 
(A & B), 40X inset in Figure A, 63X (C & D) 
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contrast, almost half of the samples collected from patients with triple-negative breast 
cancers had strikingly elevated levels of ANXA1 expression (Figure 2.4C&D). 
Moreover, the association of ANXA1 with basal-like breast cancer, which is considered 
to be a subset of triple-negative breast cancer, was further substantiated by a positive 
correlation  
with basal cytokeratin CK5/6 (r = 0.72, p-value < 0.001) (data not included). Notably, 
most but not all HER2-positive samples (approx. 90%) were found to be negative for 
ANXA1 (Figure 2.4E,F&G).  
 
Altered Pattern of ANXA1 Expression Correlates with a Subset of High-Grade 
Breast Cancers. 
In Grade I, Grade II and 70.4 % of Grade III breast cancer, ANXA1 expression 
could not be detected in tumor cells (Figure 2.5A-C). However, 29.6% of Grade III breast 
cancer patients showed ectopic expression of ANXA1 in tumor cells (Figure 2.5D-G). 
Another key finding is the disordered cellular distribution of ANXA1 labeling in high-
grade breast cancers. Whereas ANXA1 expression is normally restricted to the 
myoepithelial cells in a typically uniform fashion, the pattern observed in tumor cells 
markedly departed from that of normal cognate cells.  Indeed, the staining pattern in 
tumors is at odds with that observed in normal myoepithelial cells. Some tumors exhibit 
ANXA1 staining mainly in the cytoplasm with only a few cells harboring nuclear 
staining. Other tumors demonstrate predominantly nuclear staining with only very faint 
cytoplasmic staining. On occasion, we have observed an intense nuclear and cytoplasmic 
staining. Lastly, strong membranous staining along with weak cytoplasmic staining was 
found in few high-grade breast cancers (Figure 2.5D-G). Taken together, our results 
indicate that not only ANXA1 is aberrantly accumulating in a significant minority of high 
grade tumor cells but also that there is an accompanying defect in its cellular 
translocation, distribution and compartmentalization 
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Figure 2.4. Expression of ANXA1 in different molecular subtypes of breast cancer. 
A. Luminal A, B. Luminal B. Luminal A and B tumor cells fail to express ANXA1. A 
subset of triple negative (C&D) and HER2-positive (E&F) tumors express high level of 
ANXA1 (D&F). G. Diagram showing the percentage of patients with high and low 
expression of ANXA1 in each molecular subtype of breast cancer Magnification: 20X 
(A-F) 
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 Figure 2.5. ANXA1 expression in breast cancer of different histological grades. 
100% of Grade I & Grade II breast cancer and 70.4% of Grade III fail to express ANXA1 
in the cancer cells while stromal cells show positive staining (A-C). However, 29.6% of 
Grade III breast cancers showed high ANXA1 expression along with varied subcellular 
localization (D-G).  Magnification: 20X (A-C), 40X (D-G) 
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Positive Correlation Between ANXA1 and Vimentin and Negative Correlation 
Between ANXA1, ESR1 and FOXA1. 
The RNA sequencing data derived from TCGA dataset [38, 416] was analysed 
using the MiSTIC visualization tool to identify genes that are positively or negatively 
correlated with ANXA1 in normal breast tissue (102 cases) and in breast cancer (756 
patients). A positive correlation was observed between ANXA1 and VIM, one of the 
EMT markers in breast cancers (r =0.73). In the same group of tumors, ANXA1 is 
negatively correlated with several luminal markers such as FOXA1 (r =-0.66), ESR1 (r 
=-0.46), GATA3 (r =-0.47) and XBP1 (r = -0.47) (Figure 2.6).  To substantiate these 
observations, we next assessed the mRNA levels of ANXA1, VIM, ESR1 and FOXA1 
using publically available microarrays and mRNA sequencing breast cancer patients’ 
datasets. The microarray included 51 breast cancer cell lines [416] and 247 patients [417] 
and mRNA sequencing included 844 patients. Similar correlations could be established 
using mRNA in sequenced transcriptome datasets strengthening the above mentioned 
association. Specifically, a positive correlation between ANXA1 and VIM was detected 
(r = 0.75 Figure 2.7A) while a negative correlation was established between ANXA1 and 
ESR1 (r = -0.47 Figure 2.7B) and between ANXA1 and FOXA1 (r = -0.46 Figure 2.7C).  
In order to expand on the data obtained from the in silico analyses, we used 
additional sections of our human breast cancer TMAs to ascertain the expression of VIM, 
ESR1 and FOXA1 at the protein level. Again, a positive correlation between ANXA1 
and VIM was confirmed (r = 0.48, p-value < 0.001).  In triple-negative breast cancer, 
62% of patients had a high expression of both proteins. In contrast, 100 % of luminal A 
patients and 95.6 % of luminal B had low expression of ANXA1 and VIM. Similarly, 
77.3% of HER2-positive patients also had low expression of ANXA1 and VIM with only 
4.6 % showing high expression of both proteins. 
We were also able to confirm the negative correlation between ANXA1 and ESR1 
(r =-0.45, p-value < 0.001) and between ANXA1 and FOXA1 (r =-0.51, p-value < 0.001) 
using TMAs. Specifically, in luminal A &B breast cancer, 100% of the patients had a 
high degree of expression of ESR1 and FOXA1 and no detectable levels of ANXA1 
expression (Figure 2.8A). In triple-negative breast cancer where ESR1 and FOXA1 are 
negative, 45.5% of patients had high levels of ANXA1 (Figure 2.8B). 
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Figure 2.6. Genes that are positively (left side) or negatively correlated (right side) with 
ANXA1 in 756 breast cancer patients based on RNA-sequencing data derived from 
TCGA dataset.  
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Figure 2.7. Correlation between ANXA1 and VIM, ESR1 and FOXA1 using RNA 
sequencing data of 844 breast cancer patients. There is positive correlation between 
ANXA1 and VIM. In contrast, ANXA1 is negatively correlated with both ESR1 and 
FOXA1. 
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Figure 2.8. Correlation between ANXA1, ESR1 and FOXA1 in different molecular 
subtypes of breast cancer using immunohistochemistry and tissue microarray. A. 
Luminal breast cancers, B. Subset of triple negative breast cancer. Magnification: 10X  
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Discussion 
 
ANXA1 belongs to a family of calcium and phospholipid binding proteins 
initially considered to have an anti-inflammatory function. However, many recent 
publications also stressed its role in key cellular processes such as proliferation, 
differentiation, cytoskeletal organization, cell migration and apoptosis. Although ANXA1 
expression has been studied in different types of cancer, so far results have been rather 
conflicting, with reports in the literature describing variable levels of expression in 
normal and breast cancer tissue. This also holds true for breast cancer where the status of 
ANXA1 expression in normal mammary gland and breast cancers is currently unsettled. 
In the present work, we have investigated the expression of ANXA1 in human breast 
cancer tissues. We found that deregulated ANXA1 expression is observed only in high-
grade breast cancers that comprise clinically aggressive tumors such as triple-negative 
and HER2-positive breast cancers supporting the view that ANXA1 is a valuable marker 
for a subset of aggressive breast tumors. 
Using TMAs comprising normal breast tissue and breast carcinomas of various 
histological grades, we conclusively demonstrated that ANXA1 expression is confined to 
the myoepithelial cell layer and to a few adjacent stromal cells of normal breast tissue. 
Myoepithelial cell identity was confirmed by their typical localization around the luminal 
cells, their characteristic flattened morphology and more directly by the co-expression of 
ANXA1 with the specific myoepithelial cell marker p63 using confocal microscopy. This 
constitutive pattern of ANXA1 expression is also highly conserved in the myoepithelial 
cell layer surrounding the ducts and lobules of in situ carcinomas. Notably, there is a 
complete absence of ANXA1 in malignant epithelial cells where the normal regulatory 
pathways continue to operate. These results are consistent with those of Ang et al. who 
reported similar pattern of expression of ANXA1 in myoepithelial cells [359]. However, 
they are clearly at odds with the observations of Elshimali & Lui who found that ANXA1 
is expressed in both epithelial and myoepithelial cells of normal breast tissue [424].  
Since there is complete disappearance of the myoepithelial cells layer during 
stromal infiltration, the lack of ANXA1 positive myoepithelial cells was an expected 
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finding. This is consistent with the inability to detect ANXA1 in low-grade (Grade I) and 
intermediate-grade (Grade II) and 70.4 % of high-grade (Grade III) breast cancer. 
Strikingly however, 29.6% of Grade III breast cancer patients showed ectopic expression 
of ANXA1 in tumor cells. The morphology of tumor cells and the failure to express any 
of the other myoepithelial cell markers are inconsistent with the possibility that those 
cells represent a residual myoepithelial population. Although it is tempting to hypothesize 
that positive tumor cells are derived from a progenitor cell endowed with both luminal 
and myoepithelial features, this view nevertheless fails to explain the absence of ANXA1 
positive tumor cells in both grade I and grade II tumors. In our opinion, ANXA1 
expression in tumor cells more likely represents an abnormal, deregulated cellular 
process due to a failure of the checks and balances that operates under normal conditions 
in the breast tissue. 
Our results on human breast cancer cell lines indicate that triple-negative cell 
lines expressed ANXA1 at significantly higher levels than those observed in both luminal 
A or B cell lines. This result is also consistent with the observations of Kang et al. that 
breast cancer cell lines with high expression of ANXA1 are invasive by nature, whereas 
lines with low or undetectable expression of ANXA1 had a poor capacity for migration 
[425]. Additionally, we found that enhanced expression of ANXA1 is a characteristic of a 
subset of triple-negative and, to a lower extent, HER2-positive breast cancers. It is also 
worth noting that we were able to relate ANXA1 expression to basal-like breast cancer as 
shown by a positive correlation with basal cytokeratin CK5/6. Again, this supports a 
similar finding by Yom et al. who demonstrated that ANXA1 expression was 
significantly correlated with unfavorable prognostic factors such as hormone receptor 
negativity, HER2-positive tumors and triple-negative breast cancer [379]. To our surprise 
though, Wang et al. found that low ANXA1 expression was significantly associated with 
advanced stage breast cancer and a worse overall survival when compared to patients 
with high ANXA1 expression [371].  The fact that an enhanced expression of ANXA1 
was found in the so-called normal-like breast cancer subtype supports the view that this 
molecular category may simply reflect the high degree of contaminating normal breast 
tissue and hence residual myoepithelial cells in the tumor samples [426]. Future 
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experiments with preclinical models will help solving this issue and/or this apparent 
contradiction 
Concerning the putative role of ANXA1 in the EMT, in this study we found a 
positive correlation between ANXA1 and VIM, one of EMT markers. Supporting data 
came from both the mRNA level using in silico analysis and from ANXA1 cell labeling 
on the TMAs. This may suggest that ANXA1 exerts a positive effect in EMT, consistent 
with reports indicating that ANXA1 promotes metastasis formation in basal-like breast 
cancer cells by enhancing TGFβ/smad signaling and actin reorganization [375]. Likewise, 
ANXA1-null mice were found to develop fewer metastases than wild type littermates 
[414]. However tantalizing this hypothesis might be, it is severely challenged in view of 
the findings by Maschler et al. who demonstrated that forced ANXA1 expression in 
metastatic mouse and human mammary carcinoma cells reversed EMT and abolished 
metastasis [376]. Clearly, more work is needed to sort out the exact role of ANXA1 in 
tumor progression and metastasis. The use of a comprehensive panel of EMT markers on 
human breast tumors expressing ANXA1 could help clarifying the issue. Of note, MSN 
and LYN that are known to play roles in EMT [427, 428]	  have also positive correlation 
with ANXA1 (For MSN r =0.69, for LYN r =0.54). (Figure 2.6) 
A negative correlation between ANXA1 and both ESR1 and FOXA1 has been 
uncovered using in silico study.  This was further substantiated using a large cohort of 
breast cancer patients tissues and cell lines. 100% of patients with luminal breast cancer 
subtypes had positive expression of ESR1 and FOXA1 while they completely lack 
ANXA1 expression. In contrast, 43% of triple negative breast cancers that are ESR1 and 
FOXA1 negative, display high levels of ANXA1. Recently, FOXA1 was reported to be 
necessary not only for maintaining luminal-specific gene expression, but also for 
repressing numerous genes specific to basal breast cancer cells including ANXA1 [429]. 
Interestingly, our in silico study confirmed that ANXA1 promoter contains FOXA1 
responsive element (two regions within 5kb of ANXA1 transcription start site) but none 
for ESR1. Given the suppressive roles of FOXA1 [430-432], it would be of great interest 
to determine how FOXA1 suppresses ANXA1 expression. 
Lastly, one has to remind that ANXA1 is only one member of a broad family of 
annexins many of which have been reported to be directly or indirectly involved in breast 
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cancer tumorigenesis such as Annexin A2, A4, A5, A6, A7, A8 [38, 416, 433, 434]. At 
present, the degree of functional overlap and crosstalk between each annexin variant has 
not been addressed.  
To conclude, ANXA1 expression is restricted to high-grade breast cancers, mostly 
triple-negative breast tumors that are notoriously known for their aggressive clinical 
behavior. We propose that ANXA1 is deregulated in a significant proportion of high 
histological grade breast cancers, thereby underlining the complexity and heterogeneity 
of breast cancers especially those that belong to the triple-negative category. Developing 
new biomarkers will help dissect out subsets of triple-negative tumors and facilitate the 
identification and further characterization of unique and specific regulatory pathways 
paving the way to targeted therapy. A better understanding of the complex cross-
regulatory networks between ANXA1, Vimentin, ESR1 and FOXA1 signaling pathways 
is clearly needed to pinpoint and identify subsets of tumors with non-overlapping and 
unique mechanisms leading to tumor progression and metastasis. 
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Abstract  	  
Background	  
In 2014, breast cancer remains a major cause of mortality worldwide mostly due 
to tumor relapse and metastasis. There is currently a great interest in identifying cancer 
biomarkers and signalling pathways mechanistically related to breast cancer progression. 
Matrix metalloproteinase-9 (MMP-9) is a member of matrix degrading enzymes involved 
in cancer development, invasion and metastasis. Our objective was to investigate MMP-9 
expression in normal human breast tissue and to compare it to that of breast cancer of 
various histological grades and molecular subtypes. We also sought to correlate MMP-9 
expression with the incidence of metastasis, survival rates and relapse in breast cancer 
patients.  
 
Methods	  
MMP-9 was first studied using in silico analysis on available DNA microarray 
and RNA sequencing data of human breast cancer tissues and human breast cancer cell 
lines. We next ascertained MMP-9 expression in both normal breast tissue and in human 
breast carcinoma tissue microarrays. 
 
Results	  
Significant increase in MMP-9 expression was found in breast cancer cells when 
compared to normal breast tissue. A positive correlation could also be established 
between elevated levels of MMP-9 and breast cancer of high histological grade. 
Furthermore, our results indicate that not only MMP-9 is differentially expressed between 
each molecular subset but also; more importantly MMP-9 overexpression revealed itself 
as a startling feature of triple-negative and HER2-positive breast cancers. Lastly, the 
clinical relevance of MMP-9 overexpression is strongly supported by its significant 
association with a higher incidence of metastasis and relapse. 
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Conclusions	  
Differential expression of MMP-9 reflects the extent of cellular differentiation in 
breast cancer cells and is closely related to the most aggressive subtypes of breast cancer. 
Hence, MMP-9 is a promising prognostic biomarker of high-grade breast cancer. In our 
opinion, MMP-9 expression could help segregate subsets of aggressive breast cancer into 
clinically meaningful subtypes 
 
 
Keywords: MMP-9, human breast cancers, metastasis, in silico analysis, tissue 
microarrays. 
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Introduction 	  
Breast cancer is the most common malignancy and the second leading cause of 
cancer-related death after lung cancer among women in the United States and Europe 
[435]. Due to major advances in screening and early diagnostic procedures, most breast 
cancer patients are diagnosed at an early stage. However, 6% to 10% of patients still 
present with metastatic breast cancer at the time of diagnosis; for those patients, relapses 
tend to occur earlier and survival rates are shortened [436]. Cancer metastasis is 
considered to develop in a step-wise fashion leading to the acquisition of new capabilities 
by tumor cells helping them to thrive and evade natural barriers [437]. Cancer cells 
detach themselves from the primary tumor, migrate and invade surrounding tissues, enter 
the vasculature, circulate throughout the body and eventually reach secondary sites where 
they extravasate, and populate distant organs [438].  
Degradation of the extracellular matrix (ECM) is thought to be a crucial step in 
the formation of tumor metastasis. Multiple proteolytic enzymes such as plasmin, 
cathepsins, and matrix metalloproteinases (MMPs) are known to degrade ECM [439]. 
Matrix metalloproteinase-9 (MMP-9) is a zinc-dependent peptidase that belongs to the 
gelatinase subfamily of MMPs. It is excreted as an inactive pro-enzyme that undergoes 
activation upon cleavage by different types of extracellular proteases [381]. MMP-9 
activity is thought to be regulated by different biochemical stimulators such as growth 
factors and cytokines whose expression appear to modulate intracellular signaling 
pathways [382]. MMP-9 has the ability to degrade denaturated collagens which have 
been first cleaved by various collagenases such as MMP-1, MMP-8 and MMP-13 [440, 
441]. In addition, MMP-9 degrades type IV collagen which is the main component of the 
basement membrane [442]. It exerts different roles in the dissemination process such as 
tumor invasion, tumor-induced angiogenesis, and immunomodulation of the tumor 
microenvironment. In addition, MMP-9 is instrumental in creating so-called 
premetastatic niches that foster colonization of distant organs [443]. Elevated tissue 
levels of MMP-9 are also associated with invasion, metastasis and poor prognosis in 
different types of cancer including cervical [395], colorectal [396], ovarian [397] and 
breast cancer [398]. Furthermore elevated levels of MMP-9 in the serum and urine have 
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also been found to be associated with metastasis and poor prognosis in a diversity of 
cancers [399].     
Our goal was to assess the potential clinical usefulness of MMP-9 as a prognostic 
biomarker of breast cancer. To achieve that aim, we first studied MMP-9 mRNA 
expression using in silico analysis on available DNA microarray and RNA sequencing 
data of human breast cancer tissues and breast cancer cell lines. We next evaluated 
MMP-9 expression at the protein level using immunohistochemical analyses on tissue 
microarrays containing both normal and neoplastic breast tissues. Our data were next 
correlated with patients’ outcome specifically looking at the incidence of metastases, 
relapse and overall survival. Our results indicate that MMP-9 is not only differentially 
expressed in different molecular breast cancer subtypes but also overexpressed in triple-
negative and HER2-positive breast cancers. Overexpression of MMP-9 tightly correlates 
with a higher incidence of metastasis and relapse. Taken together, our data indicate that 
differential expression of MMP-9 reflects the degree of differentiation of breast cancer 
cells and that its overexpression tightly correlates with the most aggressive subtypes of 
breast cancers. Hence, MMP-9 is a potentially useful biomarker of aggressive and 
metastatic subtypes of breast cancer. 
 
Material and Methods 	  
In silico Analysis 
The web application bc-GenExMiner [415] was used for correlation analysis of 
MMP-9 gene expression on a dataset comprising over 3,063 microarrays. However, only 
1210 patients could be correctly assigned precisely to each molecular subtype. The "aov" 
and "TukeyHSD" functions were carried out to compare the mRNA levels within each 
breast cancer molecular subtypes. The ANOVA was applied to check for an overall 
difference of expression levels between each molecular subtypes. The Tukey multiple 
comparisons of means were used to test for a significant difference between two subtypes 
(e.g. luminal A vs. basal). For both tests, a p-value < 0.05 was considered significant. The 
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mRNA level of MMP-9 in 51 breast cancer cell lines were also studied using publically 
available microarrays and mRNA sequencing breast cancer cell line datasets [416].   
 
Patients and Tissue Samples 
A retrospective study was carried out using a cohort of 300 female breast cancer 
patients comprising tumors of different histological grades. Archived formalin-fixed, 
paraffin-embedded (FFPE) samples containing tumor tissues were collected for the study. 
Tumor grades were confirmed using the Modified Scarff-Bloom-Richardson-Elston-Ellis 
grading system (SBR-EE) [444]. A complete set of follow-up data including the onset of 
metastasis and relapse were acquired.  We also obtained 19 normal breast tissues from 
healthy women undergoing plastic surgery to serve as internal controls. Benign breast 
conditions such as mammary fibroadenoma and myofibroblastoma were included as 
negative controls [403]. In addition, a number of extraneous tissues such as colon, thyroid 
and placenta were included in each TMA. All samples were obtained from Centre 
Hospitalier de l’Université de Montréal (CHUM) after granting the approval of the 
research ethical committee (Comité d'éthique de la recherche du CHUM CENTRE DE 
RECHERCHE, Approval No. SL 05.019).  
 
Tissue Microarray (TMA)  
Sections (4 µm) from each paraffin block were stained with hematoxylin and 
eosin (H&E) and examined by two independent pathologists. Core punches, 1mm in 
diameter, were drilled from representative areas contained within each FFPE tumor 
blocks. Each core was realigned in duplicate or triplicate into recipient blocks according 
to the intended design of the map using a Manual Tissue Arrayer I (Beecher Instruments). 
Blocks were next inverted and incubated overnight in the oven over a glass slide. TMA 
blocks were allowed to cool until they could easily detach from the glass slide. Tissue 
sections from each TMA were prepared and one slide from each block was stained with 
H&E to review the diagnoses and histological grades on all tissue samples. Additional 
representative sections from each block were submitted to automated 
immunohistochemical (IHC) staining. 
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Immunohistochemistry 
Immunohistochemical assays were performed on FFPE tissues obtained from 
each TMAs. These assays were carried out according to manufacturer recommendations 
on an automated immunostainer (Discovery XT system, Ventana Medical Systems, 
Tucson, AZ). Immunohistochemical analysis of MMP-9 (polyclonal; ab38898, dilution 
1/100, no pretreatment, Abcam, Canada) was carried out to detect both the pro- and the 
active form of MMP-9 [445]. In addition, immunohistochemical analysis of estrogen 
receptor (ER; monoclonal, clone SP1, RTU, sCC1, Ventana Medical Systems), 
progestrone receptor (PR; monoclonal, clone 1E2, RTU, sCC1, Ventana Medical 
Systems), HER2 (monoclonal, clone 4B5, RTU, sCC1, Ventana Medical Systems), Ki-67 
(monoclonal, clone SP6, dilution 1/100, pretreated sCC1, BioCare medical) were used as 
surrogate markers of breast cancer molecular subtypes [421]. Antigen retrieval was 
performed with proprietary reagents followed by incubation with the primary antibody. 
Sections were then incubated with a specific secondary biotinylated antibody for 32 
minutes. Streptavidin horseradish peroxidase, and 3,3-diaminobenzidine were used 
according to the manufacturer’s instructions (DABmap detection kit, Ventana Medical 
Systems). Sections were next counterstained with Gill’s hematoxylin and sodium 
bicarbonate. Finally, each slide was scanned at high resolution (40X) using the 
Nanozoomer Digital Pathology equipment (Hamamatsu, Bridgewater, NJ). Two 
independent pathologists reviewed all stained sections on two separate occasions.  
Estrogen receptor (ER) and progesterone receptor (PR) status were scored using 
Allred's method. In brief, the sum of the proportion and average intensity scores of 
positive tumor cells were calculated and results displayed on a scale ranging from 0 to 8. 
The cutoff point used to differentiate between positive and negative samples were as 
follows: tumors with Allred scores ≥ 3 (corresponding to as few as 1% to 10% weakly 
positive cells) were considered to be positive. Those tumors that had Allred score of less 
than 3 were considered to be negative. HER2 overexpression was carried out according to 
the College of American Pathologists (CAP)-approved scoring system as follows: no 
immunostaining or membrane staining which is incomplete or barely perceptible within ≤ 
10% of the invasive tumor cells à 0; incomplete membrane or barely perceptible 
staining within >10% of invasive tumor cells à 1+; circumferential membrane staining 
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that is incomplete and/or weak/moderate within >10% of the invasive tumor cells or 
complete membranous staining that is intense within ≤ 10% of the invasive tumor cells 
à 2+ and circumferential membranous staining that is complete and intense à 3+ [420]. 
Scoring of MMP-9 and Ki-67 expression on each core was carried out using a two tier 
scoring system. The first parameter corresponds to the percentage of immunoreactive 
cells also known as the quantity score (QS). QS was estimated as follows (no staining 
was scored as 0, 1-10% of cells with positive staining were scored as 1, >10- 50% as 2, 
>50-70% as 3, and >70-100% as 4). We next assessed the second parameter (staining 
intensity score), which was rated as follows: No staining à 0, weak staining à1, 
moderate staining à 2, and strong staining à 3. The product of multiplying the quantity 
and the staining intensity scores represents the total IHC score that ranges from 0 to 12 
[364, 446]. IHC scores of 0 to 4 were considered to represent low levels of expression 
while score from >4 to 12 were considered as high levels of expression. 
IHC staining for ER, PR, HER2 and Ki-67 were used as surrogate markers to 
classify breast cancer tumors into luminal A, luminal B, HER-2 positive and triple- 
negative breast cancer. Luminal A was defined as being (ER positive, PR positive, 
HER2-negative and Ki-67 < 14%), luminal B was defined as being either (ER, PR, HER-
2 positive) or (ER positive, PR positive, HER2-negative and Ki-67 ≥ 14%). Triple 
negative breast cancers consisted of tumors that lack expression of ER, PR and HER2. 
HER2- positive tumors that failed to express either ER or PR were considered to belong 
to the HER2-positive subtype [421].   
 
Statistical Analyses 
All statistical analyses were carried out using different packages of the R 
language (http://www.R-project.org/). The distribution of MMP-9 among different 
molecular subtypes is depicted using bar charts. Non-parametric tests were used due to 
the nature of ordinal and categorical data. The overall relationship between MMP-9 
scores and molecular subtypes was evaluated using the chi-square test. Correlation 
analysis for immunohistochemical expression levels was carried out using the 
Spearman’s rho correlation coefficient. Chi-square test was realized with Yates’ 
continuity correction and a two-sided Fisher exact test was performed to analyze 
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metastasis. Kaplan-Meier plot was drawn to show the overall survival for low-level and 
high-level expression of MMP-9. Statistical significance was considered, with a p-value 
less than 0.05. Univariate and multivariate logistic regression were used to identify the 
significant factors among histological grades, histological subtypes, molecular subtypes, 
metastasis and age that affect the level of MMP-9 expression. The results were 
interpreted in terms of odds ratio (OR). Univariate and multivariate Cox models were 
used in survival analysis and the results were interpreted in terms of relative risk (RR). 
Statistical significance was determined by the confidence interval (CI). Only CI that does 
not include 1 are considered significant. 	  
Results  	  
 In silico analysis: MMP-9 is overexpressed in basal-like and HER2-positive breast 
cancers.  
The web application bc-GenExMiner [415] was used to compare the mRNA 
levels within each breast cancer molecular subtype on a dataset comprising 1210 
microarrays. In brief, the gene expression data is given for those patients that could be 
assigned to a certain molecular subtype (robust classifications for 1210 patients). In 
figure 3.1, the table indicates for each subtype the proportion of patients with low, 
intermediate, and high gene expression. Gene expression values were being beforehand 
split in order to form three equal groups.  This means that "high expression" is the 1/3 of 
the patients with highest expression of MMP-9 and "low expression" is the lower 1/3 of 
the patients. As depicted in Figure 3.1, 57% of basal-like and 50% of HER2-positive 
breast cancer patients expressed high levels of MMP-9. In comparison, only 12% of those 
subtypes had a reduced expression of MMP-9. In sharp contrast, only 16% of the luminal 
A breast cancer subtype demonstrate increased expression of MMP-9. Data from the 
luminal B subtype indicate that 36% of patients have high levels of MMP-9 expression 
while approximately 30% maintained low levels of MMP-9. 
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Figure 3.1: In silico analysis of MMP-9 mRNA expression in breast cancer subtypes. 
The heat map and table are produced from the bc-GenExMiner database v3.0 showing the 
expression of MMP-9 at mRNA level in different molecular subtypes of breast cancer as 
determined by PAM50. Overexpression of MMP-9 is associated with basal-like and 
HER2-positive breast cancers. The "aov" and "TukeyHSD" functions were carried out to 
compare the mRNA levels within each breast cancer molecular subtypes. 
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Figure 3.2: Expression of MMP-9 mRNA in human breast cancer cell lines. 
In silico analysis showing elevated MMP-9 mRNA expression levels in basal-like breast 
cancer cell lines (e.g. CAL85-1, HCC1395, HCC1143, DU4475, HCC1937, MDA-MB-
231 and HCC38). Luminal breast cancer cell lines with HER2 amplification also display 
stronger MMP-9 mRNA expression (AU565, UAA-893 and HCC2218). MCF7 and 
KPL1 cell lines are the only luminal cell lines with mildly elevated MMP-9 mRNA 
expression. (B= basal, L= luminal, L+H= Luminal with HER2 amplification) 
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To expand on the results obtained from the microarray datasets, we investigated 
mRNA expression of MMP-9 in 51 breast cancer cell lines of different molecular 
subtypes [447-449] using publically available microarrays and mRNA sequencing breast 
cancer cell line datasets [416]. As shown in Figure 3.2, overexpression of MMP-9 was 
present in basal-like breast cancer cell lines CAL85-1, HCC1395, HCC1143, DU4475, 
HCC1937, MDA-MB-231 [450] and HCC38. Interestingly, many luminal breast cancer 
cell lines known to have HER2 gene amplification (AU565, UAA-893 and HCC2218) 
also exhibited high levels of MMP-9 expression. Notably, MCF7 and KPL1 cell lines 
were the only luminal cell lines that revealed a modest increase in MMP-9 expression 
above baseline levels [451].  
 
MMP-9 expression is markedly decreased or absent in normal human breast tissue.  
Optimization of MMP-9 immune reactivity was a prerequisite to validating the 
specificity of the IHC reaction. In accordance with the Human Protein Atlas [95] and a 
review of the literature, human colorectal carcinoma was used as a positive control to 
assess the levels of MMP-9 expression in human cancers [452]. Our results are in 
complete agreement with this prediction as shown by the strong cytoplasmic labeling 
observed in colorectal carcinoma cells (Figure 3.3A). Additional adjacent sections from 
the same colonic tumor incubated with a non-immune serum containing IgG (same 
isotype/ same species) remained entirely negative. Of note, all subsequent steps of the 
immunostaining reaction such as addition of the secondary antibody and the revealing 
reaction were carried out in a strictly identical fashion (Figure 3.3B). We also thought fit 
to include benign breast lesions such as myofibroblastoma (Figure 3.3C) and 
fibroadenoma (Figure 3.3D) as negative controls [403]. Again, no immune reactivity 
could be detected after the successive addition of MMP-9 primary antibody, secondary 
antibody and chromogen. 
Once all immunostaining conditions were satisfactorily established, we carried 
out IHC reactions on TMAs comprising both normal and neoplastic breast tissues. Our 
results indicate that 74% of normal breast tissues fail to express any MMP-9 reactivity in 
the luminal, myoepithelial cells and stromal cells surrounding normal breast ducts (Figure 
3.4A). However, in a minority of normal breast tissues (26%) MMP-9 was faintly  
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Figure 3.3: Validation of MMP-9 antibody specificity for IHC studies. 
(A) Human colorectal carcinoma with intense cytoplasmic labeling of the cancer cells 
after incubating the section with MMP-9 primary antibody. (B) Adjacent section from the 
same colorectal tumor incubated with a non-immune serum that contains IgG (same 
isotype/ same species) showing complete lack of expression of MMP-9. (C) Benign 
myofibroblastoma of breast tissue and (D) Benign breast fibroadenoma do not express 
MMP-9. Magnification 20X (A-D) 
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Figure 3.4: Expression of MMP-9 in normal breast tissue. 
(A) Normal breast lobule lacking MMP-9 expression in both luminal and myoepithelial 
cells. Adjacent stromal cells also fail to express MMP-9 (74% of the patients). (B) 
Normal breast tissue exhibiting faint expression of MMP-9 in the cytoplasm of luminal 
cells, myoepithelial cells and in a few stromal cells surrounding normal breast acini. A & 
B are two distinct normal breast tissue from the same TMA incubated with anti-MMP-9 
antibody. Magnification 40X (A&B), 63X inset in Figure 3.4B. 
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expressed and restricted to the cytoplasm of luminal, myoepithelial and a few adjacent 
stromal cells (Figure 3.4B). MMP-9 did not label either the nucleus or the cell membrane 
of any of these cells. Notably, the level of MMP-9 expression in the luminal cells 
consistently exceeded that present in the adjacent stromal cells.  
 
Elevated levels of MMP-9 are present in carcinoma cells of triple-negative, HER2-
positive tumors and nodal metastases. 
Next we aimed to validate the results obtained from the in silico analysis on 
human breast tissue. We studied the expression of MMP-9 at the protein level and 
assessed the cellular and subcellular localization of MMP-9. MMP-9 expression was 
evaluated in 300 human tumor tissues representative of each molecular subtypes of breast 
cancer whose definition was based on the use of the following surrogate markers: ER, 
PR, HER2 and Ki-67 [421]. As shown in figure 3.5A, only 33.3% of luminal A (p = 0.05) 
and 43.3% of luminal B (p < 0.01) expressed elevated levels of MMP-9. In contrast, high 
levels of MMP-9 expression were found in 87.9% of HER2-positive and 79.4% of triple-
negative breast cancer when compared to normal (p < 0.001). Low levels of MMP-9 
expression were detected in the cytoplasm of cancer cells in both luminal A and B breast 
tumors. Indigenous stromal cells surrounding cancer cells in luminal A and B revealed 
only faint levels of MMP-9 expression (Figure 3.5B and C). On the other hand, elevated 
levels of MMP-9 expression were detected in the stroma surrounding cancer cells in both 
triple-negative and HER2-positive breast cancer. Nevertheless, the level of MMP-9 in the 
cytoplasm of cancer cells always exceeded that found in adjacent stromal cells (Figure 
3.5D and E). Furthermore, when MMP-9 levels were evaluated in the cytoplasm of 
carcinoma cells present in 13 metastatic lymph nodes, it was found that tumor cells in 
100% of our samples displayed elevated levels of MMP-9 whereas the surrounding 
lymphocytic and stromal cells failed to express MMP-9 (Figure 3.5F). 
We next conducted univariate logistic-regression analysis on our data to sort out 
the role of a number of parameters such as histological grades, molecular subtypes and 
metastasis on the level of MMP-9 expression. This analysis confirmed the association 
between the high levels of MMP-9 expression (total scores > 4) with tumors of high 
histological grade (Grade III) including both HER2-positive and triple-negative breast 
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Figure 3.5: Overexpression of MMP-9 is associated with triple-negative, HER2-
positive breast tumors and nodal metastases. 
(A) Histogram showing percentage of breast cancer patients in each molecular subtype 
category that express low and high level of MMP-9. Both HER2-positive and triple-
negative subtypes demonstrate elevated levels of MMP-9 that are significantly different 
from those observed in normal breast tissue. The number of patients in each group was 
mentioned over each bar. The overall relationship between MMP-9 scores and molecular 
subtypes was evaluated using the chi-square test. (B) Luminal A and (C) Luminal B 
subtypes showing low level of MMP-9 expression. (D) HER2-positive and (E) Triple-
negative subtypes displaying strong cytoplasmic labeling in cancer cells and surrounding 
stromal cells. (F) Metastatic lymph node demonstrating elevated levels of MMP-9 
expression in the cytoplasm of metastatic breast cancer cells. The surrounding 
lymphocytic and stromal cells did not stain with anti-MMP-9 antibody. Magnification 
20X (B-E), 5X (F), 40X inset in Figure 3.5F.  
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Table 3.1: Univariate analysis of different factors that could affect level of MMP-9 
expression. 
 
Parameters OR 95% CI p-value 
Grades    
Grade I Reference   
Grade II 1.74 0.82-3.73 0.15 
Grade III 2.61 1.36-5.08 < 0.001 
Molecular subtypes    
Luminal A Reference   
Luminal B 0.51 0.26-0.99 0.05 
HER2-positive 8.01 3.85-18.46 0.001 
Triple-negative 3.90 2.48-6.19 0.001 
Metastasis (No) Reference   
Metastasis (Yes) 2.17 1.48-3.23 0.001 
OR= odds ratio, CI= confidence interval. 
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cancers (Table 3.1). Hence, we can safely conclude that MMP-9 protein expression in 
vivo strongly supports both in silico analyses on microarray dataset as well as data 
gathered from analysis of breast cancer cell lines.  
 
Overexpression of MMP-9 is associated with a higher incidence of metastases. 
We next investigated whether elevated levels of MMP-9 protein expression in 
carcinoma cells could predict the occurrence of metastases, relapse and poor survival 
rates. To that end, we reviewed the clinical charts of 200 patients for the period extending 
from 2000 to 2013. Out of 200 Patients, 121 (60.5%) patients have high MMP-9 
expression and 79 (39.5%) patients have low MMP-9 expression. Increased levels of 
MMP-9 were found to be associated with a higher incidence of metastasis (Figure 3.6). 
The results were considered significant when the percentage of patients who developed 
metastases significantly differed in terms of low and high levels of MMP-9 expression. 
Only lymph node (p < 0.001), lymphovascular invasion (p = 0.007) and lung metastasis 
(p = 0.001) reached statistical significance when compared to patients with low MMP-9 
expression. Additional file 1 indicates the distribution of high and low MMP-9 
expression in patients with and without metastases.  
Univariate analysis of our data demonstrated the association between elevated 
levels of MMP-9 expression and the increased likelihood to develop metastasis (OR = 
2.17, 95%CI = 1.48-3.23, p-value = 0.0001) (Table 3.1). Moreover, to examine which 
clinical factors could affect the relationship between MMP-9 and metastasis, multivariate 
logistic-regression analysis was carried out. Triple-negative molecular subtype proved to 
be the only statistically independent predictor of metastasis (OR = 7.92, 95%CI = 2.90-
21.6, p-value = 0.0001) (Table 3.2). This suggests that triple-negative breast cancer have 
a stronger clinical value in predicting metastasis rather than any of the other biological 
factors examined. 
 
High levels of MMP-9 are associated with a shorter latency to relapse and shorter 
survival after relapse (SAR) 
Likewise, when we looked at the association between MMP-9 and relapse, we 
found that enhanced expression of MMP-9 was associated with a shorter latency to 
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Figure 3.6: Overexpression of MMP-9 is associated with a higher incidence of 
metastases.  
Increased expression of MMP-9 is associated with higher incidence of metastasis. Only 
lymph node, lymphovascular invasion and lung metastases reached the level of statistical 
significance when compared to patients with low MMP-9 expression. Chi-square test was 
realized with Yates’ continuity correction and a two-sided Fisher exact test were 
performed to analyze metastases. 
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Table 3.2: Multivariate analysis model of MMP-9 that include metastasis, histological 
subtypes and molecular subtypes. 
 
Parameters OR 95% CI p-value 
Metastasis    
Luminal A 0.97 0.45-2.07 0.93 
Luminal B 3.52 0.81-15.27 0.12 
HER2-positive 0.77 0.16-3.61 0.79 
Triple-negative 7.92 2.90-21.61 0.001 
OR= odds ratio, CI= confidence interval 
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Figure 3.7: Overexpression of MMP-9 is associated with shorter time to relapse and 
shorter survival after relapse. 
(A) High levels of MMP-9 expression are associated with shorter time to relapse 
(p=0.014). (B) High levels of MMP-9 expression are associated with shorter survival 
after relapse (p=0.04). 
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clinical relapse: (Mean time for relapse = 3912 days, n=121) which is statistically 
significant (p = 0.014). This contrasts with the values observed in patients with low 
MMP-9 levels of expression (Mean time for relapse = 4957 days, n=79) (Figure 3.7A). 
However, using a multivariate analysis, histological grades, histological subtypes and 
molecular subtypes were found to have no impact on relapse in this patient’s population. 
Finally, the Kaplan-Meier overall survival (OS) curve obtained from the same 
cohort of patients indicates that increased expression levels of MMP-9 are associated 
with a shorter OS (Mean OS= 6469 days, n=16) when compared to those tumors 
expressing low levels of MMP-9 (Mean OS= 6984 days, n=6). However, no significant 
difference could be identified between OS for patients having high or low levels of 
MMP-9 expression. Interestingly, univariate analysis shows that patients with higher 
levels of MMP-9 expression harbor a significant high risk of death after relapse 
(RR=3.05, p=0.04) (Figure 3.7B). It is also worth mentioning that we could not find any 
statistically significant correlation between the expression of MMP-9 in the tumor stroma 
and the occurrence of metastasis or overall survival in the same patients. 
 
Discussion  	  
In the present paper, we provide both indirect and direct evidence that MMP-9 
participates to breast cancer progression and impact on clinical outcome. There are many 
studies reporting the association of elevated levels of MMP-9 with a higher incidence of 
metastases and poor clinical outcome. We found that high expression of MMP-9 is 
specifically correlated with high-grade breast cancers that include both triple-negative 
and HER-2 positive breast cancers. 
Previous studies have provided conclusive evidence that MMP-9 is involved in 
several key processes that contribute to breast cancer development, progression, invasion 
and metastasis [393, 453, 454]. Here we performed in silico analysis of 1210 DNA 
microarrays of human breast cancer tissues and RNA sequencing data of 51 human breast 
cancer cell lines to assess MMP-9 mRNA expression. We found that MMP-9 mRNA 
expression in both basal-like and HER2-positive tumors reached significantly higher 
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levels than those observed in the luminal A category. When the expression of MMP-9 in 
breast cancer cell lines is considered, it is worth mentioning that cell lines with a basal-
like phenotype and those that are luminal with overexpressed HER2 reached the highest 
levels of MMP-9 expression. In contrast, cell lines with luminal phenotype failed to 
demonstrate elevated levels of MMP-9. This strongly suggested to us that MMP-9 
expression varied according to cell differentiation and histological grades. Hence, we 
decided to construct human breast cancer tissue microarrays (TMA) comprising a wide 
selection of tumors belonging to each category of breast cancer molecular subtypes. 
Those tumors were classified as triple-negative, HER2-enriched, luminal A and luminal 
B based on the expression profile of four surrogate markers (ER, PR, HER2, Ki-67) 
[421]. We also included normal breast tissue to serve as a basis for comparison.  
To thoroughly validate the robustness of our IHC assay we first included a 
number of internal and external controls. Whereas colonic adenocarcinoma strongly 
expressed MMP-9, two benign breast lesions (fibroadenoma and myofibroblastoma) 
failed entirely to express MMP-9 under the same conditions. Once the experimental 
procedures were set up, we performed the IHC assay on TMAs.  One important finding 
was that normal breast tissue displayed either a complete lack of positivity or barely 
perceptible labeling with the antibody directed against MMP-9. This is consistent with 
previous observation by others reporting only a weak expression of MMP-9 in normal 
breast tissue [384, 455]. Indeed, low levels of MMP-9 expression in normal breast tissue 
are expected since in most tissues MMP-9 is an inducible and not a constitutively 
expressed gene [456]. Evidently, this sharply contrasts with the high levels of expression 
of MMP-9 found in the cytoplasm of both HER2-positive and triple-negative breast 
cancers cells. Hence, our findings support the conclusions of recently published studies 
indicating a positive correlation between high levels of MMP-9 expression and triple-
negative breast cancers [403, 457, 458]. Our results may also explain the findings of La 
Rocca et al. who showed that high serum levels of MMP-9 are present in HER2 amplified 
breast cancers [404]. In this context, abnormally elevated levels of MMP-9 can be 
envisaged as a response to local secretion of inflammatory cytokines and growth factors, 
such as interleukin 1 (IL-1) and tumor necrosis alpha (TNFα), which may lead to either 
activation of NF-kB, a well-known inducer of MMP-9 production, or hypomethylation of 
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its promoter [459]. One cautionary note should be raised though, since high levels of 
MMP-9 do not necessarily imply high MMP-9 activity as the protein is produced as an 
inactive pro-enzyme. Moreover, active MMP-9 can be completely neutralized by protease 
inhibitors such as tissue inhibitors of metalloproteinases (TIMPs) [405]. As for the 
production site of MMP-9 in breast tumors, our results suggest that carcinoma cells are 
the main source of MMP-9 given that adjacent stromal cell consistently exhibited a much 
weaker degree of expression.  
Finally, we wanted to correlate clinical outcome characteristics such as onset of 
metastasis, survival rates and tumor relapse with MMP-9 levels. Our results confirm that 
overexpression of MMP-9 is tightly correlated with lymphovascular invasion, regional 
node metastasis, a shorter time to relapse and a reduced SAR. Taken together, our data 
underscore the role of MMP-9 in promoting breast cancer metastases in lymph node and 
lungs. This finding is consistent with both in vitro and in vivo studies reporting high 
levels of MMP-9 expression in highly metastatic cell lines [460] and its contribution in 
metastatic progression [458]. Also, this supports the finding of van 't Veer et al. [156] 
who demonstrated in a DNA microarray study that MMP-9 is significantly upregulated in 
poor prognosis signature of breast cancer. Although we have not directly addressed the 
question on how MMP-9 fosters invasion and nodal metastasis, there are numerous 
conceivable explanations that can be put forth such as alteration of basal membrane 
components, diminished cell-to-cell adhesion, release of ECM-bound growth factors and 
chemotactic molecules, stimulation of angiogenesis and induction of the epithelial-
mesenchymal transition (EMT) [387, 392, 461-463]. 
 At any rate, our findings clearly emphasized the clinical potential of MMP-9 as a 
prognostic biomarker in breast cancer. This is in agreement with Wu et al. [464] who 
suggested the potential role of MMP-9 as a biomarker for breast cancer progression. 
Interestingly, the first fully commercialized and FDA approved microarray-based 
multigene assay for breast cancer, MammaPrint®, does include MMP-9 among its 70 
panel genes [272, 465]. Given on the one hand the overwhelming interest in developing 
prognostic and predictive breast cancer assays and, on the other, the recognition that so 
called “wound-healing” or “invasion” gene signatures are important to predict tumor 
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relapse and benefit to chemotherapy, one might consider including MMP-9 alone or in 
combination with other genes in the development of other multigene multiplex assays. 
Conclusion 
 
In summary, our results indicate that overexpression of MMP-9 is closely 
associated with breast cancers of high histological grade including triple-negative and 
HER2-positive molecular subtypes. Increased levels of expression of MMP-9 are also 
correlated with the onset of nodal metastases, a reduced time interval to relapse and a 
shorter SAR. Taken together, our findings suggest that the differential expression of 
MMP-9 contributes to breast cancer heterogeneity and is a key characteristic of the 
“molecular signature” of subsets of breast cancer.  In our opinion, MMP-9 expression 
could help segregate subsets of aggressive breast cancer into clinically meaningful 
subtypes. Lastly, our results suggest that MMP-9 is a valuable gene/protein candidate to 
be considered in the development of a multi-gene panel or multiplex proteomic assay to 
predict clinical outcome. 
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Additional materials 
Additional file 1: Number of patients with or without metastasis associated with 
either high or low MMP-9 expression. 
  Metastasis High Expression Low Expression 
Lymph node       
      (L.N.) 
Yes 53 12 
No 68 67 
Lympho-
vascular (L.V.) 
Yes 44 14 
No 77 65 
Blood vessels   
      (B.V.) 
Yes 10 3 
No 111 76 
Perineural 
Yes 6 3 
No 115 76 
Skin 
Yes 13 7 
No 108 72 
Bone 
Yes 14 5 
No 107 74 
Brain 
Yes 6 1 
No 115 78 
Lung  
Yes 15 0 
No 106 79 
Liver 
Yes 8 4 
No 113 75 
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Abstract  
 
Background 
Breast cancer is a heterogeneous disease comprising a diversity of tumor subtypes 
that manifest themselves with a wide variety of clinical, pathological and molecular 
features. One important subset, luminal breast cancers (ER+/HER2-), comprises two 
clinically distinct subtypes: luminal A and luminal B each of them endowed with its own 
genetic program of differentiation and proliferation. Luminal B tumors tend to be less 
differentiated and exhibit a higher rate of proliferation than luminal A breast cancers.  
There is currently a need for a clinically robust and validated immunohistochemical assay 
to help distinguish between luminal A and B breast cancer. MCM2 is a family member of 
the mini-chromosome maintenance protein complex whose role in DNA replication and 
cell proliferation is firmly established. It has been reported to be a promising proliferative 
marker in many types of cancer including thyroid, rectal and breast cancers. As MCM2 
appears to be an attractive alternative to Ki-67, we sought to study the expression of 
MCM2 and Ki-67 as they relate to different histological grades and molecular subtypes 
of breast cancer focusing primarily on ER-positive tumors.  
 
Methods 
MCM2 and Ki-67 mRNA expression were first studied using in silico analysis of 
available DNA microarray and RNA sequencing data of human breast cancer tissues. We 
next used immunohistochemistry to evaluate protein expression of MCM2, Ki-67 and a 
wide array of breast cancer biomarkers on tissue microarrays constructed from a cohort 
of 266 breast cancer patients  
 
Results 
Both MCM2 and Ki-67 are highly expressed in breast cancer of high histological 
grades that comprise clinically aggressive tumors such as triple-negative, HER2-positive 
and luminal B subtypes of breast cancer. MCM2 expression was also found to express at 
higher levels than Ki-67 (p < 0.0001) in normal breast tissues, and in breast cancers. Two 
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distinct subgroups among ER+/HER2- breast cancer could be easily identified using a 
MCM2 threshold of 40%.  
 
Conclusion 
MCM2 expression can help in distinction between two clinically important 
subsets of luminal breast cancer whose treatment and clinical outcomes are likely to 
diverge. An independent validation cohort is needed to confirm the clinical utility of 
MCM2. 
 
 
Keywords: MCM2, Ki-67, human breast cancers, in silico analysis, tissue microarray 
(TMA) 
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Introduction 	  
According to the last annual report of the American Cancer Society, it is 
estimated that 232,670 new cases of invasive breast cancer will be diagnosed among 
women in the United States in 2014 resulting in an estimated 40,000 breast cancer deaths. 
Only lung cancer exacts a larger toll from women in terms of mortality [19]. Breast 
cancer is a heterogeneous disease that manifests itself with an embarrassing variety of 
morphological characteristics, a complex array of clinical and pathological features, 
contrasting molecular subtypes, as well as variable responses to treatment [421, 466].  
Molecular subtypes of breast cancer, primarily identified by gene expression 
profiling, harbor distinct gene expression patterns that translate into characteristic disease 
phenotypes with significant differences in outcomes [36, 467]. Molecular classification 
can, to a certain extent, be clinically approximated using IHC expression profiles of four 
surrogate markers: ER, PR, HER2 and Ki-67 [23, 44, 50]. Molecular subtypes include 
estrogen receptor positive (ER+) breast cancer (luminal A and luminal B) and estrogen 
receptor negative (ER-) breast cancer (HER2-positive, basal-like and a so-called normal 
breast-like breast cancer subtype) [468]. Luminal A and luminal B breast cancers are 
significantly distinct at the molecular level as luminal A breast cancer express the highest 
level of ER-related and the lowest level of proliferation-related genes, while luminal B 
breast cancer show the opposite pattern of gene expression [41, 44, 45].  
The proliferation signature of tumor cells, comprised of cell-cycle regulated genes 
whose expression correlates with rapid cell proliferation [469, 470], has been detected in 
different types of cancer such as breast, prostate, liver and lung [43, 471-473]. There is 
now growing evidence that the proliferative capacity of breast cancer impacts on the 
prognosis, clinical behavior and aggressiveness of the tumor suggesting that accurate 
measurement of cell proliferation may help selecting a more appropriate treatment [280, 
474, 475]. Indeed, proliferation is considered as the highest weight component in the 
Oncotype DX recurrence score (RS) [476]. While DNA microarray is an ideal way to 
measure multi-gene expression proliferation signature in a quantitative and automated 
manner, the need for a histological-based proliferation test is crucial for pathologist 
routine clinical assessment of breast cancer [469, 477]. Currently, mitotic index and 
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immunohistochemistry of proliferation-associated antigen such as Ki-67, cyclins, 
minichromosome maintenance (MCM) proteins and topoisomerase IIα are the most 
common practical histological methods to assess proliferation [474, 478].  
Ki-67 is one of the most important cell proliferation related genes and, as such, it 
has been widely investigated as a proliferative marker in breast cancer with the hope of 
distinguishing luminal A from luminal B breast cancer [50, 479, 480]. However, Ki-67 
assessment in breast cancer has failed to impose itself as an accepted proliferative 
biomarker because of a lack of reproducibility and the difficulty to establish an 
appropriate cutoff (i.e. 10%, 14% and 20%) [45, 50, 282, 327-329]. Indeed, neither the 
ASCO nor the NCCN has included Ki-67 in its recommended list of routine breast cancer 
biomarkers [281, 330]. Furthermore, the IMPAKT 2012 working group pointed out that 
there was not enough evidence to support using a Ki-67 labeling index of 14% to identify 
clinically relevant subtypes of breast cancer [112]. In this context, it is undeniable that 
identification of a robust breast cancer proliferation marker would be of the utmost 
interest. MCM2, whose role in initiating DNA replication is now firmly established 
[283], appears to be an appealing alternative to Ki-67. 
MCM2 belongs to the mini-chromosome maintenance (MCM) proteins complex 
or pre-replicative complex, which consists of six highly conserved proteins (MCM2-
MCM7) collectively interacting to bring about initiation of DNA replication [334]. This 
complex is considered to be the converging point that connects the growth signaling 
pathways with the initiation of DNA replication [481]. MCMs are expressed in actively 
proliferating cells and non-cycling cells with proliferative potential [482]. Recently, it has 
been recognized that cancers arising in different anatomic sites such as stomach, colon 
and skin are associated with MCM2 overexpression [483-485]. Furthermore, recent 
reports are now ready to support the notion that MCM2 is a promising proliferative 
marker in many other types of cancer including thyroid, rectal and breast cancers [348, 
349, 351].  
In this study, we reasserted the expression of MCM2 and Ki-67 as they relate to 
breast cancers of different histological grades and molecular subtypes focusing primarily 
on ER-positive tumors. To achieve that aim, we first studied MCM2 and Ki-67 mRNA 
expression using in silico analysis on available DNA microarray and RNA sequencing 
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data of human breast cancer tissues. We next used immunohistochemical (IHC) staining 
to evaluate expression of MCM2, Ki-67 and a wide array of breast cancer biomarkers on 
tissue microarrays (TMAs) constructed from a cohort of 266 breast cancer patients. Our 
results indicate that both MCM2 and Ki-67 are highly expressed in breast cancer of high 
histological grades that comprise clinically aggressive tumors such as triple-negative, 
HER2-positive and luminal B subtypes of breast cancer. MCM2 expression was also 
found to express at higher levels than Ki-67 (p < 0.0001) in normal breast tissues, and in 
breast cancers of different histological grades and molecular subtypes. Notably, two 
distinct subgroups among hormonally responsive luminal breast cancer (ER+/HER2-) 
could be easily identified using a MCM2 threshold of 40% which is easier and 
convenient to use than the unyielding 14% index of Ki-67. Importantly, a bimodal 
frequency distribution of MCM2 scores could be conclusively demonstrated among 
luminal breast cancers. In brief, our data strongly support the notion that MCM2 
expression can help teasing out two clinically important subsets of luminal breast cancer 
whose treatment and clinical outcomes are likely to diverge. Evidently, an independent 
validation cohort is needed to confirm the clinical applicability of MCM2 to tailor breast 
cancer treatment. 
 
Material and methods  	  
In silico Analysis 
The web application bc-GenExMiner [415] was used for correlation analysis of 
MCM2 and MKI67 gene expression on a dataset comprising over 3,063 microarrays. 
However, using the criteria selected for this application, only 1260 microarrays could be 
positively ascribed to one of the five different molecular subtypes of breast cancer. Study 
into the differential expression of mRNA level of both MCM2 and MKI67 between 
different molecular subtypes of breast cancer was carried out on the same cohort of 
patients. Gene expression values were determined beforehand and split in order to define 
three equal groups (low, intermediate and high expression). This means that “high 
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expression” is the 1/3 of the patients with highest expression of MCM2 or MKI67 and 
“low expression” is the lower 1/3 of the patients. 
 To validate results obtained from bc-GenExMiner application, MiSTIC dataset 
(RNAseq data of 756 breast cancer patients) and The University of California Santa Cruz 
(UCSC) Cancer Genomics Browser (Gene expression array of 597 patients 
(AgilentG4502A_07_3 array)) were also used [486]. The heat map (Additional file 1) 
produced from the USCS cancer genomic browser displays the expression of different 
genes using distinct sets of colors, red representing data values > 0, green values < 0 and 
black value = 0. The "aov" and "TukeyHSD" functions were carried out to compare the 
mRNA levels within each breast cancer molecular subtype. The ANOVA was applied to 
check for an overall difference of expression levels between each molecular subtype. The 
Tukey multiple comparisons of means were used to test for a significant difference 
between two subtypes (e.g. luminal A vs. luminal B). For both tests, a p-value < 0.05 was 
considered significant. Pearson correlation coefficient between set of genes was 
calculated with the "cor.test" function of the R language and environment for statistical 
computing (http://www.R-project.org/).  
 
Patients and Tissue Samples  
A cohort of 266 female breast cancer patients comprising tumors of different 
histological grades was selected for the present study. Formalin-fixed, paraffin-embedded 
(FFPE) samples containing tumor tissues were collected after surgery (lumpectomy or 
mastectomy) (Table 4.1). Tumor grades were confirmed using the Modified Scarff-
Bloom-Richardson-Elston-Ellis grading system (SBR-EE) [444]. A complete set of 
follow-up data including the onset of relapse and death was available for review.  We 
also added 21 normal breast tissues from healthy women undergoing plastic surgery to 
serve as internal controls. Normal human brain was included as negative control for 
MCM2 [403]. In addition, a number of extraneous tissues such as colon, thyroid and 
placenta were included in each TMA. All samples were obtained from Centre Hospitalier 
de l’Université de Montréal (CHUM) after granting the approval of the research ethical 
committee (SL 05.019). Since all donor blocks remained anonymous no individual 
patient consent was required. 
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Table 4.1: Clinico-pathological data of tissues used in TMAs 
 
Variables No. of cores % 
Organs used in TMA 469   
Colon 3 0.64 
Lymph node 26 5.54 
Mammary gland 
• Normal breast tissue 
• In situ carcinoma 
• Benign breast tumors 
• Invasive breast cancer 
421 
21 
14 
6 
380 
89.77 
 
 
 
 
Placenta 1 0.21 
Rectum 12 2.56 
Thyroid 6 1.28 
Grade 355   
I 32 9.01 
II 63 17.75 
III 260 37.24 
Molecular subtypes 364   
Luminal A 108 29.67 
Luminal B 48 13.19 
HER2-positive 64 17.58 
Triple-negative 144 39.56 
 
 
 
 
 
Tissue Microarray (TMA)  
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Sections (4 µm) from each paraffin donor block were stained with hematoxylin 
and eosin (H&E) and examined by two independent pathologists. Core punches, 1mm in 
diameter, were plucked from representative areas contained within each FFPE tumor 
blocks. Each core was realigned in duplicate or triplicate into recipient blocks according 
to the intended design of the map using a Manual Tissue Arrayer I (Beecher Instruments). 
Blocks were next inverted and incubated overnight in the oven over a glass slide. TMA 
blocks were allowed to cool until they could easily detach from the glass slide. Tissue 
sections from each TMA were prepared and one slide from each block was stained with 
H&E to review the diagnoses and histological grades on all tissue samples. Additional 
representative sections from each block were submitted to IHC staining. 
 
Immunohistochemistry 
IHC assays were performed on FFPE tissues obtained from each TMA. These 
assays were carried out according to manufacturer recommendations on an automated 
immunostainer (Discovery XT system, Ventana Medical Systems, Tucson, AZ). IHC 
analysis of MCM2 (monoclonal; #12079, dilution 1/200, citrate buffer (sCC1), Cell 
signaling) was carried out. Specificity of the anti-MCM2 monoclonal antibody was 
confirmed using normal colonic mucosa [487] and normal cerebral cortex as positive and 
negative controls, respectively (Additional file 2), based on the expression data in the 
Human Protein Atlas database [14]. In addition, IHC analysis of estrogen receptor (ER; 
monoclonal, clone SP1, RTU, sCC1, Ventana Medical Systems), progestrone receptor 
(PR; monoclonal, clone 1E2, RTU, sCC1, Ventana Medical Systems), HER2 
(monoclonal, clone 4B5, RTU, sCC1, Ventana Medical Systems), Ki-67 (monoclonal, 
clone SP6, dilution 1/100, pretreated sCC1, BioCare medical) was carried out as 
previously described [488].   
 
Scoring of stained slides 
The scoring systems used for each antibody are listed in additional file 3. The 
expression of MCM2 and Ki-67 in breast epithelium was studied by calculating the 
percentage of positively stained nuclei [50, 344]. Two different approaches of scoring 
were used, a visual method using conventional light microscopy and computer-assisted 
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automated scoring method using Visiomorph©, Tissuemorph© Digital Pathology (DP) 
softwares. Visual scoring of MCM2 and Ki-67 staining reactions is labor-intensive, time 
consuming and is subjected to intra-observer and inter-observer variability. To increase 
reproducibility in the visual scoring system, evaluation was performed by two 
independent observers. Automated MCM2 and Ki-67 scorings were also carried out 
resulting in a much more rapid and accurate readout. Visiomorph© DP has the distinct 
advantage of leaving out stromal cells from the analysis retaining only cancer cells in the 
Region Of Interest (ROI). As for Tissuemorph© DP, it allows accurate counting of the 
positive and negative nuclei in the ROI. ER, PR, HER2 and Ki-67 were also used as 
surrogate markers to sub-classify breast cancers into different molecular subtypes as 
listed in additional file 4 [112, 421].   
 
Statistical Analyses 
All statistical analyses were carried out using XLSTAT 
(http://www.xlstat.com/en/) and different packages of the R language (http://www.R-
project.org/). The allocation of MCM2 and Ki-67 positive cases among different 
histological grades and molecular subtypes is depicted using boxplots and scatter plots 
for both visual and automated cell counts. The overall relationship between MCM2 and 
Ki-67 scores and both histological grades and molecular subtypes was evaluated using 
the chi-square test and Mann-Whitney test / Two-tailed test. Correlation analysis for IHC 
expression levels was carried out using the Spearman’s rho correlation coefficient for 
visual scores and Pearson correlation coefficient for automated score. Concordance of 
automated and visual scoring was also achieved using Intra-class Correlation Coefficient 
(ICC) [489].  
The Receiver-Operating Characteristic (ROC) curve was used to detect the 
optimal cutoff point, which simultaneously reached maximum sensitivity and specificity 
values for MCM2 score. This could be achieved only for the automated MCM2 scores. 
Using this cutoff point, continuous variables could then be treated as dichotomous 
variables (low and high MCM2 expression) [490]. Distribution of MCM2 and Ki-67 in 
luminal breast cancer was displayed using histograms. Kaplan-Meier plot was drawn to 
show the overall survival and survival after relapse for low and high levels of MCM2 
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expression. Cox regression was used for multivariate survival analysis. Statistical 
significance was considered with a p-value less than 0.05. 
 
Results 
 
MCM2 is highly expressed at the mRNA level in basal-like, luminal B and HER2-
positive but not luminal A breast cancer. 
The web application bc-GenExMiner was used to compare the mRNA levels 
within each breast cancer molecular subtype on a dataset comprising 1260 microarrays 
[415]. As shown in Figures 4.1A, 1B & additional file 1, basal-like, luminal B and 
HER2-positive breast cancers show higher expression of MCM2 and MKI67 mRNA 
levels in comparison with both luminal A and normal-like breast cancers (P < 0.0001). 
Notably, there is no overlap between individual boxes in the boxplot when luminal A 
were compared to luminal B breast cancers (Figure 4.1A & 1B). The percentage of 
patients with low, intermediate and high levels of MCM2 and MKI67 expression in each 
molecular subtype of breast cancer is depicted in figure 4.1C. In this microarray data set, 
74% of basal-like (total no. = 388), 62% of luminal B (total no. = 116) and 49% of 
HER2-positive (total no. = 103) breast cancer patients show high level of MCM2 mRNA 
expression. In contrast, only 7% of luminal A (total no. = 443) and 5% of normal-like 
(total no. = 210) breast cancer show high level of MCM2 mRNA expression. Similar 
figures were observed in the different molecular subtypes of breast cancer using MKI67 
mRNA expression data (Figure 4.1C).  
MCM2 was next correlated with MKI67 and ESR1 in breast cancers based on 
RNA-sequencing data derived from The Cancer Genome Atlas (TCGA). As predicted, a 
strong positive correlation could be detected between MCM2 and MKI67 (r = 0.73), 
whereas a negative correlation was observed between ESR1 and both MCM2 and MKI67 
(r = -0.33, r = -0.38 respectively) (Figure 4.1D). This close similarity between the in 
silico profiles of MCM2 and MKI67 prompted us to pursue assessment of MCM2 protein 
expression in breast carcinoma tissue microarrays along with cognate normal breast 
tissue.  
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High concordance between automated and visual scores 
After confirming MCM2 immune reactivity, sensitivity and specificity, we carried 
out high-throughput IHC reactions on TMAs comprising normal, benign and malignant 
breast tissues. Two different approaches were used to calculate the percentage of positive 
nuclei of MCM2 and Ki-67 in the stained sections, a visual scoring and an automated 
quantifying method. Intraclass Correlation Coefficient (ICC) was calculated to compare 
visual and automated scores and to evaluate their relative performance [489]. ICC was 
obtained for the 365 pairs of automated and visual scores of MCM2 and Ki-67. Our 
results demonstrated that ICCs for MCM2 automated versus visual scoring were 0.94 
(95% CI= 0.93-0.95, p < 0.0001) for single measures and 0.97 (95% CI= 0.96-0.97, p < 
0.0001) for average measures. ICCs for Ki-67 automated versus visual scoring were 0.90 
(95% CI= 0.87-0.91) for single measures and 0.94 (95% CI= 0.93-0.95) for average 
measures. Therefore, there is an excellent agreement (ICC > 0.90) between automated 
and visual scorings for both MCM2 and Ki-67 [489]. Taken together, our results suggest 
that both methods can be used to reliably assess MCM2 and Ki-67 expressions in breast 
cancer. 
 
A 40% index cutoff point can distinguish between two distinct subgroups of low and 
high expression of MCM2 in breast cancer 
A ROC curve was used to set the optimal cutoff point based on the continuous 
automated MCM2 data set. When the accuracy and the sum of sensitivity and specificity 
were taken into account, the optimal cutoff point corresponded to a value of 40%. Using 
this cutoff value, the sensitivity of MCM2 index was found to be 69% and specificity 
91%. We next evaluated the accuracy of the test by measuring the Area Under the Curve 
(AUC) as it provides clear indication on how well the ROC curve separates out the group 
being tested into two distinct subgroups. When our scores were considered, the 
approximate AUC was found to be 0.81 (p < 0.0001, 95% CI = 0.221–0.391). This 
implies that a 40% cutoff point can be considered a “good” discriminating value in 
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Figure 4.1: In silico analysis of MCM2 and MKI67 mRNA expression in PAM50 
molecular subtypes of breast cancer  
A) & B) Boxplots depicting higher levels of MCM2 and MKI67 mRNA levels in basal-
like, luminal B and HER2-positive breast cancers in comparison to luminal A and 
normal-like breast cancers (p-value <0.0001). Notably, there is no overlap between 
individual boxes when luminal A were compared to luminal B breast cancers. C) 
Representation from bc-GenExMiner database v3.0.A showing the number of patients 
with low, intermediate and high MCM2 and MKI67 expression in each molecular subtype 
of breast cancer. Elevated expression of MCM2 and MKI67 is present in basal-like, 
luminal B and HER2-positive breast cancer. D) Correlation diagrams using MiSTIC 
visualization tool to correlate MCM2 with MKI67 and ESR1 in breast cancers based on 
RNA-sequencing data derived from The Cancer Genome Atlas (TCGA). A strong 
positive correlation could be detected between MCM2 and MKI67 (r = 0.73), whereas a 
negative correlation is observed between ESR1 and both MCM2 and MKI67 (r = -0.33, r 
= -0.38 respectively). 
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separating low and high MCM2 expression levels [491]. In other words, tumors with 
scores ranging from 0-40% could be considered to have low MCM2 expression while 
those with scores exceeding 40% were considered to have high MCM2 expression. As for 
Ki-67, we maintained the canonical 14% threshold used in the literature [44, 50]. Of note, 
Cheang et al. used a similar approach to determine the cutoff of Ki-67 to distinguish 
luminal A from luminal B breast cancer [50]. 
 
Two distinct patterns of MCM2 expression were detected in normal breast tissues  
The majority (62%) of normal breast tissue samples exhibit MCM2 nuclear 
labeling in only a few scattered luminal cells lining the terminal duct lobular units (Figure 
4.2A). This pattern of expression was also found in 100% of normal breast tissues using 
Ki-67 (Figure 4.2B). However, as many as 36% of normal breast tissues demonstrated a 
strong MCM2 nuclear labeling in most if not all of the luminal cells lining the normal 
breast ducts (Figure 4.2C). Of note, there was no MCM2 or Ki-67 labeling neither in the 
myoepithelial cell layer nor in the surrounding stromal cells. Also, we never observed 
cytoplasmic or membranous staining in any of the labeled cells. Although a positive 
correlation could be established between MCM2 and Ki-67 scores in normal breast tissue 
(r = 0.45, p = 0.04), MCM2 was expressed at higher levels in normal breast tissue 
compared to Ki-67 (Mean difference between two scores = 40%, 95% CI = 22.21-56.94, 
P < 0.0001).  
 
Higher levels of expression of MCM2 are associated with breast cancers of high 
histological grades.  
The expression of MCM2 and Ki-67 was then examined in breast cancers of 
various histological grades. Based on the previously defined 40% cutoff, our results 
demonstrated that 97% of grade I breast cancer expressed low levels of MCM2. On the 
other hand, high levels of MCM2 expression were detected in 29% of grade II (p < 
0.0001) and 74% of grade III breast cancer (p < 0.0001) which is statistically significant 
when compared to grade I breast cancer (Figure 4.3A-D). We also found significantly 
higher levels of expression of Ki-67 in grade II (p < 0.014) and grade III breast cancers (p 
< 0.0001) in comparison to grade I tumors (Figure 4.3E).   
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Figure 4.2: Patterns of MCM2 and Ki-67 expression in normal breast tissue  
A) The majority (62%) of normal breast tissue samples displays nuclear labeling in only a 
few scattered luminal cells lining the terminal duct lobular units. B) All normal breast 
tissues labeled with Ki-67 have shown nuclear labeling in only a few scattered luminal 
cells lining the terminal duct lobular units. C) In contrast, 36% of normal breast tissues 
demonstrated a strong MCM2 nuclear labeling in most if not all of the luminal cells 
lining the normal breast ducts. There was neither MCM2 nor Ki-67 labeling either in the 
myoepithelial cell layer or in the surrounding stromal cells. Of note, we never observed 
cytoplasmic or membranous staining in any of the labeled cells. Magnification 20X 
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Figure 4.3: Overexpression of MCM2 is associated with high histological grade of 
breast cancer. 
A) Grade I, B) Grade II, C) Grade III breast cancer stained with MCM2 (upper panels), 
Ki-67 (lower panels). Overexpression of MCM2 and Ki-67 is associated with breast 
cancer of higher histological grade. Levels of MCM2 expression characteristically 
exceeded that of Ki-67 in different grades of breast cancers (pictures were taken from the 
same area of adjacent slides). D) Histograms displaying the percentage and number of 
patients with low and high MCM2 expression in breast cancer of different histological 
grade. Most of grade I breast cancer (97%) expressed low levels of MCM2. On the other 
hand, high levels of MCM2 expression were detected in 29% of grade II (p < 0.0001) and 
74% of grade III breast cancer (p < 0.0001) which is statistically significant when 
compared to grade I breast cancer. E) Histograms displaying the percentage and number 
of patients with low and high Ki-67 expression in different histological grade of breast 
cancer. Significant higher levels of Ki-67 expression in grade II (p < 0.014) and grade III 
breast cancers (p < 0.0001) in comparison to grade I tumors was also detected.  
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As far as the cellular localization is concerned, MCM2 and Ki-67 reactivity was 
restricted to the nuclei of cancer cells. Neither of the two markers was detected in the 
adjacent stromal cells. Again, levels of MCM2 expression in breast cancers exceeded that 
of Ki-67 (Mean difference between two scores = 25%, 95% CI = 20.12-29.54, P-value < 
0.0001) (Figure 4.3 A-C). As expected, we could find a positive correlation between 
MCM2 and Ki-67 in breast cancer of different histological grades (Grade I r = 0.69, 
Grade II r = 0.73, Grade III r = 0.91, p < 0.0001). We next addressed the question of Ki-
67 cell labeling variability and heterogeneity in tumors since this issue has been raised 
previously for different types of cancers [492, 493]. Among the 380 representative breast 
cancer cores that we analyzed for Ki-67 and MCM2, 20 cores (5.3%) show marked intra-
tumoral heterogeneity using Ki-67. Notably, MCM2 labeling in the same regions failed to 
show any significant degree of heterogeneity (Figure 4.4). 
 
Increased expression of MCM2 is associated with luminal B, triple-negative, and 
HER2-positive breast cancer 
To validate the results of the in silico analysis in breast tumors, we studied the 
expression of MCM2 and Ki-67 at the protein level in breast cancer of different 
molecular subtypes and assessed their respective cellular and subcellular localization. 
Molecular subtypes were operationally defined using the following four surrogate 
markers: ER, PR, HER2 and Ki-67 as shown in additional file 4 [112]. As shown in table 
4.2, 95% of luminal A breast cancer expressed low levels of MCM2 with only 5% 
showing high expression of MCM2. In contrast, high levels of MCM2 expression were 
detected in luminal B (79%, p < 0.0001), HER2-positive (81%, p < 0.0001) and triple-
negative (81%, p < 0.0001). As far as MCM2 is concerned, all subtypes display 
significant differences when compared to luminal A breast cancer (Figure 4.5A). 
Likewise, significant differences could be detected between Ki-67 expression in luminal 
B, HER2-positive and triple negative breast cancer (p < 0.0001) when compared to 
luminal A subtype (Figure 4.5B). As mentioned earlier, levels of MCM2 expression are 
significantly and consistently higher than those of Ki-67 for each molecular subtype. The 
mean difference between the two scores in luminal A subtype is 13.10% (95% CI = 0.01-
16.02, P-value < 0.0001), luminal B subtype is 18.98% (95% CI = 0.008-30.11, P-value 
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= 0.001), HER2-positive breast cancer is 24.99% (95% CI = 0.015-34.67, P-value < 
0.0001) and triple-negative breast cancer is 18.67 % (95% CI = 0.01-25.65, P-value < 
0.0001) (Figure 4.5C-F). 
In agreement with the in silico correlation analyses, we found a negative 
correlation between MCM2 and ER (r = -0.54, p < 0.0001) and MCM2 and PR (r = -
0.49, p < 0.0001) in breast cancer at the level of protein expression. In contrast, we could 
establish a positive correlation between MCM2 and Ki-67 in different molecular subtypes 
of breast cancer (luminal A r = 0.55 (p < 0.0001), luminal B r = 0.46 (p = 0.001), HER2-
positive r = 0.65 (p < 0.0001), triple-negative r = 0.62 (p < 0.0001)).  
 
MCM2 scores in luminal breast cancer follow a bimodal frequency distribution. 
Luminal A (108 patients) and luminal B (48 patients) breast cancer were defined 
by positive expression of ER and/or PR, lack of HER2 expression and 14% labeling 
index of Ki-67. As shown in figure 4.6, these subtypes are depicted in black for luminal 
A and in red color for luminal B tumors. The frequency distribution of MCM2 scores for 
all luminal breast cancer (156 patients) was carried out. It is worth mentioning that we 
could find a bimodal distribution of MCM2 scores in luminal breast cancer suggesting 
that MCM2 can separate out two distinct subgroups among hormonally responsive 
luminal breast cancers (Figure 4.6A). Indeed, among the 156 samples of luminal breast 
cancer, 70% showed scores ranging from 0 to 38.4% that represent luminal breast cancer 
with low proliferation. On the other hand, approximately 30% of patients showed MCM2 
scores ranging from 38.5-100% defining a class of luminal breast cancer endowed with 
high proliferation. This distribution pattern readily emphasizes the usefulness of a 40% 
threshold, which is very close to 38.4%, as a cutoff point to distinguish between MCM2 
high and low expression. When the same type of analysis was applied to Ki-67 scores 
using the same set of 156 luminal breast cancer tissue cores, we failed to observe a 
similar bimodal distribution in luminal breast cancers (Figure 4.6B).  
As shown in figure 4.6A, one can appreciate that some of the luminal A breast 
cancer, as defined by 14% index of Ki-67, are present in the area of MCM2 high 
expression while some of luminal B breast cancer, are found in the area of MCM2 low 
expression. Based on this observation, we tried to classify luminal breast cancer samples  
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Figure 4.4: Intratumoral heterogeneity for Ki-67 labeling but not for MCM2, in 
breast cancer tissues. 
Adjacent sections of the same breast cancer core stained with Ki-67 (on the left) and 
MCM2 (on the right). One observes conspicuous intratumoral heterogeneity for Ki-67 
(only half of cells display nuclear labeling). However, no such heterogeneity was found 
with MCM2 on adjacent section of the same core (most of the cells are labeled with 
MCM2. Magnification 5X 
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Figure 4.5: Overexpression of MCM2 is associated with triple-negative, luminal B 
and HER2-positive breast cancer 
A) Elevated levels of MCM2 expression were detected in luminal B, HER2-positive and 
triple-negative breast cancer. Significant differences (p < 0.0001) were detected between 
these three subtypes and luminal A breast cancer. B) Significant differences (p < 0.0001) 
could also be detected between Ki-67 expression in luminal B, HER2-positive and triple 
negative breast cancer when compared to luminal A tumors. C) Luminal A, D) Luminal 
B, E) HER2-positive, F) Triple-negative breast cancer stained with MCM2 (upper panel), 
Ki-67 (lower panel). Overexpression of MCM2 and Ki-67 is associated with luminal B, 
HER2-positive and triple-negative breast cancer. MCM2 expression is consistently higher 
than of Ki-67 expression in different molecular subtypes of breast cancer. (Pictures were 
taken from adjacent sections of the same punches). Magnification 20X (C-F) 
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Figure 4.6: A bimodal frequency distribution of MCM2 scores is detected in luminal 
breast cancer 
A) Frequency distribution analysis showing a bimodal distribution of MCM2 scores 
among luminal breast cancer. MCM2 labeling helps to distinguish two distinct subgroups 
in luminal breast cancers. Tumors with scores ranging from 0 to 38.4% are considered to 
represent tumors with low proliferative potential, while tumors whose scores are found to 
be between > 38.5-100% are considered to be tumors with high proliferative potential. B) 
When the same type of frequency distribution analysis was applied to Ki-67 scores, no 
such bimodal distribution pattern could be observed. 
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into luminal A and B based on the following criteria: luminal A (ER+, PR+, HER2-, 
MCM2 ≤ 40%), luminal B (ER+, PR+, HER2-, MCM2 > 40%). Our results indicate that 
if we were to apply a 40% index of MCM2 instead of 14% index of Ki-67 roughly 10% 
of tumors (15 out of 156) would have to be reclassified. 
 
High levels of MCM2 are associated with a shorter latency to relapse 
We next reviewed the clinical charts of 200 patients for the period extending from 
2000 to 2013, to sort out the association between MCM2 and Ki-67 expression with 
clinical relapse. Our results demonstrate that enhanced expression of both of MCM2 and 
Ki-67 are associated with a shorter latency to clinical relapse in a statistically significant 
manner. However, the association between MCM2 expression and relapse (p = 0.0003) is 
tighter than that of Ki-67 (p = 0.0458) (Figure 4.7 A&B). We next conducted univariate 
Cox regression analysis on our data to determine the role of a number of factors such as 
level of MCM2, histological grades, histological subtypes and molecular subtype on the 
incidence of relapse for our patients. Results of the univariate analysis confirmed the 
association of MCM2 overexpression with a higher risk of relapse (HR = 6.98, 95%CI = 
2.00-24.40, p-value = 0.002). Moreover, it shows that luminal A breast cancer has a 
significantly lower risk to develop relapse than HER2-positive breast cancer (HR = 0.11, 
95%CI = 0.02-0.56, p-value = 0.01) (Table 4.3).  However, no other factor was found to 
be significant in multivariate analysis. 
Likewise, the Kaplan-Meier overall survival (OS) curve obtained from the same 
cohort of patients showed no significant association between both MCM2 and Ki-67 
levels of expression and OS (Figure 4.7 C&D). The log-rank test demonstrated that the 
survival intervals are not significantly different in both groups at 5% level of 
significance, for MCM2 (p = 0.0631) and for Ki-67 (p = 0.453). It is interesting to note 
that the difference in survival after 5.76 years is almost 10% lower in patients with high 
MCM2 expression. The difference remains the same even after 10 years, indicating that 
patients who survive after 5.76 years maintain a constant risk of dying. Finally, no 
significant difference could be identified between survival after relapse (SAR) for 
patients having high and low levels of MCM2 (p = 0.0817) and Ki-67 expression (p = 
0.355). Univariate and multivariate analyses confirmed the association between triple-  
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Figure 4.7: High levels of MCM2 are associated with a shorter latency to relapse 
A) & B) Elevated levels of MCM2 and Ki-67 expression are associated with a shorter 
latency to clinical relapse. The association between MCM2 and relapse (p=0.0003) is 
tighter than that of Ki-67 (p= 0.0458). C) & D) No significant association between both 
MCM2 (p=0.0631) and Ki-67 (p=0.453) levels of expression and overall survival could 
be identified. 
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Table 4.3: Univariate Cox regression analysis of different factors that could affect 
OS, SAR and relapse. 
 
 Relapse Overall survival (OS) Survival after relapse (SAR) 
Parameters HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value 
MCM2: 
High 
6.98 2.00-
24.40 
0.002 2.43 0.77-7.64 0.128 2.43 0.75-7.35 0.14 
Molecular 
subtypes 
         
HER2-
positive 
Reference   Reference   Reference   
Luminal 
A* 
0.11 0.02-0.56 0.01       
Luminal B 0.94 0.27-3.22 0.92 0.87 0.25-2.97 0.82 0.97 0.28-3.31 0.96 
Triple-
negative 
0.89 0.30-2.60 1.12 0.23 0.07-0.78 0.0185 0.25 0.07-0.85 0.03 
HR= hazard ratio, CI= confidence interval. * No event occurred for Luminal A with OS 
and SAR 
 
 
Table 4.4: Multivariate Cox-regression analysis of different factors that could affect 
OS and SAR. 
 
 Overall survival (OS) Survival after relapse (SAR) 
Parameters HR 95% CI p-value HR 95% CI p-value 
MCM2: High 0.90 0.28-2.86 0.86 0.89 0.28-2.80 0.84 
Molecular subtypes       
HER2-positive Reference   Reference   
Luminal A*       
Luminal B 0.86 0.25-2.96 0.86 0.96 0.27-3.29 0.95 
Triple-negative 0.23 0.07-0.78 0.019 0.25 0.07-0.85 0.027 
HR= hazard ratio, CI= confidence interval, * No event occurred for Luminal A 
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negative breast cancer and risk of death (overall survival) (HR = 0.23, 95% CI=0.07-
0.78, p-value=0.0185) and survival after relapse (HR = 0.25, 95%CI=0.07-0.85, p-
value=0.03) in patients with high MCM2 expression. No other factors such as 
histological grades, histological subtypes and other molecular subtypes appeared to be 
significant in case of survivals (Tables 4.3&4). 
 
Discussion 
 
In the present study, we have compared the levels of expression of both MCM2 
and Ki-67 as a means to assess cellular proliferation in a large cohort of patients with 
breast cancer of different grades and different molecular subtypes. We also compared the 
prognostic value of these two markers in predicting the overall survival, incidence of 
relapse and survival after relapse. Our findings confirmed that both MCM2 and Ki-67 are 
highly expressed in higher histological grades tumors especially in clinically aggressive 
breast cancers such as triple-negative, HER2-positive and luminal B subtypes tumors. 
Importantly, in contrast to Ki-67, two distinct subgroups among luminal breast cancer 
(ER+/HER2-) could be easily detected using a MCM2 labeling index of 40%. 
Using TMAs comprising normal breast tissue and human breast cancers of 
different grades and subtypes, we found that MCM2 is present at higher levels than Ki-67 
both in normal breast tissue and in different types of breast cancer (mean difference 
between the two scores reaching 40% in normal breast tissue and 25% in breast cancer p 
< 0.0001). This is consistent with previous observations by others reporting higher 
expression of MCM2 when compared to Ki-67 in normal breast tissues and breast 
carcinoma [344, 494]. In our opinion this indicates that MCM2 labeling is able to detect 
subsets of proliferating mammary epithelial cells that cannot be detected by Ki-67 alone. 
This is in line with the findings of Lopez et al. [305] who confirmed that Ki-67 is 
completely absent in the initial G1 phase of the cell cycle. Alternatively, one might 
surmise that Ki-67 protein is present inside the cells but cannot be detected due to pre-
analytical condition such as fixation or because of altered biological properties of Ki-67 
such as conformational changes or stable interactions with other proteins [347].  
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The dual pattern of MCM2 expression in normal breast tissue is intriguing. 
Whereas 62% of normal breast tissues (n =21) show MCM2 nuclear labeling in only a 
few scattered cells lining the terminal duct units, a significant proportion  (36%) of 
normal tissues (n =21) display MCM2 expression in the vast majority of normal breast 
cells. The biological significance of these two sub-populations with distinct patterns of 
MCM2 expression is presently unknown and need further clarification. At this point, one 
can only hypothesize that the highly proliferative group reflects the state of hormonal 
stimulation in a given patient at the time of surgery. Whether or not it results in a higher 
susceptibility to neoplastic transformation is an unresolved question [495]. Clearly, more 
investigations are needed with larger cohorts of normal breast tissues and their follow up 
data to clarify this issue.  
Our results also indicate that both MCM2 and Ki-67 are highly expressed in 
breast cancer of higher histological grades. This is in agreement with Ali et al. who 
reported a significant correlation between proliferative markers including both MCM2 
and Ki-67 and breast cancer grades [496]. Our findings coming from both in silico 
analyses and immunohistochemistry also support the notion that Ki-67 and MCM2 are 
highly expressed both at the mRNA and protein levels in subgroups of triple-negative and 
HER2-positive as well as in luminal B subtypes of breast cancer [497-500]. Indeed, our 
data revealed that MCM2 expressed at higher levels than Ki-67 in aggressive molecular 
subtypes of breast cancer such as triple-negative, HER2-positive and luminal B breast 
cancer when compared to luminal A breast cancer. To our knowledge, there has been no 
previous report in the literature that specifically correlated MCM2 expression with 
individual breast cancer molecular subtypes.  
Based on Ki-67 labeling distribution, it has been previously proposed that ER-
positive breast cancer form a continuum rather than segregating into distinct subtypes 
[23]. Our data presented herein clearly challenge this interpretation showing that two 
distinct subgroups of hormonally responsive breast cancers (ER+/HER2-) can be 
identified based on the estimated percentage of MCM2 positive tumor cells using a 
threshold of 40% set in accordance with the ROC curve. Hence, ER+/HER2- tumors with 
MCM2 expression ranging from 0-40% are considered to be luminal breast cancer with 
low proliferative potential, while ER+/HER2- tumors with over expression of MCM2 
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(>40%) are considered to represent luminal breast cancer with high proliferative 
potential. The fact that we observed a convincing bimodal distribution of MCM2 in 
luminal breast cancer along with a recent gene expression study reporting that MCM2 but 
not Ki-67 belongs to a class of breast cancer genes with bimodal distribution [501] 
supports our views.  
Lastly, we sought to correlate the expression profiles of MCM2 and Ki-67 with 
clinical outcome characteristics such as survival rates and tumor relapse. Our results 
confirmed that overexpression of both markers is associated with shorter latency to 
clinical relapse. However, the association between MCM2 and relapse (p = 0.000347) is 
more tightly correlated than that of Ki-67 (p = 0.0458). Our data strongly support the role 
of Ki-67 and MCM2 as prognostic markers in breast cancer [50, 344]. One conceivable 
explanation to the poor outcome associated with high MCM2 expression is the flawed 
DNA replication licensing system, MCM2-MCM7, which leads to uncontrolled cell 
proliferation [502].  
There are many reasons to believe that MCM2 outperforms Ki-67 as a tool to 
assess cell proliferation in breast cancer. Firstly, in contrast to Ki-67, MCM2 can label all 
proliferative cells during the active phases of the cell cycle, disappearing only when cells 
are quiescent [503]. Moreover, Ki-67 labeled only a fraction of proliferating cells 
entering the G1 phase of the cell cycle for the onset of sustained Ki-67 expression occurs 
only in late G1 [305, 306]. Secondly, Ki-67 labeling (clone SP6, BioCare medical) 
suffers from both intra-and inter-sample heterogeneity as well as unpredictable changes 
in labeling intensity, a phenomenon that has not been observed to the same extent with 
MCM2 staining. One plausible explanation to the variability of Ki-67 staining may be 
related to the normal variation of Ki-67 concentration during different phases of the cell 
cycle with accumulation during G2 and S phases and a nadir during anaphase and 
telophase of the mitotic cycle [307-309]. One should also bear in mind that the half life of 
Ki-67 is estimated to be approximately 90 minutes followed by its rapid degradation 
[504]. Evidently, one does not expect such variability in staining intensity with MCM2 as 
it remains confined to the nuclei at all times exerting its function through reversible 
binding to the chromatin instead of undergoing alternating cycles of synthesis and 
degradation as Ki-67 [334]. Thirdly, the role of MCM2 in DNA replication is now firmly 
	  	  	  
	  	  
145	  
established, as eukaryotic cells cannot proliferate in the absence of MCM2 [334]. 
Although Ki-67 plays an important role in cell division its mechanism of action inside the 
cell is poorly understood [281]. Notably cells that are depleted of Ki-67, maintain a 
normal cell-cycle profile albeit their smaller nuclei [310].  
Even though we feel that the data presented in this paper are quite compelling, it 
is fair to say that there are a few intrinsic limitations to our study. Firstly, our definition 
of luminal A and luminal B tumors was based on the following surrogate markers; ER, 
PR, HER2 and 14% index of Ki-67. Assessment of MCM2 expression in these two 
groups defined by mRNA expression should clearly be performed as a follow-up study. 
Secondly, our results, including the scoring methods (visual and automated) and the 
proposed cutoff point, need to be validated on another independent cohort of patients. 
Thirdly, follow up data on a new set of patients is required to independently confirm our 
findings. Lastly, whole sections rather than TMA cores are needed to check on the 
robustness of MCM2 especially in regions found to be heterogeneous using Ki-67 
staining. 
 
Conclusion 
In conclusion, our results indicate that MCM2 outperforms Ki-67 as a 
proliferative and prognostic marker of breast cancer. Although Ki-67 revealed itself an 
independent prognostic marker, many practical issues are associated with its clinical use:  
tumor heterogeneity often observed in cancers, the unyielding 14% threshold, and the fact 
that some proliferating cells escape Ki-67 labeling. In contrast, MCM2 seems to 
overcome many of these shortcomings as it detects all proliferating cells including those 
that are not detected by Ki-67. It also provides similar or even better prognostic 
information more likely to be clinically applicable because of a more convenient to use 
40% cutoff point. It is our opinion that, MCM2 has the ability to classify ER+/HER2- 
breast cancer into two subsets of hormone sensitive tumors with diverging proliferative 
status. It is hoped that such defined subsets of tumors will facilitate the management of 
hormone sensitive breast cancers. 
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Additional materials 
Additional figures: 
 
Additional file 1: In silico analysis of MCM2, MKI67, ESR1 and PGR mRNA 
expression in PAM50 molecular subtypes of 597 breast cancers obtained from 
UCSC Cancer Genomics Browser 
The heat map exhibits the expression of MCM2, MKI67, ESR1 and PGR in different 
molecular subtypes of breast cancer. Red represents data values > 0, green represents 
values < 0 and black represents value = 0. MCM2 and MKI67 are highly expressed in 
basal-like, HER2-enriched and luminal B breast cancer while low levels of expression 
were detected in luminal A and normal-like subtypes. 	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Additional file 2: Validation of MCM2 antibody specificity for IHC studies. 
A) Normal human colonic mucosa showing an intense nuclear labeling of the epithelial 
cells lining the colonic glands after incubating the section with an anti-MCM2 primary 
antibody (positive control). B) Adjacent section from the same colonic tissue incubated 
with a non-immune serum (IgG same isotype/ same species) showing a complete lack of 
MCM2 labeling (negative control). C) Human cerebral cortex incubated with an anti-
MCM2 primary antibody showing complete lack of MCM2 expression (negative 
control). Magnification 40X	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Additional tables: 
Additional file 3: Immunohistochemical scoring systems 
 
Marker Subcellular 
localization 
Scoring 
system 
Total 
Score 
Criteria Results 
ER 
and PR 
 
Nuclei Allred 
score 
0-8 Sum of the proportion and 
average intensity scores of 
positive tumor cells 
Negative = 
0-2  
Positive = 
3-8 
HER-2 Membrane CAP-
approved 
scoring 
system 
0, 1+, 
2+, 
3+ 
0= No immunostaining or 
membrane staining which is 
incomplete or barely perceptible 
within ≤ 10% of the invasive 
tumor cells. 
1+= Incomplete membrane or 
barely perceptible staining within 
>10% of invasive tumor cells 
2+= Circumferential membrane 
staining that is incomplete and/or 
weak/moderate within >10% of 
the invasive tumor cells or 
complete membranous staining 
that is intense within ≤ 10% of 
the invasive tumor cells 
3+= Circumferential 
membranous staining that is 
complete and intense in >10% of 
tumor cells 
0-1+ are 
negative 
2+ is 
equivocal 
3+ is 
positive 
Ki-67 Nuclei % of 
positively 
0-
100% 
% of positively stained nuclei Ki-67 low = 
0-<14% 
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stained 
nuclei 
Ki-67 high= 
≥14-100% 
MCM2 Nuclei % of 
positively 
stained 
nuclei 
0-
100% 
% of positively stained nuclei MCM2 Low  
= 0-40% 
MCM2 
High  >40-
100% 	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Additional file 4: Classification of molecular subtypes of breast cancer based on 
IHC surrogate markers [112, 421]. 
 
Molecular subtypes  IHC expression of surrogate markers 
Luminal A ER positive and/or  
PR positive 
HER2 negative 
Ki-67 <14% 
Luminal B A. ER positive and/or  
       PR positive 
       HER2 negative 
       Ki-67 ≥14% 
B. ER positive and/or 
       PR positive 
       HER2 positive 
       Any Ki-67 
HER2-positive ER negative  
PR negative 
HER2 positive 
Any Ki-67 
Triple negative ER negative  
PR negative 
HER2 negative 
Any Ki-67 
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CHAPTER V 
Discussion  	  
During the past decade, pioneering unsupervised gene expression profiling studies 
on invasive breast cancers have identified different molecular subgroups with distinct 
patterns of gene expression: luminal A, luminal B, normal breast-like, HER2-positive and 
basal-like breast cancer [36]. Breast tumors of the luminal subtypes express genes 
characteristic of luminal epithelial cells whereas the basal-like breast cancers express 
genes that are normally found in normal basal and/or myoepithelial cells [36]. Amongst 
the two hormonally responsive tumors types: luminal A and luminal B tumors there are 
significant biological and clinical differences.  Indeed, it is known that luminal B breast 
cancer are associated with an overall worse prognosis than luminal A tumors, akin with 
two other notoriously aggressive breast cancers: HER2-enriched and basal-like subtypes [41,	   49]. Because of the lack of actionable therapeutic targets, basal-like breast 
carcinomas have been associated with a worse prognosis, higher rates of recurrence and 
shorter survival when compared to other types of breast cancer [64,	   66]. The high 
mortality rate of basal-like breast cancer is reflected by the higher incidence of visceral 
and brain metastases [65,	   505]. Lack of expression of the three main surrogate breast 
markers ER, PR and HER2 has been used to operationally define basal-like breast cancer 
also known as triple-negative breast cancer [22].  
During the past several years, it has become apparent that invasive breast cancers 
of similar clinical stage and histological grade may behave differently not only in terms 
of clinical outcome but also in their ability to respond to treatment [156]. This 
emphasizes the need for new prognostic biomarkers of breast cancer that can better 
stratify patients with breast cancers. The fundamental aim of the prognostic biomarkers is 
to give an idea about the behavior of the tumor, regardless of the type of treatment, such 
as its aggressiveness, probability of its recurrence and the risk of developing metastases 
with the highest possible sensitivity and specificity [126,	  135]. Our main hypothesis is 
that differential patterns of gene expression in breast cancer can help distinguish 
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subgroups of tumors with specific clinical outcomes and response to treatment. During 
the course of my doctoral studies, my aim has been to identify and characterize new 
biomarkers that could best define aggressive subtypes of breast cancer focusing primarily 
on triple-negative cancers. A second albeit related aim was to identify novel biomarkers 
that could help distinguish luminal A from luminal B breast cancer.  
To achieve those aims, I first conducted in silico analysis studies on available 
DNA microarray and RNA sequencing data of human breast cancer tissues and breast 
cancer cell lines. The in silico analyses helped us identify two types of genes: those that 
are differentially expressed in triple-negative breast cancer and those that are 
significantly associated with luminal B breast cancers but not with luminal A subtype 
(unpublished results, see Appendix IV). Evidently, we had to limit ourselves to the 
markers that appeared more robust or, at least, promising such as ANXA1, MMP-9 and 
DP103 for triple-negative breast cancer and MCM2 for luminal breast cancer. To that 
end, in silico analysis proved invaluable to study the expression of genes of interest found 
in different molecular subtypes of breast cancer and to correlate their expression with that 
of clinically relevant markers such as ER, PR and HER2. With this information at hand 
we constructed seven tissue microarrays (TMAs) from paraffin blocks containing human 
breast cancers and normal breast tissues obtained at surgery. We also thought fit to 
include cell microarrays (CMAs) from a panel of human breast cancer cell lines with 
varying degree of ER, PR and HER2 expression. In all cases, levels of protein expression 
were detected using automated immunohistochemistry and compared to that of other 
conventional breast cancer markers (ER, PR, HER2, Ki-67, CK 5/6, VIM, FOXA1). 
Lastly, our IHC assays were correlated with patients’ clinical data (metastasis, relapse 
and survival rates). All our aims and objectives were accomplished, with the scientific 
relevance and importance of our findings being discussed in each related chapter (II, III 
& IV).  However, in this discussion, I will focus on the main results of our biomarkers 
and discuss their clinical significance as potential biomarker in breast cancer. 
 
I. Novel biomarkers in triple-negative molecular subtype of breast cancer 
Differential expression of ANXA1 has been detected in normal human breast 
tissue and in breast cancers. ANXA1 expression is severely deregulated in high-grade 
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breast cancers with poor clinical outcomes. About half of the samples collected from 
patients with triple-negative and 10% of HER2-positive breast cancers had strikingly 
elevated levels of ANXA1 expression. Moreover, human triple-negative breast cancer 
cell lines expressed ANXA1 at significantly higher levels when compared to all other 
groups. This supports similar findings by Yom et al. who demonstrated that ANXA1 
expression was significantly correlated with hormone receptor negativity, HER2-
positivity and triple-negative breast cancers [379]. In addition, the association of 
ANXA1 with basal-like breast cancer, which is considered to be a subset of triple-
negative breast cancer, was further established using concomitant basal cytokeratin 
CK5/6. All in all, these results are in agreement with those of Perou et al. who 
demonstrated an association between the ANXA1 gene and basal subtype phenotype of 
breast cancer [36].  
Notably, we also demonstrated that ANXA1 expression is normally confined to 
the myoepithelial cell layer surrounding ducts and lobules present in normal breast tissue 
and in situ carcinomas. Again, our results are consistent with those of Ang et al. who 
reported a similar pattern of expression of ANXA1 in myoepithelial cells [359]. 
Although we were tempted to raise the possibility that basal-like breast cancer originate 
from myoepithelial cells, findings by Livasy et al. failed to support a myoepithelial origin 
for basal-like breast cancers as they completely fail to express other myoepithelial 
markers such as P63 and αSMA [100]. Furthermore, constitutive expression of ANXA1 
in myoepithelial cells provided a likely explanation for the high level of ANXA1 
expression found by in silico analysis in normal-like breast cancer subtype given the high 
degree of contaminating normal breast tissue in these tumor samples [426]. Of note, our 
results indicated a complete lack of ANXA1 expression in all luminal A and luminal B 
breast cancer tissue as well as luminal cell lines.  Taken together, these results indicate 
the ability of ANXA1 to dissect out subsets of high histological grades breast cancers and 
help provide a better understanding of breast cancer heterogeneity.  
Several studies have emphasized a potential role of ANXA1 in enhancing the 
EMT and increasing metastatic potential of breast cancer cells [374,	  425]. For example, 
de Graauw indicated that ANXA1 promotes metastasis development in basal-like breast 
cancer cells by enhancing TGFβ/SMAD signaling and actin reorganization [375]. Based 
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on in silico analysis and IHC, our results, suggested a positive correlation between 
ANXA1 and EMT associated markers including VIM, MSN and LYN. We therefore 
suspected a potential role for ANXA1 in enhancing EMT and breast cancer cell 
metastasis. However, to our surprise, others have shown that ANXA1 attenuates EMT 
and inhibits metastasis of breast cancer [108,	  376]. Further experiments are warranted to 
resolve this issue and explore the role of ANXA1 in breast cancer progression and further 
development of metastasis. 
Previous studies have established a role for MMP-9 in several key processes that 
contribute to breast cancer development and progression including cancer cell migration, 
invasion and metastasis [393,	  395-­‐400]. In line with recent studies by others, our results 
have demonstrated a significant increase in MMP-9 expression in breast cancer cells 
where compared to normal breast tissue. Notably, we have established that elevated 
levels of MMP-9 are closely associated with breast cancers of high histological grade, 
which has been supported by recent literature [506]. High level of MMP-9 was detected 
in 79.4% of triple-negative and 87.9% of HER2-positive breast cancer tissues and in all 
samples of lymph nodal metastases. Again, our results are in agreement with that of Zhao 
et al. who demonstrated that high MMP-9 expression is correlated with triple negative 
breast cancers [403]. Of note, La Rocca reported elevated serum level of MMP-9 in 
HER2-positive subtypes of breast cancers using gelatin zymography providing additional 
evidence on the role of MMP-9 [404].  
It is well documented that both triple-negative and HER2-positive breast cancer 
molecular subtypes are associated with aggressive behavior and high metastatic potential [55,	   507]. Our results provide strong evidence that increased expression of MMP-9 
contribute to breast cancer cell dissemination and poor clinical outcome. In our opinion, 
MMP-9 overexpression could help segregate subsets of aggressive breast cancer into 
more clinically meaningful subtypes. This is substantiated by our data confirming that 
overexpression of MMP-9 is tightly correlated with lymphovascular invasion, regional 
node metastasis, a shorter time to relapse and a reduced SAR. Interestingly, our findings 
are also supported by independent work by others who also established that up-regulation 
of MMP-9 is associated with metastasis, lymphatic invasiveness, poor prognosis and 
unfavorable clinical course of breast cancer [402,	   403,	   464]. Taken together, several 
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lines of investigations underpinned the contribution of MMP-9 in promoting breast 
cancer metastasis and collectively highlighted the clinical relevance of MMP-9 
overexpression in subsets of breast cancer. In addition, MMP-9 has been included among 
the MammaPrint® 70 genes panel, the first fully commercialized and FDA approved 
microarray-based multigene assay for breast cancer [272, 465]. Hence, we strongly 
believed that MMP-9 overexpression is sufficiently compelling to warrant clinical studies 
to validate its clinical utility as a breast cancer prognostic biomarker. Furthermore, one 
might consider including MMP-9 alone or in combination with other genes in the 
development of other multigene multiplex assays. 
 
II. Novel biomarkers to distinguish luminal A and luminal B molecular subtypes of 
breast cancer 
Estrogen receptor positive (ER+/HER2-) breast cancers comprise two distinct 
subtypes; luminal A and luminal B. Each of them differs from one another by clinical 
outcomes, biological characteristics such as proliferation and response to treatment [41,	  44,	  45]. Because Ki-67 assessment has raised a number of practical issues, it has failed to 
impose itself as a routinely utilized proliferative marker to discriminate between luminal 
A and luminal B molecular subtypes of breast cancer [45,	  50,	  281,	  282,	  327-­‐330]. Since 
cell proliferation is known to be the single most important parameter apart from ER, PR 
and HER2 in luminal breast cancers, there is a critical need for a robust and validated 
immunohistochemical assay to distinguish between luminal A and luminal B tumors. 
Interestingly, MCM2, whose role in DNA replication and cell proliferation is now firmly 
established, has been reported to be a promising proliferative marker in many different 
types of cancer [283,	  483-­‐485].  
Our results indicate that MCM2 is highly expressed in breast cancer of high 
histological grades that comprise clinically aggressive tumors such as triple-negative 
(81%), HER2-positive (81%) and luminal B (97%) subtypes of breast cancer. Our results 
confirm findings by Ali et al. who reported a significant correlation between MCM2 and 
Ki-67 in high-grade breast cancers [496]. However, to our knowledge, there has been no 
previous report in the literature that specifically correlated MCM2 expression with 
individual breast cancer molecular subtypes. In agreement with the work of others [344,	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494], our findings demonstrate that MCM2 is often expressed at significantly higher 
levels than Ki-67 in normal breast tissues and in breast cancers. We believe that MCM2 
labeling is able to detect subsets of proliferating mammary epithelial cells that cannot be 
detected by Ki-67 alone. Alternatively, one might assume that Ki-67 protein is present 
inside the cells but cannot be detected due to pre-analytical condition such as fixation or 
because of altered biological properties of Ki-67 such as conformational changes or 
stable interactions with other proteins [347]. 
During the course of our investigation on luminal (ER+/HER2-) breast cancers we 
found out a bimodal frequency distribution of MCM2 scores with regards to luminal 
breast cancers. This distribution pattern agrees with that of Bessarabova et al. who 
demonstrated that MCM2, but not Ki-67, was one of the bi-modally expressed genes 
based on published dataset of multiple microarray platforms [501]. Of note, two distinct 
subgroups among hormonally responsive luminal breast cancer could be easily identified 
using a 40 % index of MCM2.  
In our hands, MCM2 provided similar or even better prognostic information than 
Ki-67. On the one hand, an enhanced expression of both of MCM2 and Ki-67 were found 
to be associated with a shorter latency to clinical relapse in a statistically significant 
manner. Moreover, MCM2 expression and relapse is more tightly associated than with of 
Ki-67. On the other hand, high expression of MCM2 is associated with shorter overall 
survival than that of Ki-67 but neither of them reached statistical significance. The above-
mentioned findings support the results of two clinical investigations that stressed the 
potential role of Ki-67 and MCM2 as prognostic markers in breast cancer, which 
highlight the importance of extending the analysis of MCM2 on new cohorts of patients [50,	  344].  
The dual pattern of MCM2 expression in normal breast tissue is intriguing. 
Whereas 62% of normal breast tissues (n =21) show MCM2 nuclear labeling in only a 
few scattered cells lining the terminal duct units, a significant proportion (36%) of normal 
tissues (n =21) display MCM2 expression in the vast majority of normal breast cells. The 
biological significance of these two sub-populations with distinct patterns of MCM2 
expression is presently unknown and need further clarification. At this point, one can 
only hypothesize that the highly proliferative group reflects the state of hormonal 
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stimulation in a given patient at the time of surgery. Whether or not it results in a higher 
susceptibility to neoplastic transformation is an unresolved question [495]. Clearly, more 
investigations are needed with larger cohorts of normal breast tissues and their follow up 
data to clarify this issue.  
In the present work, we provided strong evidence that Ki-67 can be 
advantageously substituted by MCM2 to measure cell proliferation in breast cancer, as it 
seems to overcome many of Ki-67 shortcomings. Firstly, MCM2 can label all 
proliferative cells since it is present at all stages of the cell cycle and disappears only 
when cells become quiescent. Secondly, variability in staining intensity was minimal and, 
so far, no heterogeneity could be detected using MCM2 labeling. Lastly and more 
importantly, a bimodal distribution of MCM2 labeled luminal tumors could be observed 
using a 40% MCM2 threshold suggesting that one can readily distinguish two distinct 
groups of patients whose treatment and clinical outcomes are likely to diverge.  
The use of in silico analyses in our work was a powerful approach for identifying 
candidate biomarkers with potential clinical significance in breast cancer. In addition, 
combining IHC together with TMA was a very efficient high throughput methodology 
that helped us assess different biomarkers on a large number of tissue samples 
simultaneously. Using IHC can be considered as one of the most readily applicable 
techniques for routine clinical practice as it is already used for ER, PR and HER2. 
Furthermore, it has been validated in different studies that IHC define clinically and 
biologically relevant breast cancer subgroups comparable to that identified by gene 
expression profiling [110].  
However, many limitations have been reported with using IHC such as the 
technical reproducibility and the interpretation and quantifications of the obtained 
expression [108,	   109]. During our work, we tried to overcome these issues by 
standardization of various aspects of IHC techniques such as using comparable 
experimental conditions during slide preparations, automated IHC staining and whole 
slide scanning. Also, to reduce the subjectivity in interpreting and quantifying biomarker 
expression, we used two different scoring methods: a visual method using conventional 
light microscopy and a computer-assisted automated scoring method using Visiomorph© 
and Tissuemorph© Digital Pathology (DP) softwares. Although visual scoring of IHC 
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reactions is labor-intensive, time consuming and is subject to intra-observer and inter-
observer variability, two independent observers performed the evaluations to increase the 
reproducibility of this scoring system. Using the automated scorings resulted in a much 
more rapid and accurate readout. Of note, assessment of concordance between the two 
scoring systems to compare visual and automated scores and to evaluate their relative 
performance was carried out. Finally, determining the cutoff points of high and low 
expression was very tricky with the first biomarkers (ANXA1 and MMP-9). However, 
with MCM2 we tried to overcome this limitation by applying the ROC curve on the 
continuous automated scores to precisely detect the optimal cutoff point. 
That being said, there are still a number of shortcomings that we cannot ignore in 
our studies. Firstly, using TMA allowed us to study only small portions of tissues from 
carcinoma. Due to the heterogeneity of breast cancer, using only small cores of tissue 
may not accurately match the expression of certain biomarker or for that matter the 
proliferative activity of cancer cells. Although excellent concordance between TMAs and 
complete section has been reported [508], whole sections rather than TMA cores are 
required to check on the robustness of our biomarkers expression. Secondly, our 
definition of luminal A and luminal B tumors was based on the following surrogate 
markers: ER, PR, HER2 and 14% index of Ki-67. This is hard to reconcile with our work 
on MCM2 as we demonstrated that Ki-67 is not an ideal proliferative biomarker in breast 
cancer. Using DNA microarray analysis could be a good way to better determine 
different molecular subtypes of breast cancer. Thirdly, single antibody for each 
biomarker has been tested and we are not absolutely certain that our results would be 
similar using another panel of antibodies. Lastly, our results need to be validated on an 
independent cohort of patients to check on the robustness and reproducibility of our 
findings. 
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Conclusion 
Taken together, the experimental work presented herein revealed that ANXA1, 
MMP-9 and MCM2 are new biomarkers that can help dissect out subsets of aggressive 
breast cancer into clinically meaningful subtypes. Not only they can facilitate the 
identification and further characterization of unique and specific regulatory pathways, 
they also lead to a better understanding of the pathophysiological mechanisms involved 
in tumor progression and metastasis. If the clinical validity and utility of these markers 
can be confirmed on independent cohorts of breast cancer patients, they will have a 
significant impact on clinical practice and precision medicine. In conclusion, ANXA1, 
MMP-9 and MCM2 are valuable gene/protein candidates to be used alone or in 
combination with other genes in the development of a multi-gene panel or multiplex 
proteomic assay to predict clinical outcome. 
 
Perspectives 
This work emphasizes the need for further investigation into different molecular 
subtypes of breast cancer especially the aggressive subtypes. In addition, it highlights the 
importance of developing new prognostic biomarkers in breast cancer as this provides a 
more comprehensive picture of breast cancer heterogeneity and helps identify new 
targeted therapies specific for the different groups of breast cancer. Additional questions 
have been proposed to continue this work in the future including the following: 
 
A) Development of multiplex IHC-based proteomic assay: 
In the future, accurate breast cancer diagnosis and patient stratification will 
require the analysis of multiple biomarkers rather than the use of single gene assays [509].  The combined use of several markers such as ANXA1, MMP-9, MCM2 and 
DP103 may be a better tool than to use each candidate molecule individually in order to 
best stratify triple-negative breast cancers.  A new cohort of patients with complete 
clinical follow up data, should make it possible to determine the usefulness of assessing 
the combined expression of these biomarkers.  
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B) Future work for MCM2: 
Two important issues have been proposed to continue our work on MCM2; the 
first one concerns the possibility of using MCM2 expression to detect breast cancer 
recurrence instead of using the Oncotype Dx
 
® (RT-PCR based, Recurrence Score 
Assay). The second question revolves around the role of MCM2 expression in predicting 
clinical response in the context of neoadjuvant chemotherapy. To answer these questions, 
we need to construct new TMAs from a cohort of patients preferably those with ER+, 
node negative tumors that already had an Oncotype Dx assay and who are candidate for 
neoadjuvant chemotherapy. Follow up data (relapse, survival and metastasis) on this new 
cohort of patients should be available for review. Furthermore, DNA microarrays will be 
used to identify the luminal subtypes of breast cancer based on expression profile of a 
cluster of cell proliferation associated genes.  
MCM2 need to be further investigated in a new cohort of breast cancer patients by 
IHC to confirm the reproducibility of a 40% cutoff point. We also need to check on the 
MCM2 status on patients whose recurrence scores are available. Finally, we need to 
compare the expression of MCM2 in breast cancer tissues from the same patients before 
and after receiving neoadjuvant chemotherapy. 
 
c) Future work for other proliferative markers: 
By continuing the work on other proliferation associated markers already 
identified by in silico analysis (Appendix IV) it may be possible to develop a protein/s 
based assay, which precisely defines the proliferation status of breast cancer patients. 
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APPENDIX  
Appendix I: Panel of genes in MammaPrint assay (70-gene 
assay) [272]. 	  
Groups of genes Gene name Gene description 
Genes regulating 
cell cycle (15 
genes) 
CCNE2 
ECT2 
CENPA 
LIN9 
KNTC2 
MCM6 
NUSAP1 
ORC6L 
TSPYL5 
RUNDC1 
PRC1 
RFC4 
RECQL5 
CDCA7 
DTL 
Cyclin E2 
Epithelial cell transforming sequence 2 
oncogene 
Centromere protein A 
lin-9 homolog 
Kinetochore associated 2 
Minichromosome maintenance complex 
component 6 
Nucleolar and spindle associated protein 1 
Origin recognition complex, subunit 6 like 
TSPY-like 5 
RUN domain containing 1 
Protein regulator of cytokinesis 1 
Replication factor C 4, 37 kDa 
RecQ protein-like 5 
Cell division cycle associated 7 
Denticleless homolog 
Genes regulating 
cell growth and 
apoptosis  
(9 genes) 
ESM1 
IGFBP5 
FGF18 
SCUBE2 
TGFB3 
WISP1 
Endothelial cell-specific molecule 1 
Insulin-like growth factor binding protein 5 
Fibroblast growth factor 18 
Signal peptide, CUB domain, EGF-like 2 
Transforming growth factor, beta 3 
WNT1 inducible signaling pathway protein 1 
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TGFB3 
BBC3 
EGLN1 
Transforming growth factor, beta 3 
BCL2 binding component 3  
egl nine homolog 1 
Genes regulating 
cell proliferation 
(12 genes) 
FLT1 
HRASLS 
STK32B 
RASSF7 
DCK 
MELK 
EXT1 
GNAZ 
EBF4 
MTDH 
PITRM1 
QSCN6L1 
fms-related tyrosine kinase 1 
HRAS-like suppressor 
Serine/threonine kinase 32B 
Ras association (RalGDS/AF-6) domain 
family 7 
Deoxycytidine kinase 
Maternal embryonic leucine zipper kinase 
Exostoses 1 
Guanine nucleotide binding protein, alpha z 
polypeptide 
Early B-cell factor 4 
Metadherin 
Pitrilysin metallopeptidase 1 
Quiescin Q6-like 1 
Genes controlling 
cell invasion and 
metastasis 
(8 genes) 
COL4A2 
GPR180 
MMP9 
GPR126 
RTN4RL1 
DIAPH3 
CDC42BPA 
PALM2 
Collagen, type IV, alpha 2 
G protein-coupled receptor 180 
Matrix metallopeptidase 9 
G protein-coupled receptor 126 
Reticulon 4 receptor-like 1 
Diaphanous homolog 3 
CDC42 binding protein kinase alpha 
Paralemmin 2 
Genes controlling 
adaptation to 
unfamiliar 
microenvironment 
(7 genes) 
ALDH4A1 
AYTL2 
OXCT1 
PECI 
GMPS 
Aldehyde dehydrogenase 4 family, member 
A1 
Acyltransferase like 2 
3-oxoacid CoA transferase 1, nuclear gene 
encoding mitochondrial protein 
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GSTM3 
SLC2A3 
Peroxisomal D3,D2-enoyl-CoA isomerase 
Guanine monphosphate synthetase 
Glutathione S-transferase M3 
Solute carrier family 2, member 3 
Genes controlling 
angiogenesis 
(6 genes= 3 new 
+ 3genes 
mentioned before) 
FLT1 
FGF18 
COL4A2 
GPR180 
EGLN1 
MMP9 
fms-related tyrosine kinase 1 
Fibroblast growth factor 18 
Collagen, type IV, alpha 2 
G protein-coupled receptor 180 
egl nine homolog 1 
Matrix metallopeptidase 9 
Miscellaneous 
genes 
(16 genes) 
LOC100288906 
C9orf30 
ZNF533 
C16orf61 
SERF1A 
C20orf46 
LOC730018 
LOC100131053 
AA555029_RC 
LGP2 
NUM 
UCHL5 
JHDM1D 
AP2B1 
MS4 A7 
RAB6B 
Hypothetical protein LOC100288906 
Chromosome 9 open reading frame 30 
Zinc finger protein 533 
Chromosome 16 open reading frame 61 
Small EDRK-rich factor 1A 
Chromosome 20 open reading frame 46 
Similar to hCG1980668 
Hypothetical LOC100131053 
No significant similarity found 
Likely ortholog of mouse D11lgp2 
Neuromedin U 
Ubiquitin carboxyl-terminal hydrolase L5 
Jumonji C domain containing histone 
demethylase 1 homolog D 
Adaptor-related protein complex 2, beta 1 
subunit 
Membrane-spanning 4-domains, subfamily 
A, member 7 
RAB6B, member RAS oncogene family 	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Appendix II: Panel of genes in PAM50 Breast Cancer Intrinsic 
Classifier™ assay (50-gene assay) [276]. 	  
Gene name Gene description 
CDC6 Cell Division Cycle 6 
CDC20 Cell Division Cycle 20 
PGR Progesterone Receptor 
EGFR Epidermal growth factor receptor 
ESR1 Estrogen receptor 1 
MKI67 Marker of proliferation Ki-67 
UBE2T Ubiquitin-conjugating enzyme E2T 
BIRC5 Baculoviral IAP repeat containing 5 
NUF2 NUF2, NDC80 Kinetochore Complex Component 
TYMS Thymidylate synthetase 
MYBL2 v-myb avian myeloblastosis viral oncogene homolog-like 2 
CEP55 Centrosomal protein 55kDa 
MELK Maternal embryonic leucine zipper kinase 
ACTR3B ARP3 actin-related protein 3 homolog B 
NDC80 NDC80 kinetochore complex component 
RRM2 ribonucleotide reductase M2 
UBE2C Ubiquitin-conjugating enzyme E2C 
CENPF Centromere protein F 
PTTG1 Pituitary tumor-transforming 1 
EXO1 exonuclease 1 
ORC6L Origin recognition complex, subunit 6 
CCNE1 Cyclin E1 
CCNB1 Cyclin B1 
ANLN Anillin, actin binding protein 
KIF2C Kinesin family member 2C 
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MYC v-myc avian myelocytomatosis viral oncogene homolog 
PHGDH phosphoglycerate dehydrogenase 
CDH3 Cadherin 3 
MIA Melanoma inhibitory activity 
SFRP1 Secreted frizzled-related protein 1 
SLC39A6 Solute carrier family 39 (zinc transporter), member 6 
BAG1 BCL2-associated athanogene 
MAPT Microtubule-associated protein tau 
CXXC5 CXXC finger protein 5 
MLPH melanophilin 
BCL2 B-cell CLL/lymphoma 2 
MDM2 MDM2 oncogene, E3 ubiquitin protein ligase 
NAT1 N-acetyltransferase 1 
BLVRA biliverdin reductase A 
MMP11 Matrix metallopeptidase 11 
GPR160 G protein-coupled receptor 160 
FGFR4 Fibroblast growth factor receptor 4 
GRB7 Growth factor receptor-bound protein 7 
TMEM45B transmembrane protein 45B 
ERBB2 v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 
2 
KRT17 Keratin 17 
KRT14 Keratin 14 
KRT5 Keratin 5 
FOXA1 Forkhead box A1 
FOXC1 Forkhead box C1 	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Appendix III: DEAD-box helicase DP103 defines metastatic 
potential of human breast cancers 
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Abstract 
 
Despite advancement in breast cancer treatment, 30% of patients with early breast 
cancers experience relapse with distant metastasis. It is a challenge to identify patients at 
risk for relapse; therefore, the identification of markers and therapeutic targets for 
metastatic breast cancers is imperative. Here, we identified DP103 as a biomarker and 
metastasis-driving oncogene in human breast cancers and determined that DP103 elevates 
matrix metallopeptidase 9 (MMP9) levels, which are associated with metastasis and 
invasion through activation of NF-κB. In turn, NF-κB signaling positively activated 
DP103 expression. Furthermore, DP103 enhanced TGF-β–activated kinase-1 (TAK1) 
phosphorylation of NF-κB–activating IκB kinase 2 (IKK2), leading to increased NF-κB 
activity. Reduction of DP103 expression in invasive breast cancer cells reduced 
phosphorylation of IKK2, abrogated NF-κB–mediated MMP9 expression, and impeded 
metastasis in a murine xenograft model. In breast cancer patient tissues, elevated levels of 
DP103 correlated with enhanced MMP9, reduced overall survival, and reduced survival 
after relapse. Together, these data indicate that a positive DP103/NF-κB feedback loop 
promotes constitutive NF-κB activation in invasive breast cancers and activation of this 
pathway is linked to cancer progression and the acquisition of chemotherapy resistance. 
Furthermore, our results suggest that DP103 has potential as a therapeutic target for 
breast cancer treatment. 
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Introduction 
Breast carcinoma is one of the most common malignancies in women around the 
world. Mortality from breast cancer is almost entirely the result of invasion and 
metastasis of neoplastic cells from the primary tumors to distant organ sites [135, 433, 
510-515]; therefore, identifying genes involved in breast cancer metastasis is important. 
Since it is not possible to accurately predict the risk of metastasis in individual patients, at 
the present time, more than 80% of them receive adjuvant chemotherapy, but 
approximately 40% of the patients suffer relapse and ultimately die of metastatic disease. 
Cancer metastasis is a multistage process by which cancer spreads from the place at 
which it first arose as a primary tumor to distant locations in the body. These stages are 
interconnected through a series of adhesive interactions and invasive processes, including 
tumor angiogenesis, invasion, and colonization [437, 516-521]. Due to its heterogeneity 
and nature, mechanisms involving metastasis remain poorly understood. Degradation of 
the extracellular matrix (ECM) by matrix metalloproteinases (MMPs) [381, 522] is 
essential for almost every step in metastasis [453, 523]. It is now accepted that the strong 
and direct causal association of MMPs in breast cancers makes the inhibition of these 
enzymes a worthwhile strategy for impeding tumor metastasis. However, due to the 
multiplicity of MMPs and the widespread effects of their actions, inhibitors of MMPs 
have not been successful as anticancer agents. Indeed, there is a significant unmet need 
for identifying novel mechanisms to inhibit selective MMP functions in invading tumor 
cells. 
DP103 belongs to the family of DExD/H-box proteins, named after the signature 
Asp-Glu-Ala-Asp/His motif within the helicase domain [524-530]. The 824-aa DEAD-
box protein, DP103 (Gemin3, DDX20), was originally cloned and characterized as a 
component of the splicing machinery in concert with SMN, Sm, and other Gemin 
proteins [531-534]. DP103 is a transcriptional repressor for Egr2 in hind brain 
development [535] and forms a repressor complex with METS–PE-1 to silence 
transcription of Ets target genes involved in Ras-dependent macrophage proliferation and 
differentiation [530]. We have previously shown that DP103 transcriptionally represses 
the nuclear receptor SF-1 in a SUMO-dependent manner [527]. SUMOylation of SF-1 is 
mediated by PIASy, an E3 SUMO ligase, and this reaction is catalyzed in the presence of 
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DP103 as a cofactor. However, the role of DP103 as a cofactor in SUMOylation or other 
covalent modifications of cellular substrates and its involvement in cancer initiation or 
metastasis have never been explored. 
The NF-κB family of transcription factors comprises 5 structurally related proteins 
that form homo- and heterodimers through their highly conserved DNA 
binding/dimerization Rel homology domain [536]. Binding of NF-κB to IκB proteins 
maintains NF-κB in an inactive state [537]. Activation of NF-κB in normal cells is 
inducible and is a tightly controlled event. Upon stimulation, IκBs are phosphorylated by 
the IκB kinase (IKK) complex (consisting of IKK1, IKK2, and NEMO proteins) [538-
541]. IκB phosphorylation leads to its rapid proteolysis, thereby allowing NF-κB to 
function as a transcription factor. Temporally, IκBα is one of the first target genes that 
NF-κB activates very rapidly, and hence, this forms a feedback loop that shuts off the 
activity of NF-κB under normal circumstances. In many malignancies, including that of 
the breast, however, NF-κB is found to be constitutively activated [542-553]. Yet the 
molecular mechanism for such constitutive activation of NF-κB signaling in solid tumors 
is not clear. TGF-β–activated kinase-1 (TAK1), a member of the MAPK family, is a key 
regulator of signal transduction cascades, leading to the activation of the transcription 
factor NF-κB. Stimulation of cells with cytokines and microbial pathogens results in the 
activation of TAK1, which subsequently activates the IKK complex and MAPKs, 
culminating in the activation of NF-κB and AP-1, respectively [543, 544, 554-558]. 
TAK1 is recruited to the TNF-α receptor complex in an RIP-dependent manner following 
the stimulation of TNF-α receptor 1 and serves as a pivotal intermediate for IKK 
activation [543, 544, 548]. Apart from its critical role in immunity [559], wherein TAK1 
is mostly activated by membrane or cytoplasmic cues, TAK1 is also essential for NF-κB 
activation in response to DNA damage, which is initiated from the nucleus [550, 560]. 
Although hypothesized, overexpression of molecules such as IKK2 and TAK1 as likely 
causes of constitutive NF-κB apparent in most malignancies has not been documented, 
despite sequencing of several cancer genomes. 
In a search for markers of metastasis, we uncovered a molecule whose levels are 
upregulated in metastatic human breast cancers. Depletion of endogenous DP103 in 
invasive breast cancer cells led to decreased expression of matrix metallopeptidase 9 
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(MMP9) and impeded cell migration and invasion. Conversely, forced expression of 
DP103 in mammary carcinoma and non-malignant cells both in vitro and in vivo 
increased oncogenicity and the cells’ capacity to invade. Mechanistic studies showed that 
DP103 is a critical cofactor for TAK1-mediated activation of IKK2, the key NF-κB–
activating kinase in its activation loop. Hence, the observed effects of DP103 are mostly 
due its ability to activate NF-κB, an oncogenic transcription factor. Since a body of 
research indicates that TAK1-dependent NF-κB activation has a direct role in various 
aspects of cancer [543, 560], our identification of DP103 as the rate-limiting factor that 
mediates TAK1 signaling adds an important previously unidentified regulator that could 
be used as a drug target, since its levels specifically increase in cancer cells. Interestingly, 
NF-κB signaling also positively activates DP103 expression. Since levels of DP103 are 
limiting in normal cells, the existence of a tonic DP103–NF-κB– positive feedback loop 
in cancer cells could also explain how constitutive NF-κB activation is documented in 
most human cancers despite the absence of amplification of TAK1 or IKK2. 
 
Results 
Expression of DP103 is significantly upregulated in basal subtype human breast 
cancers.  
Recently, a study showed increased expression of DP103 in a protein microarray 
done on tissues from mantle-cell lymphoma patients [561]. This prompted us to explore 
the role of DP103 in breast cancer. Tissue microarray (TMA) slides consisting of 
invasive ductal carcinoma (IDC) cases from 399 patients and normal nonmalignant ductal 
tissues from 61 women were obtained from the Department of Pathology, Singapore 
General Hospital. Clinicopathological features are shown in Supplemental Table 1A 
(supplemental material available online with this article; doi:10.1172/JCI73451DS1). 
Typical DP103 staining in normal versus tumor samples is shown in Figure 1, A and B, 
respectively. Based on DP103 staining, the cut-off value for low or high expression of 
DP103 was scored as 0 and 1+ versus 2+ and 3+. As a result of tissue loss during 
immunohistochemical processing, 330 cases of IDC and 38 cases of normal 
nonmalignant ductal tissues could be evaluated. As shown in Supplemental Table 2A, all 
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38 normal tissues showed low DP103 expression, while a significantly higher proportion 
(267 out of 330 patients) of specimens showed high DP103 expression in the tumor cores 
(P < 0.001). These findings were further extended using another cohort from the 
Montreal University Health Centre (Supplemental Figure 1, A and B, and Supplemental 
Table 2D). Clinico-pathological features are shown in Supplemental Table 1C. Taken 
together, these data sets reveal that expression of DP103 is significantly higher in tumors 
(across ethnic groups and regardless of the source of patient material). 
To further delineate the expression profile of DP103 in various subtypes of breast 
cancer, 11 cohorts containing 1,325 breast tumors were collected and compiled from the 
NCBI’s Gene Expression Omnibus (GEO) (see Methods). These 1,325 tumors were then 
classified using Single-Sample Gene Set Enrichment Analysis (ssGSEA) [562] and breast 
cancer subtype signature from Prat et al. [4]. As shown in Figure 1C, DP103 expression 
is significantly higher in basal subtype (Mann-Whitney test, P = 4.88 × 10–11). No 
significant difference in DP103 expression in claudin-low and luminal B were seen, 
while luminal A, ERBB2, and normal-like subtypes showed significantly lower 
expression (Mann-Whitney test, P = 4.5 × 10–5; P = 0.0048; P = 0.0281, respectively). 
Consistent findings were seen on a validation data set (GEO GSE3494) not included in 
the 11 meta-analysis cohorts, where basal subtype had significantly higher DP103 
expression when compared against other subtypes (Mann-Whitney test, P = 1.09 × 10–4; 
see Supplemental Figure 1C). Since protein expression levels provide a more reliable 
quantification for function compared with mRNA quantification, as shown in Figure 1C 
and Supplemental Figure 1C, we then assessed protein expression of DP103 in the same 
2 cohorts by immunohistochemistry (IHC). In agreement with our microarray results, the 
highest protein expression of DP103 correlated with the basal subtypes (Supplemental 
Figure 1, D–H; Supplemental Table 2B, Singapore cohort; Supplemental Figure 1, I–M; 
and Supplemental Table 2E, Canada cohort). 
 
DP103 expression levels correlate with malignancy and with patient survival.  
We then analyzed DP103 expression in breast tumors using a multi-institutional 
“microarray meta-analysis cohort” with a sample size of 669 primary breast cancer cases 
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and found levels of DP103 to be significantly elevated in poorly differentiated grade 3 
tumors compared with those in well-differentiated grade 1 or 2 tumors (n = 669, P = 
0.008) (Supplemental Figure 1N). We also validated the microarray data in Supplemental 
Figure 1N by analyzing DP103 protein expression by IHC. Corroborating our microarray 
results was the finding that DP103 protein is significantly higher in high-grade IDC 
compared with low-grade IDC (Supplemental Figure 2, A–D; Supplemental Table 2C, 
Singapore cohort; Supplemental Figure 2, E–G; and Supplemental Table 2F, Canada 
cohort). 
Kaplan-Meier analysis using the cohort consisting of 399 patients (Supplemental 
Table 1A) revealed that high DP103 protein levels correlated with reduced survival. 
Patients with high DP103 expression (mean overall survival (OS), 132 months; n = 61) 
had significantly shorter survival (P = 0.010) compared with those with low DP103 
expression (mean OS, 149 months) (Figure 1D). In addition, analysis of survival after 
relapse (SAR) revealed that patients with high DP103 expression (mean SAR, 63 months; 
n = 61) had significantly shorter survival (P = 0.009) compared with those with low 
DP103 expression (mean, 116 months) (Figure 1E). To investigate whether a meaningful 
functional correlation between DP103 expression levels and increasing tumor malignancy 
does exist, we determined basal DP103 expression in an isogenic cell xenograft–derived 
MCF10 breast cancer progression model system [563-565] that included the 
immortalized breast epithelial cell line MCF10A (10A1), the premalignant MCF10AT 
(AT1k), low-grade MCF10CA1h (CA1h), and high–metastatic grade MCF- 10CA1aCl.1 
(CA1a) cell lines (Figure 1F). We found that DP103 protein (Figure 1G) and mRNA 
(Figure 1H) levels directly correlated with increasing invasive potential of these cell 
lines, with the highest levels of DP103 expression observed in the most metastatic CA1a 
cells (Figure 1, G and H). 
 
DP103 expression correlates with metastasis gene signatures and breast cancer 
metastasis.  
A recent US patent application on the use of compounds that block cancer 
metastasis showed DP103 (DDX20) as the only DEAD-box helicase member listed in the 
microarray data (publication number: US 2010/0004190 A1; ref. [566]), thereby  
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Figure 1. DP103 levels correlate with invasiveness and malignancy.  
DP103 staining of (A) normal ductal tissue and (B) an IDC. (C) Gene expression value of 
DP103 (y axis) plotted for each breast cancer subtype, namely basal, claudin-low, 
luminal-A, luminal-B, ERBB2 (HER2+), and normal-like. (D) Kaplan-Meier curves 
showing DP103 expression in relation to patients’ OS. Cases that have not experienced a 
positive event are censored at the date of last follow-up (small vertical lines on the line 
plots). (E) Kaplan-Meier curves showing DP103 expression in relation to SAR. Cases 
that have not experienced a positive event are censored at the date of last follow-up 
(small vertical lines on the line plots). (F) Breast cancer progression model showing 
isogenic cell lines with increasing invasive potential. (G) Western blotting with DP103 
antibody in lysates from the isogenic cell lines (F). (H) qPCR with DP103 mRNA 
expression in RNA from the isogenic cell lines (F). (I) Gene expression of DP103 
correlates with breast metastasis activity by Spearman correlation [65]. Red dotted line is 
curve fitted by linear regression. (J) Primary breast tissues from patients with benign 
disease, no lymph node metastases (Non-Met), and lymph node metastases (Met) 
collected and analyzed for DP103 mRNA expression **P < 0.01; ***P < 0.001. (K) RNA 
from breast cell lines and qPCR performed with DP103 primers. (L) Protein from breast 
cell lines extracted and levels of DP103 protein evaluated. Fold difference in protein 
expression indicated in G and L. 
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encouraging us to determine whether expression of DP103 correlates to the metastatic 
potential of tumor cells. Using breast cancer metastasis signature from Zucchi et al. 
[567], we employed ssGSEA to estimate the degree of cancer metastasis for breast 
tumors. Figure 1I shows a strong positive correlation in the meta-analysis cohort for 
breast cancer metastasis with DP103 expression (Spearman ρ = 0.21, P = 7 × 10–15), 
suggesting that DP103 may have a role in breast cancer metastasis. From this metastasis 
gene signature list [567], the association of the 2 most positively correlated metastasis 
genes, HMGB1 and H2AFZ, to expression of DP103 was then validated by quantitative 
PCR (qPCR) in a cohort of 63 breast cancer and 22 benign breast tissue samples derived 
from 85 patients who underwent surgery at the First Affiliated Hospital of Anhui Medical 
University, Hefei, China (Supplemental Figure 2, H and I). Clinicopathological status of 
this cohort is provided in Supplemental Table 1D. In this cohort, we then assessed 
whether expression of DP103 alone is predictive for lymph node metastasis. This analysis 
mirrored our gene expression analysis from above in that DP103 expression was lower in 
primary breast tissues that did not develop lymph node metastasis, while increased 
DP103 levels were observed in primary breast cancer tissues of patients who developed 
lymph node metastasis (Figure 1J). Benign breast tissue samples that were used as a 
reference demonstrated the least DP103 expression levels (Figure 1J). The role of DP103 
in metastasis gained further credence by its listing in microarray data done on colorectal 
cancer (CRC) patients’ tissues (n = 100), comparing gene expression profile in primary 
tumors with and without distant metastasis. When retrieved (ArrayExpress E-GEOD-
18105), DP103 was found to be upregulated in CRC patients that developed distant 
metastasis (n = 100; P < 1 × 10–10). These results then encouraged us to screen a panel 
of breast cancer cell lines for DP103 expression. Interestingly, cell lines that are highly 
metastatic, such as MDA-MB-231 and BT549, display high levels of DP103 mRNA 
(Figure 1K) and protein (Figure 1L). On the other hand, non- invasive SKBr3, MCF7, 
and BT474 cells have much lower DP103 expression; while normal breast cells MCF10A 
and 184A1 have the lowest DP103 expression. 
 
Suppression of DP103 decreases migratory ability of breast cancer cells.  
To evaluate the functional consequence of DP103 expression in breast cancer 
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metastasis, we assessed cells’ migratory behavior following RNAi-mediated knockdown 
of DP103 in metastatic MDA-MB-231 cells. To exclude off-target effects, we performed 
these assays using 2 independent siRNAs against DP103 (Supplemental Figure 3A) either 
singly or in combination. DP103 depletion led to decreased migration (by 40%) when 
siDP103#1 and siDP103#2 were used alone or (by 80%) when they were used together 
(siDP103 #1+2) (Figure 2, A and B) in a classical wound- healing assay. These 
observations were further confirmed by using a 2D nonwound migration assay 
(Supplemental Figure 3B). The 2D track plots of the cells are depicted in Supplemental 
Figure 3C, which shows reduction in cell motility, with the left panels showing cells 
transfected with control siRNA and the right panels showing cells transfected with 
siRNA against DP103. The top panels show the entire tracks made by the 50 cells, while 
the bottom panels show the ending points of each cell track (Supplemental Figure 3C). 
The data of individual cell tracks from this assay were then analyzed for various cell 
migration parameters, as shown in Supplemental Figure 3D. Accumulated distance is an 
indicator of motility of individual cells, whereas Euclidean distance gives an idea about 
the actual dispersion of the cells with respect to their starting positions. Confinement ratio 
is an indicator of directionality of the cells over time. In summary, we concur that 
suppression of DP103 affects the intracellular motility mechanisms in MDA-MB-231 
cells but not the directionality of motion (Supplemental Figure 3D). 
 
Suppression of DP103 decreases invasive ability of breast cancer cells.  
Given that DP103 is upregulated in invasive breast cancer cells, we next explored 
effects of decreasing DP103 expression on tumor cell invasion by the use of Matrigel-
coated Transwell chambers. In highly invasive MDA-MB-231 and BT549 cells, transient 
knockdown of DP103 resulted in about 50% less invasion through the Matrigel-coated 
inserts (Figure 2, C–E). The combined use of siDP103 resulted in about an 80% decrease 
in invading cells (Fig- ure 2, C–E). To mimic in vivo conditions as closely as possible, 
we then monitored luciferase-expressing MDA-MB-231 cells with and without 
suppression of DP103 expression using a 3D collagen gel assay. siDP103 reduced cells’ 
invasiveness in 3D collagen hydrogel; notably, the spread of green tracks (ctsi) surpassed 
that of red tracks (siDP103) (Supplemental Figure 4A). Cell speed of the knock- down 
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cells was also averaged over each track and plotted into a histogram (Supplemental 
Figure 4B). As an additional indicator of invasive potential, MDA-MB-231 cells 
characteristically induce a branching morphogenesis. Interestingly, we observed a loss of 
this branching morphogenesis and reduction in cell spreading in cells depleted of DP103 
expression (Supplemental Figure 4C). 
 
Ectopic expression of DP103 enhances cell invasion.  
Induction of tumor cell invasion is an important step in tumor metastasis and 
transition to a more malignant form of cancer at distant sites [6]. To further substantiate 
our findings, we then evaluated whether ectopic expression of DP103 would result in 
altered invasion by noncancer cells. Ectopic expression of DP103 alone had a dramatic 
effect on the phenotypic conversion of the MCF10A normal human breast epithelial cell 
line, increasing its invasion potential by 4-fold (Figure 2, F–H). In addition, forced 
overexpression of DP103 in MDA-MB-231 cells (Supplemental Figure 4, D–F) 
significantly promoted cells’ invasive capacity. To validate these findings in vivo, we 
injected luciferase-expressing MDA-MB-231 cells stably transfected with either empty 
vector (MDA-MB-231-EV) or DP103 plasmid (MDA-MB-231-DP103) in the mammary 
fat pads of nude mice. Supplemental Table 3 compares the incidence of pulmonary and 
liver metastases at necropsy from primary tumors formed by the 2 breast cancer cell 
lines. Of 12 mice inoculated with MDA-MB-231-EV, only one was found to have lung 
and liver metastases by bioluminescence imaging. In contrast, 4 out of 11 mice injected 
with MDA-MB-231-DP103 cells developed distant metastasis to lung and liver 
(Supplemental Table 3). Figure 2I shows the ex vivo images of the lung and liver lobes 
from all mice that developed distant metastasis.  
We validated differences in protein expression levels of DP103 in primary tumors 
of MDA-MB- 231-EV cells versus MDA- MB-231-DP103 cells by IHC (Figure 2J). In 
addition, we also quantified distal metastasis in lung and liver tissues by qPCR (human 
GAPDH gene expression normalized to mouse Gapdh gene expression). Our results show 
a 2-fold increase in distal metastasis to lung (Figure 2K) and liver (Figure 2L) in the 
MDA-MB-231-DP103 mouse group compared with the MDA-MB- 231-EV mouse 
group. Taken together, mice injected with MDA- MB-231-DP103 had higher incidence  
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Figure 2. DP103 regulates invasive abilities of cancer cells.  
(A) MDA- MB-231 cells transfected with control siRNA (ctsi) and 2 different siRNAs 
against DP103. Scratch wound healing assay is shown. (B) MDA-MB-231 cells 
represented in percentage of siDP103 or ctsi cell movement after scratching. *P < 0.05. 
(C) MDA-MB-231 and BT549 cells transfected with control siRNA (ctsi) and 2 different 
siRNAs against DP103 in Transwell assays. Inset shows representative photograph. (D) 
Quantification of MDA-MB-231 cells invaded through Transwell invasion chambers 
from C. *P < 0.05. (E) Quantification of BT549 cells invaded through the Transwell 
invasion chambers from C. *P < 0.05. (F) MCF10A cells transfected with control 
pcDNA3 vector (EV) and pcDNA3-FLAG-DP103 (DP103). Cell extracts immunoblotted 
with anti-DP103 and anti–β-actin antibodies. (G) MCF10A cells transfected as in F and 
analyzed in an invasion assay as in C. (H) MCF10A cells that invaded through the 
chambers quantified and represented. *P < 0.05. (I) Pulmonary and liver metastases from 
primary tumors evaluated by bioluminescence imaging. Color scale depicts photon flux 
(p/s) emitted from the organs. (J) Left: DP103 expression in primary tumor injected with 
empty vector–transfected MDA-MB-231 cells (MDA- MB-231-EV). Right: DP103 
expression in mouse mammary fat pad injected with DP103-transfected cells (MDA-MB-
231-DP103). (K) Distal metastasis to lung tissues quantified by mRNA levels of human 
GAPDH. *P = 0.05. (L) Metastasis to liver tissues quantified by mRNA levels of human 
GAPDH. *P = 0.05. Fold difference in protein expression indicated in F. Original 
magnification, ×10; ×40 (insets). 
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of lung and liver metastases than mice injected with MDA-MB-231-EV. 
 
MMP9 levels predict survival and strongly correlate with DP103 levels in breast 
cancer.  
Cell invasion requires the complex coregulation of cytoskeletal reorganization and 
cell motility as well as proteolysis and interaction with the ECM. Therefore, we measured 
expressions of several such genes in a “metastasis qPCR array” (Table 1). While ectopic 
expression of DP103 did not change the expression of genes such as NME1, PLAU, 
SERPINB5, or MTA1, it led to upregulation of several other genes, such as MMP1, 
TIMP1, and TIMP3. MMP9 mRNA levels were increased significantly (Table 1). Since 
high MMP9 expression is closely associated with poor prognosis in other cancer types 
[568-570], we stained tissues from the same cohorts used in Supplemental Table 1, A and 
D, for MMP9 protein expression. Similarly to expression of DP103, we observed high 
expression of MMP9 in breast tumor tissues compared with normal breast tissues (Figure 
3, A and B, and Supplemental Table 4A, Singapore cohort; Supplemental Figure 5, A and 
B, and Supplemental Table 4B, Canada cohort).  
Kaplan-Meier analysis showed that high MMP9 levels were correlated with higher 
tumor recurrence risk and reduced survival. Similarly to DP103, MMP9 status correlated 
with OS, with high expression (mean OS, 132 months; n = 69) showing significantly 
shorter survival duration (P = 0.002) compared with low MMP9 expression (mean OS, 
150 months) (Figure 3C). Furthermore, cases with high MMP9 expression have shorter 
SAR (mean, 66 months; n = 69) and significantly shorter survival (P = 0.028) compared 
with those with low MMP9 expression (mean, 118 months) (Figure 3D). Having 
observed similar clinical significance for DP103 and MMP9, we then analyzed to 
determine whether there is a positive correlation between these 2 markers. Supplemental 
Table 4, C and D, indeed showed a strong positive clinical correlation between 
expression of DP103 and MMP9 (P < 0.001 in both cohorts). To further substantiate this 
finding, we next investigated whether a similar correlation between DP103 and MMP9 
expression existed in the cohort from Supplemental Table 1D. Importantly, much like 
DP103, the highest levels of MMP9 were found in primary breast tumors that showed 
metastasis compared with nonmetastatic or benign tumors (Figure 3E). Importantly, the 
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correlation between DP103 and MMP9 expression was statistically significant (P < 
0.001) (Supplemental Figure 5C) a trend that was also observed (Supplemental Figure 
5D) in data obtained from the same microarray consisting of the 11 meta-analysis cohort 
used above (Figure 1C). 
 
 
Table 1: Metastatic qPCR array 
 
Gene Gene name Fold change 
(± SD) 
P value 
MTA2 Metastasis associated gene 2 1.173883 (±0.023156) 0.1418 
NME1 Nucleoside diphosphate kinase A 0.935731 (±0.022723) 0.8644 
PLAU Urokinase-type plasminogen activator 1.089051 (±0.231132) 0.2914 
MET Hepatocyte growth factor receptor 1.458452 (±0.040862) 0.0036 
PLAUR Urokinase-type plasminogen activator receptor 1.154275 (±0.026637) 0.0499 
MMP1 Matrix metalloproteinase 1 1.88218 (±0.165944) 0.0445 
SERPINB5 Serpin peptidase inhibitor,clade B member 5 1.040501 (±0.335911) 0.5561 
MMP2 Matrix metalloproteinase 2 0.80275 (±0.110911) 0.6882 
SERPINE1 Serpin peptidase inhibitor, clade E member 1 0.845209 (±0.218096) 0.5754 
MMP9 Matrix metalloproteinase 9 2.668643 (±0.000182) 0.0026 
TIMP1 Metallopeptidase inhibitor 1 1.535293 (±0.062558) 0.0043 
MTA1 Metastasis associated gene 1 1.225943 (±0.067582) 0.0387 
TIMP3 Metallopeptidase inhibitor 3 1.659162 (±0.224292) 0.0372 
Effects of ectopic expression of DP103 in breast cancer cells. RNA from BT549 stably 
transfected with either empty vector or DP103 was extracted and qPCR was performed 
with various primers. Results are represented as fold change in mRNA levels in BT549-
DP103 cells relative to the control cells. Fold change values are representative of 3 
independent mRNA replicates. Values less than 1 indicate decreased expression and more 
than 1 indicate increased expression of the specific mRNA. Values more than 2-fold 
changes are indicated in bold. 
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Figure 3. DP103 regulates MMP9 expression and function.  
MMP9 staining of (A) normal ductal tissue and (B) IDC. (C) Kaplan-Meier curves of 
MMP9 expression in relation to OS. Cases that have not experienced a positive event are 
censored at the date of last follow-up (small vertical lines on the line plots). (D) Kaplan-
Meier curves of MMP9 expression in relation to SAR. Cases that have not experienced a 
positive event are censored at the date of last follow-up (small vertical lines on the line 
plots). (E) Primary breast tissues from patients with benign diseases, no metastases, and 
displaying metastases analyzed for MMP9 mRNA expression. **P < 0.01; ***P < 0.001. 
(F) Total RNA of different breast cell lines extracted and qPCR performed with MMP9 
primers. (G) MDA-MB-231 and BT549 cells were transfected with control siRNA (ctsi) 
and siRNA against DP103. Total RNA analyzed for mRNA expression of DP103 and 
MMP9. (H) Expression of DP103 and MMP9 in cells used in G, evaluated using DP103 
and MMP9 antibodies. (I) Suppression of DP103 in BT549 cells decreases MMP9 
activity. Enzymatic activity of MMP9 was determined by gelatin zymography. 
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Suppression of DP103 expression decreases MMP9 gene expression.  
We then screened for MMP9 expression in the panel of breast cell lines used in 
Figure 1K. We found that, mirroring the expression of DP103, metastatic breast cancer 
cell lines MDA-MB-231 and BT549 displayed the highest levels of endogenous MMP9 
mRNA expressions, while the nonmetastatic and normal breast cell lines displayed 
relatively low levels (Figure 3F). In addition, we observed that MMP9 mRNA expression 
positively correlated with DP103 mRNA expression across a panel of cell lines (Pear- 
son coefficient = 0.913) (Supplemental Figure 5E). Given the strong correlation observed 
between DP103 and MMP9 expression levels, we probed for a causal link between these 
enzymes. Transient knockdown of DP103 resulted in a significant decrease in MMP9 
mRNA levels at 24 hours and 48 hours compared with cells transfected with a scrambled 
siRNA (ctsi) in MDA-MB-231, BT549 (Figure 3G), and Hs578t cells (Supplemental 
Figure 5F). Decrease in MMP9 mRNA corroborated well with an observed drop in 
MMP9 protein levels (Figure 3H and Supplemental Figure 5G) and enzyme activities 
(Figure 3I) without affecting cell viability (Supplemental Figure 5, H and I). Conversely, 
ectopic expression of DP103, much like what is seen in cancer tissues, resulted in 
increased MMP9 expression in both malignant MDA-MD-231 and nonmalignant 
MCF10A cells (Supplemental Figure 6A). 
 
MMP9 mediates effects of DP103 in invasiveness.  
In order to ascertain whether MMP9 is the primary molecular effector of the 
observed effects mediated by DP103, we evaluated invasion of MDA-MB-231 in a 
Transwell assay using a pan-MMP inhibitor (GM6001), a MMP2/9 inhibitor (SB-3CT), 
and a selective inhibitor of MMP9 (MMP9 inhibitor I). We found that inhibition by either 
GM6001 or SB-3CT prevented invasion of MDA-MB-231 cells through the Matrigel 
matrix by 40% (Supplemental Figure 6, B and C). More importantly, we found that 
specific inhibition of MMP9 activity alone was sufficient to significantly (~50%) impede 
the invasion of MDA-MB-231 cells either with basal or ectopic expression of DP103 
(Supplemental Figure 6D), which suggests MMP9 is the key molecular effector 
mediating effects of DP103 seen in our experiments and in clinical settings. MMPs are 
known to play roles not only in metastatic progression, but also in tumor initiation and 
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formation [571], thereby suggesting that DP103-mediated regulation of these enzymes 
may have wide- spread implication in cancer initiation and progression. Indeed, although 
there was no difference in tumor size between control and DP103-overexpressing cells 
(Figure 2J and Supplemental Table 3), there were more tumors formed in DP103-
expressing mice compared with control and more mice developed tumors in this group 
(data not shown). 
 
DP103 regulates NF-κB–dependent gene expression.  
Since an increase in MMP9 mRNA levels correlated with an increase in DP103 
levels, it was likely that DP103 could be controlling the transcription of MMP9. 
Transcriptional regulation of MMP9 involves a relatively large repertoire of 
transcriptional factors that includes AP-1, AP-2, Ets, NF-κB, and SP-1, out of which AP-
1 [572-574] and NF-κB [575, 576] are considered the major regulators. Given that 
depletion of DP103 expression in 3 invasive cell lines decreased MMP9 mRNA, we 
questioned whether this downregulation is due to inhibition of NF-κB or AP-1 activity. 
Suppression of DP103 led to downregulation of basal NF-κB activity, but had no effect 
on AP-1 activity (Figure 4A). Interestingly, DP103 levels were found to change in 
response to ecteinascidin 743 (ET-743), a genotoxic stress inducer [577]. Given that 
DP103 regulated MMP9 expression via activation of NF-κB, whose transcriptional 
activity is also regulated by genotoxic chemotherapeutic agents [550, 578-580], we then 
sought to investigate effects of DP103 in the presence of known chemotherapeutic agents 
that induce NF-κB, namely doxorubicin, etoposide (VP16), and camptothecin. Indeed, 
luciferase assays with NF-κB– and AP-1–dependent reporters showed that suppression of 
DP103 reduced drug-induced NF-κB reporter activity in both MDA-MB-231 and BT549 
cells (Figure 4, B–D, and Supplemental Figure 7, A–C, respectively). Significantly, drug-
induced AP-1 activity was not affected by DP103 levels (Supplemental Figure 7, D–F). 
EMSA analysis showed that siRNA-mediated reduction of DP103 reduced both basal and 
drug-induced NF-κB DNA–binding activity seen in both MDA-MB-231 and BT549 
breast cancer cells (Figure 4E). AP-1 DNA–binding in both MDA-MB-231 and BT549 
cells remained unaffected by DP103 levels and served as control (Figure 4E). 
Conversely, ectopic expression of DP103, much like what is seen in tumors, increased 
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NF-κB DNA–binding ability (Figure 4F). siRNA to DP103 also reduced nuclear 
accumulation of p65 while causing it to accumulate in the cytoplasm (Supplemental 
Figure 7G). We next evaluated whether DP103 could regulate other clinically relevant 
NF-κB target genes in response to stress. Indeed, siRNA to DP103 significantly reduced 
the levels of NF-κB target genes, namely ICAM-1, MMP9, and CXCR4 (Figure 4G). 
Activation of NF-κB is known to protect cells from cell death induced by genotoxic 
agents. To evaluate whether reduction of NF-κB DNA binding (Figure 4, E and F, and 
Supplemental Figure 7G) and transcriptional activity (Figure 4, A–D, and Supplemental 
Figure 7, A–C) has functional significance, we treated MDA-MB-231 cells with 
doxorubicin or CPT and measured cell viability. Indeed, cells depleted of DP103 and 
hence with defective NF-κB activation were more sensitive to cell death induced by these 
genotoxic agents (Supplemental Figure 7, H and I). In addition, we found that silencing 
of DP103 led to decreased NF-κB binding to the DP103 promoter (Supplemental Figure 
7J), suggesting that the DP103–NF-κB–positive feedback loop likely contributes to 
oncogenesis. 
 
Activated NF-κB (p-p65-276) levels correlate with expression of DP103 and patient 
survival.  
Since our results indicated that DP103, a key biomarker of cancer metastasis, 
functions via activation of NF-κB, we next explored whether there is a clinical value for 
NF-κB activation per se by evaluating expression levels of phospho-p65 in patient 
tissues. IHC performed on clinical specimens from the cohort shown in the Supplemental 
Table 1A revealed that, similar to expression of DP103, expression of phospho-p65 
(Ser276), which represents the activated form of NF-κB, the competent form for 
chromatin remodeling, is significantly higher in breast tumor tissues compared with 
normal breast tissues (P < 0.001) (Figure 5, A and B, and Supplemental Table 5A). 
Analysis of phospho-p65 protein expression mirrored that of DP103, with the highest 
expression observed in basal subtypes compared with other subtypes (P = 0.0141) (Figure 
5, C–G, and Supplemental Table 5B) and closely associated with high-grade tumors (P < 
0.001) (Figure 5, H–K, and Supplemental Table 5C). Kaplan-Meier analysis on the same 
cohort revealed that high phospho-p65 (Ser276) expression (mean, 132 months; n = 62) 
	  	  	  
	  	  
189	  
correlated with reduced OS, (P = 0.002) compared with low phospho- p65 expression 
(mean, 151 months) (Figure 5L). Furthermore high phospho-p65 (Ser276) expression 
(mean, 66 months; n = 62) predicted shorter SAR (P = 0.011) compared with low 
phospho-p65 expression (mean, 120 months) (Figure 5M). Most importantly, high 
expression of phospho-p65 correlated positively with high expression of DP103 in 
clinical specimens (P < 0.001) (Supplemental Table 5D).  
 
DP103 regulates NF-κB in response to multiple stimuli.  
NF-κB can regulate gene expression in response to multiple stimuli [543, 544, 581]. 
To test whether DP103 is an essential component of NF-κB signaling, we determined 
whether DP103 can also regulate NF-κB in response to a diverse array of well-known 
NF-κB–activating agents such as TNF-α, IL-1, LPS, CPT, and Dox. These agents initiate 
NF-κB activation via very distinct cellular-signaling players [544]. However all the 
distinct signaling to NF-κB initiated by these agents converges on the IKK complex. 
DP103 depletion impeded NF-κB DNA binding in response to all the tested stimuli 
(Figure 6A). DP103 also affected kinetics of NF-κB binding in response to membrane 
(TNF-α) and nuclear (CPT) activators of NF-κB (Figure 6, B and C). Furthermore, 
reduction of DP103 caused significant reduction in TNF-α–induced NF-κB–dependent 
transcription (Figure 6D).  
Based on the finding that DP103 promoter contains κB sites (data not shown), we 
then evaluated whether DP103 itself is a target of NF-κB–activating stimuli. De novo 
DP103 protein was induced in response to both TNF-α and LPS (Figure 6E) and DP103 
induction by LPS can be strongly and specifically inhibited by IKK2 inhibitor IV among 
other kinase inhibitors tested (Figure 6F), providing evidence that DP103 is an NF-κB 
target that could form part of a positive feedback loop. Interestingly, we identified 3 
putative NF-κB– binding sites within the promoter of the DP103 gene (Figure 6G). By 
EMSA, we showed NF-κB binds to all 3 sites (data not shown). The specificity and 
identity of the NF-κB complexes could be ascertained using cold oligonucleotides and 
supershift with anti-p65 or anti-p50 antibodies, respectively (Figure 6H). Furthermore, 
EMSA with NF-κB consensus cold oligo-nucleotides abrogated NF-κB binding within 
the promoter of the DP103 gene (Figure 6I). In addition, we also showed a feedback loop 
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Figure 4. DP103 is an essential regulator of NF-κB signaling.  
(A) Control siRNA–treated (ctsi) and siDP103-treated MDA-MB-231 cells transfected 
with Renilla and luciferase reporter plasmid containing NF-κB or AP-1. Luciferase 
activity normalized and quantified. Results are average of 3 separate experiments. *P < 
0.05. Control siRNA–treated (ctsi) and siDP103-treated MDA-MB-231 cells transfected 
with Renilla and luciferase reporter plasmid driven by NF-κB– binding sites. Cells were 
stimulated with (B) 10 µM VP16, (C) 25 µM doxorubicin, (D) or 10 µM CPT for 0, 6, 
and 12 hours and harvested for luciferase assays. Results are the average of 3 separate 
experiments. *P < 0.05. (E) MDA-MB-231 and BT549 cells transfected with either 
control siRNA (ctsi) or siDP103. Cells were left either untreated (–) or treated with CPT 
(10 µM), doxorubicin (10 µM), or VP16 (10 µM) for 2 hours. Protein extracts were 
analyzed by EMSA (top panel) and Western blotting using DP103 and GAPDH 
antibodies (bottom panel). (F) MDA-MB-231 cells infected either with lentiviral empty 
vector (lanes 1–3) or pBO- BI-DP103 (lanes 4–6) were either left untreated or treated 
with CPT (10 µM) for indicated times. Protein extracts analyzed by EMSA and Western 
blotting using anti-DP103 and anti–β-actin antibodies (top panel). (G) MDA-MB-231 
cells transfected with either control siRNA (ctsi) or siRNA against DP103 and subjected 
to CPT (10 µM) stimulation at the indicated times. Cells were harvested and lysates 
evaluated by Western blotting for the indicated proteins. Fold difference in protein DNA 
binding indicated in E and F for EMSA and for protein expression changes indicated in G 
for Western blot. 
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Figure 5. Expression of active p65 (phospho-p65, Ser276) has a prognostic value. 
Staining of phospho-p65 (Ser276) in (A) normal ductal tissue and (B) IDC. 
Representative staining of phospho-p65 (Ser276) in (C) normal ductal tissue, (D) luminal 
A subtype, (E) luminal B subtype, (F) HER2 subtype, and (G) basal subtype. Phospho-
p65 (Ser276) staining in (H) normal nonmalignant ductal tissue, (I) low-grade IDC, (J) 
IDC grade 2, and (K) IDC grade 3. Cell nuclei were counterstained with hematoxylin. (L) 
Kaplan-Meier curves showing phospho-p65 (Ser276) expression in relation to OS. Cases 
that have not experienced a positive event are censored at the date of last follow-up 
(small vertical lines on the line plots). (M) Kaplan-Meier curves showing phospho-p65 
(Ser276) expression in relation to SAR. Cases that have not experienced a positive event 
are censored at the date of last follow-up (small vertical lines on the line plots). 
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following silencing of DP103 leading to decreased NF-κB binding to the DP103 
promoter (Supplemental Figure 7G), suggesting that the DP103–NF-κB–positive 
feedback loop likely contributes to this oncogenic signaling arm in cancers.  
Members of the helicase families, of which DP103 is a member, share several 
conserved motifs, including the Walker A and B motifs, which are involved in the 
binding of nucleoside triphosphates required for its helicase activity [524]. Changing the 
conserved GKT to GNT has been shown to reduce ATP binding in RNA helicases by 
98% [582]. Additionally, the helicase-dead mutant (GNT) also retained its ability to 
induce invasion in MDA-MB-231 cells (Supplemental Figure 8, A–C), demonstrating 
that the helicase activity of DP103 is not required for its role in the metastasis of breast 
cancer cells. The helicase dead mutant of DP103 also interacts with TAK1 (Supplemental 
Figure 8D). 
Given that a helicase dead DP103 functions in activating invasion and that DP103 
can regulate signaling to NF-κB in response to a wide array of stimuli that converge only 
on the key TAK1-IKK complex, these results suggest that DP103 likely regulates a 
central complex in NF-κB activation such as the TAK1 or IKK complex independently of 
its role as a helicase. We tested kinase activity of the IKK complex on phosphorylation of 
IκBα with or without DP103 depletion in response to TNF-α as stimuli (Figure 6J). 
Phosphorylation of IκBα by the IKK complex was significantly impeded upon DP103 
depletion. Furthermore, kinetics of endogenous IKK activation, as judged by 
phosphorylation of IKK1/2 in the activation loop at Ser180/Ser181 and its functional 
consequence, namely phosphorylation of IκBα (Ser32/Ser36), was markedly reduced 
when DP103 was depleted (Figure 6K), suggesting that DP103 is a key regulator of 
activating phosphorylations on the activation loop of IKKs and hence of IKK function in 
the physiological context. 
 
DP103 enhances Tak1-mediated IKK2 phosphorylation and hence NF-κB 
activation.  
Several mitogen-activated protein kinases, such as MEKK1, MEKK3, and TAK1, 
are suggested to regulate IKK activation. However, TAK1 is considered the immediate 
upstream activator of IKK and an essential component of both nuclear and receptor-
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mediated NF-κB activation, which works by phosphorylating the Ser180/Ser181 in the 
activation loop of IKKs (39, 40, 44). We first investigated whether endogenous DP103 
and TAK1 interact. Indeed, DP103 and TAK1 interacted in vivo, and this interaction was 
specific to the cytoplasm, since TAK1 is cytoplasmic (Figure 7A). Covalent modification 
of adaptor proteins by ubiquitin chains (termed as polyubiquitination) has been shown to 
be critical for activation of IKKs downstream of many NF-κB– activating stimuli. While 
there is much ongoing debate on the exact nature of the ubiquitin chains, such as in the 
K-63, linear, or K11 fashion, which is key for IKK activation, the ubiquitin-binding 
proteins TAB2/3 and NEMO are essential regulatory subunits of TAK1 and IKK 
complexes, respectively [583-585]. Indeed, deubiquitination enzymes A20 and CYLD, 
which remove these chains from adaptor proteins in NF-κB signaling, inhibit IKK and 
hence NF-κB activation. They are also known to be lost in inflammatory conditions and 
cancers, which explains the cause of hyperactivation of the pathway that characterizes 
these conditions [586].  
Indeed, we could see TAK1 interacting proteins TAB2/3 interacting with DP103 
under endogenous conditions (Supplemental Figure 9, A and B). To further verify 
whether this is a direct interaction, we purified GST-TAK1 and His-DP103 recombinant 
proteins (Supplemental Figure 9C) and tested their interaction in vitro (Figure 7B). Pull-
down using Ni-NTA beads showed physical interaction between the 2 purified molecules 
(Figure 7B), suggesting that they indeed directly interact. To test the functionality of this 
interaction, we evaluated whether DP103 regulates the ability of TAK1 to phosphorylate 
IKK2 on its activation loop (40, 44). We purified the TAK1 phosphorylation site 
(residues 152–204) on IKK2 (GST-IKK2-WT) and a protein with mutations in the TAK1 
phosphorylation domain (GST-IKK2-Mut) (Supplemental Figure 9D) and included these 
in a kinase assay with purified TAK1 and an increasing amount of DP103 (Figure 7C).  
Increasing DP103 concentration caused an increase in TAK1-mediated 
phosphorylation (hence activation) specifically of IKK2-WT but not that of IKK2-Mut 
activation loops (Figure 7C). Importantly overexpression of DP103, much like what is 
seen in cancers, caused increased recruitment of IKK2 to TAK1 upon stimulation 
(Supplemental Figure 9, E and F). These results further explain the mechanism of 
constitutive IKK activation in cancers. Furthermore, given that the results in Figure 7C 
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Figure 6. DP103 regulates NF-κB in response to multiple stimuli.  
(A) MDA-MB-231 cells transfected with either control siRNA or siDP103. Cells 
untreated (UT) or treated as indicated. Extracts analyzed with EMSA (top) and Western 
blotting (bottom). White separating lines between different stimuli. (B and C) MDA-MB-
231 cells transfected with control siRNA or siDP103. Lysates of cells untreated or treated 
with TNF-α (B) or CPT (C), tested by EMSA. (D) BT549 cells transfected as in C and 
stimulated with TNF-α. RNA analyzed for mRNA expression of NF-κB target genes. *P 
< 0.05; **P < 0.01; ***P < 0.001. (E) MCF10A cells treated with TNF-α or LPS. (F) 
MCF10A cells either untreated or treated with inhibitors for IKK2, MEK1/2, JNK, p38, 
or PI3K, then stimulated with LPS. (G) White arrowheads indicate putative NF-κB–
binding sites on DP103 promoter. (H) Nuclear proteins from MDA-MB-231 cells either 
untreated or treated with CPT tested by EMSA. Unlabeled DP103 probe as cold or IgG, 
p65, or p50 was used. (I) Nuclear proteins from MDA-MB-231 cells untreated or treated 
with TNF-α tested by EMSA using NF-κB consensus (lanes 1–3) or DP103 probe (lanes 
4–6). Unlabeled NF-κB consensus cold probe added to lanes 3 and 6. (J) Cells transfected 
either with siRNA control or siDP103. Lysates immunoprecipitated with NEMO 
antibody and kinase assay performed as previously described (36). (K) BT549 cells 
transfected either with control siRNA or siDP103 as indicated and immunoblotted. Fold 
difference in protein DNA binding indicated in EMSA for A–C and for protein 
expression changes in E, F, J, and K. 
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are derived using purified proteins, they suggest that DP103 can directly bind to TAK1 
and function as a cofactor to enhance its kinase activity toward IKK2. This reaction is 
specific, since TAK1 activity toward the GST- IKK2-Mut protein remains unaltered. 
Indeed, if DP103 levels are limiting in normal cells and overexpression of DP103 as seen 
in cancers is the mechanistic basis of increased TAK1-mediated IKK and hence NF-κB 
activation apparent in cancers, this hypothesis could be tested. Next, we included the 
GST-IKK2-WT in a kinase assay where endogenous TAK1 was immunoprecipitated 
(Figure 7D). DP103 depletion showed reduced phosphorylation on Ser181 of GST-IKK2 
by TAK1 (Figure 7D). Using MDA-MB-231 cells, we next evaluated whether DP103 
levels influence the activation of the IKK kinase complex and hence NF-κB activation. 
Mere ectopic expression of DP103 increased activity of the IKK complex, as seen by 
phosphorylation of IκBα (Figure 7E). Conversely, depletion of endogenous DP103 
expression led to reduced phosphorylation of IκBα (Figure 7E), reiterating that 
endogenous DP103 levels regulate TAK1 activity toward IKK2. Indeed, TAK1 depletion 
with siRNAs also showed downregulation of NF-κB target gene transcription (Figure 
7F). Furthermore, much like siDP103 (Figure 3I), either TAK1 kinase activity inhibition 
or IKK2 inhibition or depletion with siRNAs against TAK1 abrogated TNF-α– induced 
MMP9 activation in MDA-MB-231 cels (Figure 7, G and H). In contrast, MMP2 was not 
affected, which is in line with the existing literature showing that MMP9 but not MMP2 
is the bona fide NF-κB target. Finally, we tested functionality of these observations in 
MDA-MB-231 cells. Compared with control siRNA–treated cells, invasion of TAK1-
depleted cells was greatly decreased in MDA-MB-231 cells (Figure 7I). We conclude 
that DP103-mediated regulation of TAK1’s activity toward the major NF-κB kinase 
IKK2 regulates MMP9 expression and invasion. 
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Figure 7. DP103 is a positive cofactor of TAK1-mediated IKK2 activation in MDA-
MB-231 cells.  
(A) Nuclear and cytoplasmic fractions immunoprecipitated with TAK1 and IgG control 
antibodies and immunoprecipitate material and lysates analyzed by immunoblotting with 
the indicated antibodies. (B) GST-TAK1 and His-DP103 incubated either separately or 
together. Immunoprecipitates analyzed by immunoblotting with the indicated antibodies. 
(C) Kinase assay performed using GST-TAK1 either with GST-IKK2-WT or GST-IKK2-
Mut substrates with increasing input of His-DP103 protein. (D) Cells transfected either 
with control siRNA or siDP103 and stimulated with TNF-α. Lysates were 
immunoprecipitated using anti-TAK1 antibody, and kinase assay was performed using 
GST–IKK2 (amino acid residues 152–204) as substrate (top panel). (E) Cells transfected 
with DP103, siDP103, and respective control vectors. IKK complex immu- 
noprecipitated with anti-NEMO antibody. IKK activity was determined using 
phosphorylation of IκBα. (F) Cells transfected either with control siRNA or siTAK1 and 
stimulated with TNF-α. Total RNA analyzed for mRNA expression of NF-κB target 
genes. *P < 0.05; ***P < 0.001. (G) Cells treated with IKK2 inhibitor IV or TAK1 
inhibitor (5Z)-7-oxozeaenol and stimulated with TNF-α. MMP9 activity evaluated with 
zymography. (H) Cells treated with control siRNA (ctsi) or siRNAs against TAK1 
(siTAK1) and stimulated with TNF-α. MMP9 activity evaluated with zymography. (I) 
Cells transfected either with control siRNA or siRNAs against TAK1. Invaded cells 
through Matrigel detached and lysed in assay buffer were presented as relative 
fluorescence units (RFU). ***P < 0.001. Fold differ- ences in protein expression are 
indicated in C–E. 
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Discussion 
Breast carcinoma is the most common malignancy in women, and its treatment is 
possible with early diagnosis. Despite high survival rates for early stage breast cancer, 
most such tumors often go unnoticed without regular mammograms. While effective 
targeted therapeutic modalities exist for women with hormone receptor–positive and 
HER2-positive disease, chemotherapy is the only systemic therapy available for women 
with triple-negative breast cancer. Increased heterogeneity of tumors in a larger group of 
patients poses a huge challenge in determining whether these drugs will show good 
efficacy in the OS and disease-free survival as well as the extent of the severity of side 
effects that these drugs will deliver. Strikingly, the number of patients who develop 
resistance to these therapies as well as patients who show relapse and metastasis is on the 
rise [587-589]. Metastasis is a multifactorial process requiring the concerted effort of 
many players. As such, it is a highly complex process and therefore unraveling key 
gene(s) whose expression levels could predict metastasis or tumorigenesis is of immense 
therapeutic value [518-520]. 
In this study, we uncovered DP103 as a prognostic marker and a therapeutic target 
for breast cancer metastasis. While members of the DEAD-box family, p68/p72 and 
Ddx3, have been linked to tumorigenesis, the potential role of DP103, a relatively new 
member [532], in cancer, if any, is yet to be uncovered. Using 2 independent cohorts, we 
found that a significant number of breast cancer patients display high levels of DP103 in 
their invasive breast tumor tissue, especially the basal subtype, compared with normal 
breast tissue. The prognostic and clinical significance of DP103 expression is highlighted 
by the observation that patients with high expression of DP103 have significantly shorter 
OS and SAR. Furthermore, DP103 levels were found to be upregulated in a statistically 
significant proportion of grade 3 breast cancers according to a multi-institutional mRNA 
microarray meta-analysis cohort of primary breast cancer; this was validated by IHC for 
DP103 protein expression in 2 independent cohorts. In vitro and in vivo analyses revealed 
that expression of DP103 strongly and positively correlates with the ability of breast 
cancer cells to metastasize. Remarkably, heightened expression of DP103 (as seen in 
cancers) in the normal epithelial breast cell line, MCF10A, which normally displays very 
low levels of DP103 and is unable to invade, was sufficient to confer a 4-fold increased 
	  	  	  
	  	  
202	  
ability to these cells to invade. Overall, our study established that DP103 is not only a 
prognostic marker for breast cancer tumorigenesis and progression, but also a new 
predictive biomarker for cancer metastasis. 
Since MMP9 expression has a clinical expression profile similar to that of DP103 
and its expression is highly correlative to expression of DP103, both in clinical specimens 
and cell lines, we homed on the expression of the MMP family of proteins as a putative 
mechanism for observed effects of DP103. Our analysis further suggested that the ability 
of DP103 to regulate NF-κB but not AP1 activity may be crucial for its regulation of 
MMP9. Indeed, clinical expression of phospho-p65 (active NF-κB) mirrors the 
expression of DP103, both in terms of expression profile and survival outcomes, and 
most significantly, expression of phospho-p65 very significantly associates with 
expression of DP103. These results are significant because this study is the first, to our 
knowledge, to establish a role for DP103–NF-κB–MMP9 axis in breast metastasis. 
How does DP103 regulate NF-κB–dependent transcription? Interestingly, DP103’s 
helicase activity was not involved in the regulation of invasion. The only known helicase-
independent activity of DP103 is its ability to affect PIASy-mediated SUMOylation of 
SF1 to act as a corepressor [527, 528]. However, the underlying molecular mechanism in 
the above 2 studies remains unknown. The known function of PIASy in the NF-κB–
signaling system is limited to its ability to induce SUMOylation of NEMO in the DNA 
damage–signaling pathway [578, 590]. Indeed, DP103 could also affect PIASy 
SUMOylation, but this did not have a functional role in its regulation of MMP9 
transcription (data not shown). Our results convincingly show that DP103-induced NF-
κB and hence MMP9 activation is dependent on its ability to regulate TAK1-mediated 
activation of IKK via the phosphorylation of IKK activation loop. Knockdown and 
specific kinase inhibitors further prove that DP103-TAK1 complex is a potent activator 
of IKK2, the key NF-κB–activating kinase, and this induces MMP9 and hence invasion. 
Thus, identification of DP103 as a new limiting factor in TAK1-dependent NF-κB 
activation provides a significant mechanistic insight into the mechanism of constitutive 
NF-κB activation seen in tumors. It explains why, despite lack of overexpression of the 
TAK1 and IKK kinases, hyperactivation of NF-κB is apparent in the vast majority of 
cancers. It is due to the fact that DP103, levels of which increase in invasive or high- 
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Figure 8. Schematic model based on our study showing a role for the RNA helicase 
DP103 in its ability to bind and stabilize TAK1 and thus activate NF-κB signaling in 
cancers. 
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grade cancer, provides a tonic activation of TAK1-mediated IKK2 and hence NF-κB 
activity. Since levels of DP103 are transcriptionally controlled by NF-κB itself in breast 
cancer cells, this feedback loop maintains constitutive activation of NF-κB and hence 
chronic inflammation, another hallmark of human cancers [591]. A model based on our 
studies is depicted in Figure 8. Since it is well accepted that constitutive NF-κB activity 
also imparts cancer cells the chemo- resistant phenotype [552, 553], DP103 could also be 
a therapeutic target in these cancers. Indeed, our data showed that reduction of NF-κB 
signaling by downregulating DP103 sensitized breast cancer cells to chemotherapy-
induced cell death. DP103 on its own may not be a very attractive therapeutic target 
based on conventional targeting methods. Although small molecules and staple peptides 
have been designed to target “nondruggable” targets and even transcription factors such 
as BCL6, our finding that NF-κB itself can positively regulate DP103 expression 
provides us with an opportunity to break the positive feed-forward loop, the Achilles’ 
heel of metastatic breast cancer, by blocking NF-κB activation. However, while blocking 
NF-κB by blocking IKK activity is successful in laboratory settings, this approach hasn’t 
been successful in the clinic due to toxicity. 
In summary, we describe a function of an RNA helicase DP103 that depends on its 
ability to bind and stabilize TAK1 and thus activate NF-κB signaling. Although 
constitutive activation of NF-κB is a well-documented phenomenon in cancer, increased 
levels of enzymes such as TAK1 that could maintain IKK2 and hence NF-κB in a 
constitutively active state are not seen in cancer cells. Instead, our current study 
uncovered that it is the increase in levels of DP103 that marks the switch from a 
nonmetastatic to a metastatic state in breast cancer cells and possibly other cancer cell 
types. In addition, we also elucidated a plausible DP103– NF-κB–positive feed-forward 
loop that could be involved in the maintenance of this oncogenic signaling arm in 
cancers. Thus, we suggest that DP103 is a novel biomarker as well as a worthwhile 
therapeutic drug target. 
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Materials and methods 	  
Cell lines and reagents: MCF-7, MDA-MB-231, and BT549 human breast cancer cells 
were grown in RPMI with 10% FBS, 2 mM l-glutamine, and 0.05 mg/ml gentamicin. 
HEK293, BT474, and SKBr3 cells were grown in DMEM, DMEM/F12, and McCoy’s 
5A, respectively, with the same supplements as above. MCF10A and 184A1 cells were 
grown in MEGM with 10% FBS, 2 mM l-glutamine, bovine pituitary extract, and 0.05 
mg/ml gentamicin. Xenograft-derived breast cancer cell lines (MCF10A1, 
MCF10AT1KCl.2, MCF10CA1h, and MCF10CA1a- Cl.1) were maintained in 
DMEM/F12 with 5% horse serum, 100 U/ml penicillin/streptomycin, 10 µg/ml insulin, 
20 ng/ml EGF (Millipore), 0.5 µg/ml hydrocortisone, and 100 ng/ml cholera toxin. All 
cell lines except xenograft-derived were purchased from ATCC; media and supplements 
were from Hyclone unless otherwise indicated. Doxoru- bicin, VP16 (Etoposide), and 
camptothecin were purchased from Cal- biochem. All other chemicals and reagents were 
from Sigma-Aldrich unless otherwise indicated. 
 
Other assays: Virus preparation and infection, transfections for siRNA and plasmids, 
Western blot analysis, immunoprecipitation, real-time PCR, GST-IκBα kinase, EMSA, 
cell viability, and luciferase assays were performed as described previously [540] and are 
described in detail in Supplemental Methods. Gel zymography [382] is described in detail 
in Supplemental Methods. Primer sequences are available in Supplemental Methods. 
 
Metastatic qPCR array and microarray: Total RNA was extracted, and relative 
expressions of various genes were then analyzed using qPCR (ABI PRISM 7900; 
Applied Biosystems). Multiple gene markers distributed around the genome and 3 
housekeeping genes were used for real-time PCR analysis using the SYBR GreenER 
qPCR SuperMix for ABI PRISM (Invitrogen), done in triplicate. Sequences of primers 
used were described previously [592, 593]. DP103 expression levels were analyzed in 
breast tumors using a multi-institutional microarray meta-analysis cohort totaling 759 
primary breast cancer cases. The normalized microarray data set and associated clinical 
annotations were described previously [594]. Briefly, the microarray meta-analysis 
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cohort comprised data sets from 6 breast tumor-profiling studies. The data sets are 
accessible through MIAME-compliant public databases. Three data sets are housed in 
GEO [595] (GSE1456, ref. [596]; GSE6532, ref. [597]; and GSE9195, ref. [598]); 1 data 
set is housed in the NCI’s caArray database (mille-00271; ref; [417]). All tumor samples 
were analyzed from frozen tissue collected at surgery and pro- filed on an Affymetrix 
U133 series microarray according to standard Affymetrix protocols [594]. Raw data 
(CEL files) were normalized by Robust Multichip Average (RMA) using the 
Bioconductor Affy Package (R) as previously described [599]. Batch effects between 
cohorts were corrected using the Partek Genomics Suite Batch Remover program. Two 
Affymetrix probe sets (223331_s_at and 224315_at) were designed to detect DP103 
expression. The log2 signal intensities of these 2 probe sets were well correlated in the 
breast tumor meta- analysis cohort (r = 0.65, Pearson correlation). 
 
Data preprocessing of Affymetrix microarray gene expression: Breast cancer data 
sets were downloaded from GEO (94). Microarray data on a U133Plus2 platform were 
utilized for analysis under the following GEO accession numbers: GSE12276 (n = 204), 
GSE19615 (n = 115), GSE21653 (n = 266), GSE23177 (n = 116), GSE23593 (n = 50), 
GSE26639 (n = 226), GSE3744 (n = 47), GSE5460 (n = 127), GSE5764 (n = 10), 
GSE6532 (n = 87), and GSE9195 (n = 77). For this study, we included all publicly 
available data set in the U133Plus2 platform at the time that the analysis was initiated in 
October 2011. RMA normalization was performed on each data set. The normalized data 
were compiled and subsequently standardized using ComBat [600] to remove batch 
effect. The standardized data yielded a data set of 1,325 breast cancer tumors and 20 
normal breast tissue samples. The expression values of the DP103 gene were log 
averaged from DP103 probes in U133Plus2 platform: 223331_s_at and 224315_at. Apart 
from the 1,345 samples we compiled, we downloaded GEO GSE3494 (n = 252), data on 
both U133A and U133B platforms, and used it as validation data. GEO GSE3493 data 
were processed and normalized using the same method as described above. 
 
ssGSEA: ssGSEA was originally described in a previous study [562].  
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Identification of breast cancer subtypes: Breast cancer subtype signature was obtained 
from Prat et al. (59). Subsequently, ssGSEA was computed based on the breast cancer 
subtype signature for each sample. Each sample was then assigned to be the subtype with 
the maximum ssGSEA score [4]. 
 
2D migrational assay: in vitro and 3D invasion assay, wound healing assay. 2D 
migrational assay, in vitro and 3D invasion assay, and wound healing assay were 
performed as per standard protocols and are described in Supplemental Methods. 
 
Statistics: Statistical analyses were performed using the SPSS package (version 15.0 for 
Windows; SPSS Inc.), with significance set at the 5% level. Statistical significance 
evaluation by Mann-Whitney test and Spearman correlation test were computed using 
MATLAB. Dot plot was done using Graphpad Prism. Two-tailed Student’s t tests were 
performed using the software Origin Pro, and results are represented as mean ± SD. 
Associations among DP103, MMP9, and phospho-p65 immunohistochemical staining 
data and clinico-pathological parameters were determined using Fisher’s exact and 
Kendall tau tests. A P value below 0.05 was considered statistically significant. Survival 
curves were plotted using the Kaplan-Meier method and compared using the log-rank 
test. 
 
Study approval: All animal studies were reviewed and approved by the SingHealth 
Institutional Animal Care and Use Committee, Sing- Health Office of Research, 
Singapore, and are described in Supplemental Methods. Ethics approval for the study 
using clinical material from Singapore was obtained from the Institutional Review Board, 
Singapore General Hospital. Protocol for the use of clinical material from China was 
approved by the Institutional Review Board of Anhui Medical University, while the use 
of clinical material from Canada was approved by the Institutional Review Board, 
Montreal University Health Centre, in 2005, with a renewal in 2010. Details on clinical 
materials and immunohistochemical procedures are described in Supplemental 
Experimental Procedures. 
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Supplemental information 
 
SUPPLEMENTAL METHODS 
 
Transfection, siRNA and plasmids 
Two unique siRNAs targeting non-conserved coding regions of DP103 were used: 
#1: 5’- CCAGUGAUCCAAGUCUCAUAGCUUU-3’; #2: 5’-
GCUGCCGCUUCUCAUU CAUAU UAUU-3’ (Stealth RNAiTM, Invitrogen, Life 
Technologies, Grand Island, NY). 5’-AGC UUC AUA AGG CGC AUG CTT (luciferase 
gene sequence inverted) was used as control siRNA (Qiagen, Valencia, CA). Full length-
hFLAG-DP103 pcDNA3 was cloned from full length 2FLAG-hDP103, a kind gift from 
C. Glass (26). Helicase-dead mutant 2FLAG-hDP103-GNT pcDNA was derived from 
2FLAG-hDP103 pcDNA by PCR-mutagenesis (Stratagene, La Jolla, CA) using sense 
primer 5’-TCTGGTACCGGGAATACCTGTGTGTTC-3’ and antisense primer 5’-
GAACACACAGGTATTCCCGGTACCAGA-3. The critical lysine residue needed to 
bind ATP (GKT) was mutated to an asparagines residue (GNT). For retroviral DP103 
plasmid construction, a forward primer containing AgeI site and a reverse primer 
containing XhoI site was used to amplify the DP103 cDNA from Full length-hFLAG-
DP103 pcDNA3. The amplified fragment was cloned into AgeI-XhoI cut pBobi plasmid, 
which contains a lentiviral backbone with the restriction sites placed immediately 
downstream of the Flag tag which is preceded by a CMV promoter. The primer 
sequences are: sense primer 5’-ATTAACCGGTATGGACTACAAGGAC-3’ and 
antisense primer 5’-ATTACTCGA GTCACTGGTTACTATGCATC-3’. 
 
Western Analysis 
At the time of harvesting, the cell pellets were collected and completely lysed with 
RIPA lysis buffer (50mM Tris at pH 7.5, 150mM NaCl, 1% v/v NP-40, 1% v/v 
deoxycholic acid, 0.1% v/v SDS and 1mM EDTA) containing 1mM PMSF, leupeptin, 
pepstatin A and aprotinin before subjected to SDS-PAGE. The resolved proteins were 
then transferred onto nitrocellulose transfer membrane, blocked with 5% milk and 
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incubated with specific primary antibodies at 4°C overnight, followed by secondary 
antibodies before visualizing on X-ray films using enhanced chemiluminescence (Pierce, 
Rockford, IL). Human anti-mouse DP103 was purchased from BD Transduction 
Laboratories (San Diego, CA), human anti-rabbit MMP9, human anti-rabbit p- IκBα 
(Ser32/Ser36), human anti-rabbit ICAM, goat anti-mouse and goat anti-rabbit from Cell 
Signaling (Danvers, MA), human anti-rabbit TAK1 (H-579), TAB2 (H-300), TAB3 (H-
128), TRF2 (N-20), c-Jun (H-79), NEMO (FL-419), IKK1/2 (H-470), p65 (C-20), p50 
(H119), GAPDH (6C5), normal rabbit IgG and anti-mouse Myc (9E10) from Santa Cruz 
(CA, USA), anti-mouse Flag M2 from Sigma (St Louis, MO), anti-phospho-IKK1/2 
(Ser180/181) from bioworld Technology (Louis Park, MN) anti-rat HA from Roche 
(Indianapolis, IN), and human anti-mouse SUMO-1 from Zymed (South San Francisco, 
CA). 
 
RNA isolation, reverse transcription and realtime-PCR 
Total RNA was extracted using TRIzol® reagent according to the manufacturer's 
instructions (Invitrogen, Life Technologies, Grand Island, NY). Reverse transcription 
(RT) was then carriedout. Each RT reaction contains 1µg of total RNA, 1x RT buffer, 
5mM MgCl2, 425µM each of dNTPs, 2µM random hexamers, 0.35U/µl RNase inhibitor, 
1.1U/µl MultiScribe reverse transcriptase and made up to 10µl with sterile water. RT 
reaction was carried out at 42oC for 1h. The relative expressions of various genes were 
then analyzed using quantitative RT-PCR (ABI PRISM 7500, Applied Biosystems, 
Foster City, CA, USA) with 18S as an internal control. Primers and probes were 
purchased as kits from Applied Biosystems (Assays-on-Demand). 
 
Invasion assay 
In vitro invasion assay was performed using BD Bio-Coat Matrigel invasion assay 
system (BD Biosciences, San Jose, CA) according to the manufacturer’s instructions. 
Briefly, cells were trypsinized 48h post-transfection, 2x105 cells suspended in serum-free 
medium and seeded into the Matrigel transwell chambers consisting of polycarbonate 
membranes with 8-µm pores. After incubation for 24h, the upper surface of transwell 
chambers was wiped off with a cotton swab and invading cells were fixed and stained 
	  	  	  
	  	  
211	  
with crystal violet solution. The invading cell numbers were counted in five randomly 
selected microscope fields (x200) and their averages were converted to percentage with 
the control setup taken to be at 100%. 
 
Immunoprecipitation 
A total of 3x106 cells were treated as indicated. Cell pellets were lysed in lysis 
buffer (50mM Tris (pH 7.4), 150mM NaCl, 0.5% NP-40, 0.5mM PMSF, 20mM β-
glycerol phosphate, 1mM sodium orthovanadate, 1µg/ml leupeptin, 1µg/ml aprotinin, 
50mM sodium fluoride). Pre-cleared 0.5mg of proteins were incubated with Protein A 
Sepharose, CL-4B (GE Healthcare Life Science, Pittsburgh, PA) and indicated antibodies 
(1µg) overnight. Beads were washed four times with (200mM Tris (pH 8), 100mM NaCl, 
0.5% NP-40, 2mM DTT, 0.5mM PMSF, 1mM sodium
 
orthovanadate, 1µg/ml leupeptin, 
1µg/ml aprotinin). The samples were boiled in 4x SDS loading buffer, and proteins were 
separated by SDS-PAGE and subjected to Western blotting with the indicated antibodies. 
 
Wound healing assay 
MDA-MB-231 and BT549 cells were treated according to experimental design. 
Before plating the cells, two parallel lines were drawn at the underside of the well. These 
lines served as fiducial marks for the wound areas to be analyzed. In preparation for 
marking the wound, the cells should be fully confluent. The growth medium was 
aspirated and replaced by calcium-free PBS to prevent killing of cells at the edge of the 
wound by exposure to high calcium concentrations. Two parallel scratch wounds were 
made perpendicular to the marker lines with a 1000µl blue tip. The medium was then 
changed to complete media. After incubation for 48h, the wounds are observed using 
bright field microscopy and multiple images were taken at areas flanking the intersections 
of the wound and the marker lines at the start and end of the experiment. Three 
measurements of the gap distance between the wound were taken at the start and end of 
the experiment from the images, and their averages are converted to percentages to depict 
percentage change with the control setup taken to be at 100%. 
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Electrophoretic mobility shift assay 
Cell pellets were lysed in Totex buffer (20mM HEPES (pH 7.7), 350mM NaCl, 
20% glycerol, 1% NP-40, 1mM MgCl2, 0.5mM EDTA, 0.1mM EGTA, 0.5mM DTT) 
containing protease inhibitors, spun down at 14,000 x g for 10min at 4°C and subjected to 
EMSA as described previously (114). The supernatant collected was divided into three 
separate samples for analysis with double-stranded NFκB, AP-1 and Oct-1 (γ-32P) 
radiolabeled probes. NF- κB: 5’-TCA ACA GAG GGG ACT TTC CGA GAG GCC-3’ 
(115) AP-1: 5’- CGC TTG ATG ACT CAG CGG GAA-3’ (116) 
Oct-1: 5’- TGT CGA ATG CAA ATC ACT AGA A-3’ (117) 
The sequences of (γ-32P) radiolabeled probes used to confirm NF-κB binding sites within 
the promoter of DP103 are: 
probe#1: 5’-TCTCCTCCCTCTTGGGGCTTTCCT-3’, 
probe#2: 5’-AGAGGCGGGGCGGTGCCCCCACCG-3’ and 
probe#3: 5’-CACGGCTGGGCGGCTCCGCCCAG-3’. 
The DNA probe was radiolabeled by incubation at 37°C for 30min with the 
following: 5x forwarding buffer, 32P-γ-ATP and T4 kinase (10unit/µl). The labeled probe 
was then spun at 3000 rpm for 1min to get rid of the buffer, followed by loading into the 
G50 micro column (Pharmacia Biotech, UK) and spun for 2min for purification. EMSA 
was performed in a reaction mixture containing 2x reaction buffer (50% glycerol, 1M 
Hepes pH 7.9, 1M Tris-HCl pH 8.0, 0.5M EDTA pH 8.0, 100mM DTT), 0.5µg/µl poly 
(dI-dC), protein samples and 1µg/µl BSA and kept on ice for 10min before adding DNA 
probes. The mixture was then kept at room temperature for another 20min before loading 
into a non-denaturing polyacrylamide gel and run for 1h. The gel was then dried and 
analyzed with a PharosFX Plus system (BioRad, Hercules, CA). 
 
Gel zymography 
Equal serum-free growth media collected from tested samples as indicated were 
subject to Electrophoresis using 10% denaturing polyacrylamide gels containing 0.1% 
gelatin. Following electrophoresis, the gels were re-natured with 50mM Tris-HCl buffer 
(pH 7.5) containing 2.5% Triton X-100 for 30min, and incubated at 37°C for 16h in a 
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buffer composed of 0.15M NaCl, 10mM CaCl2 and 50mM Tris-HCl (pH 7.5). The gels 
were stained with 0.5% Coomassie blue in 5% methanol and 10% acetic acid in dH2O, 
and destained with 10% methanol and 5% acetic acid. 
 
Luciferase assay 
1.25x105cells/well was plated in 12-well plates. Experiments were set up as 
described. The cells were then transfected with luciferase reporter plasmid containing 3x 
NFκB or AP-1 binding sites together with Renilla plasmid (Clonetech, Palo Alto, CA). 
At time of harvest, the promoter activity was assessed with a dual-luciferase assay kit 
(Promega, Madison, WI). Briefly, feeding medium was removed from the wells, washed 
once with 1x PBS, and lysed with ice-cold 100µl of reporter lysis buffer. Ten microlitres 
of cell lysate was then added to 50µl of luciferase substrate solution, following which 
50µl of stop & glow buffer was added for Renilla reading. Bioluminescence generated 
was measured using a Sirius luminometer (Berthold Detection System, Pforzheim, 
Germany). The luminescence readings obtained were normalized to the protein 
concentration of the corresponding cell lysate and presented as fold difference with 
reference to the control setup. 
 
Cell viability 
MDA-MB-231 cells were plated in 12-well plates. Experiments were set up as 
described. At the end of drug treatment or transfection, medium was removed from wells. 
The cells were then washed once with 1x PBS. This was followed by incubation with 
0.5ml of crystal violet solution (0.75% crystal violet, 50% ethanol, 1.75% formaldehyde, 
0.25% NaCl) for ten minutes. Excess crystal violet solution was carefully washed away 
with distilled water for several times and the wells were left to air-dry. The remaining 
crystals were dissolved in a 1% SDS in 1x PBS solution and its absorbance read at 
595nm and converted to percentages, with control setups at 100%. 
 
Mammary fat pad spontaneous metastasis model 
Ten-week old female Balb/c nude mice (Animal Resource Centre, Western 
Australia) were anaesthetized prior to surgery and a 5mm incision was made in the skin 
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to expose the abdominal mammary fat pad (m.f.p.). Two million cells in 0.03ml were 
injected into the tissue through a 27- gauge needle. Tumor growth was monitored weekly 
by bioluminescence imaging using the IVISTM camera system (Xenogen, Alameda, CA, 
USA). For ex vivo imaging, 150mg/kg D- luciferin (Xenogen) was injected into the mice 
just before necropsy. Tissues of interest were excised, placed into tissue culture dish and 
imaged for 1min. Regions of interest from displayed images were quantified as photons 
per second (p/s) using Living Image Software (Xenogen). 
 
2D migrational assays 
Glass cylinders (Bioptechs, Butler, PA) of 6mm inner diameter were placed 
vertically on tissue culture dish. About 20000 cells were seeded inside the glass cylinders 
and incubated at 37°C in a humidified atmosphere at 5% CO2 for 24h. The cylinders 
were then carefully lifted from the dish to reveal an undisturbed circular monolayer patch 
of cells, which were then washed thrice with 1x PBS to remove dead cell debris and 
refilled with 2ml of complete medium. Live video monitoring assays of the migrating 
cells at the edge of the monolayer were performed using phase contrast microscopy 
(Biostation IM, Nikon). Rectangular fields of view with pixel resolution 1280x960 were 
chosen from the monolayer edge using the proprietary software and videos were recorded 
for 24 hours with 10min intervals in between the frames (total 145 frames). 
Fifty cells from 6-8 rows of the leading edge of the monolayer were manually 
tracked using the open source software Image J. Monolayer edge distances (MED) were 
measured as the average of the displacements (n=5 per field of view measured for 4-5 
videos per experiment) between the initial and final positions of the monolayer edge. 2D 
track plots and plot related measurements were performed using the Chemotaxis tool 
plugin (Integrated BioDiagnostics). 
 
In vitro and 3D invasion assay 
In vitro invasion assay was performed using BD Bio-Coat Matrigel invasion assay 
system (BD Biosciences, San Jose, CA) according to the manufacturer’s instructions. For 
3D invasion assay, NutragenTM collagen solution (Inamed Biomaterials, Fremont, CA, 
US) was mixed with NaOH, 10x PBS, and MDA-MB-231-GFP cells suspended in 
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serum-free DMEM on ice. The final solution contained 4mg/ml of collagen-I and around 
200,000/ml cells. 30-60min incubation under 37°C humidified chamber led to the self-
assembly of a piece of semi-spherical cell-seeded collagen gel in the central well of a 
glass-bottomed dish. Complete cell culture media were immediately supplied to the gel to 
support cell growth. After 40h, these GFP-expressing cells were imaged in 3D collagen 
hydrogel using confocal fluorescence microscopy (Nikon TE2000- EZ C1 system). Ten 
hours of time-lapsed confocal imaging was then carried out in an environment chamber 
maintaining 37°C and 5% CO2 atmosphere, which was completed within 70h post 
siRNA transfection. Quantitative image analysis was achieved using 3D reconstruction 
and cell tracking function provided by Imaris (Bitplane, Zurich, Switzerland). 
 
GST-IκBα Kinase Assay 
MDA-MB-231 cells were transfected with DP103 for overexpression or siDP103 
for knock- down. After 36 h, the cells were lysed with IP buffer and the kinase complex 
was prepared by IP using anti-NEMO antibody. GST-IκBα/1-66 was purified using 
glutathione-agarose column (Thermo Sci., MA) and used as the substrate. The reaction 
was performed with mixture of kinase complex, 0.5µg of GST-IκBα/1-66, and ATP (P32), 
in kinase buffer (20 mM Hepes (pH 7.7), 2mM MgCl2, 2mM MnCl2, 1mM DTT, 10µM 
ATP + inhibitors (0.5 mM PMSF, 10mM beta- glycerol phosphate (BGP), 300µM 
sodium othovanadate, 1µg/ml leupeptin, 1µg/ml aprotin, 10mM sodium fluoride, 10mM 
p-nitrophenyl phosohate) at 37°C for 1h. The samples were subjected to 12% SDS-PAGE 
and visualized by autoradiography. The purified IKK comlex and GST- IκBα/1-66 were 
analysed by western blotting with proper antibodies. 
 
Clinical materials 
Table S1A&B – Singapore Cohort 
Tissue microarray (TMA) slides consisting of invasive ductal carcinoma (IDC) 
cases from 399 patients and normal non-malignant ductal tissues from 61 women were 
obtained from the Department of Pathology, Singapore General Hospital. As a result of 
tissue loss during immunohistochemical processing, the following number of cases 
(invasive ductal carcinoma and normal non-malignant ductal tissues) were available for 
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evaluation: DP103 (Proteintech, Chicago, IL, USA (catalogue 11324-1-AP)) (330 and 38 
respectively); phospho-p65 (S276) antibody (Abcam, Cambridge, MA, USA (catalogue 
ab30623)) (338 and 49 respectively); MMP9 (Proteintech, Chicago, IL, USA (catalogue 
10375-2-AP)) (357 and 53 respectively). Clinicopathological features were recorded for 
statistical analyses, including age of patient, ethnic group, tumor type, and histological 
grade of tumor. Patient survival and tumor recurrence data were available for 329 cancer 
patients. The period of follow-up ranged from 0 to 156 months. Deaths (defined as being 
resultant from the cancer itself) occurred in 21.1% of patients, with the mean and median 
overall survival (OS) periods being 112 and 117 months respectively. Among patients 
with tumor recurrence, 20.1% of them were dead at the end of the study period, with a 
mean survival after recurrence (SAR) period of 17 months and median SAR of 0 month. 
OS was defined as the time from diagnosis to death. SAR was defined as the survival 
duration from the first recurrence to death. Cases that did not reach the defined end-
points of interest were censored at the date of last follow-up. 
 
Table S1C – Canada Cohort 
This study was performed on 190 archived formalin fixed paraffin embedded 
(FFPE) blocks containing tissues obtained from female patients. All samples were 
obtained from Centre hospitalier de l’Université de Montréal (CHUM). The collected 
blocks contain both invasive and in situ carcinoma of breast and normal breast tissue 
from healthy women undergoing plastic surgery. 
 
Table S1D – China Cohort 
A cohort of a total of 63 primary breast cancer and 22 benign breast tissue samples 
derived from 85 patients who underwent surgery at the First Affiliated Hospital of Anhui 
Medical University (Hefei, Anhui, People’s Republic of China) between 2009 and 2010 
was obtained. All tissue samples were hematoxylin and eosin stained and had been 
reviewed by two independent pathologists in Anhui Medical University. Total RNA from 
these breast tumor tissue samples was extracted by TRIzol® (Invitrogen, Life 
Technologies, Grand Island, NY), reversely transcribed into cDNA by using RevertAid 
First Strand cDNA Synthesis Kit (K1622, Fermentas, Germany) and Real-time PCR was 
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carried out by using SYBR Premix Ex Taq (DRR041A, TaKaRa, Shiga, Japan) in a 
Stratagene MX3000P detection system (Stratagene, La Jolla, CA, USA). The 
amplification protocol was set as following: an initial 95°C for 5min and then 40 cycles 
of denaturation at 95°C for 5sec, annealing and extension at 60°C for 30sec. Primer 
sequences used for qPCR expression in patient tissues from First Affiliated Hospital of 
Anhui Medical University are DP103-F: 5'-TGCCAGTAAACAGATGC-3', DP103-R: 
5’-GTGCCAAAGGGTATGA-3'; MMP9-F: 5'-CGAACTTTGACAGCGACAAGA-3', 
MMP9-R: 5'- AGGGCGAGGACCATAGAGG-3'; GAPDH-F: 5'-
TGCACCACCAACTGCTTAGC-3', GAPDH-R: 5'-GGCATGGACTGTGGTCATGAG-
3’; HMGB1-F: 5' TTGTCGGGAGGAGCATAA 3', HMGB1-R: 5' 
GGGCGATACTCAGAGCAGAA 3’; H2AFZ-F: 5' CAAGACAAAGGCGGTTTC 3', 
H2AFZ-R: 5' GCATTTCCTGCCAGTTCA 3'. 
 
Immunohistochemistry 
DP103, MMP9, and phospho-p65 (S276) antibodies were used for 
immunohistochemical staining of the TMA sections. Briefly, the TMA sections were 
deparaffinized in Clearene and rehydrated through a graded series of ethanol. 
Endogenous peroxidase activity was quenched with 3% hydrogen peroxide for 30 min. 
Antigen retrieval was carried out through heating in 10mM citrate buffer (pH 6.0) at 90-
100oC for 20 min. The sections were blocked with goat serum for 1hr prior to overnight 
incubation at 4oC with the primary antibody (1:50 dilution). The staining pattern was 
visualized using the Dako Envision-HRP kit with diaminobenzidine as the substrate. 
Sections were counterstained using Shandon’s hematoxylin. 
 
Immunohistochemical evaluations 
The intensity of the staining in the epithelial compartment of ductal tissues was 
noted as absent (0), weak (1+), moderate (2+), or strong (3+). Low expression of DP103, 
phospho-p65 and MMP9 was defined as staining intensity of 0 or 1+, whereas high 
expression denotes staining intensities of 2+ or 3+. Evaluation of the stained TMA 
sections was carried out by two independent blinded observers, including a trained 
histopathologist. 
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SUPPLEMENTAL FIGURES 
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Figure S1 : Expression of DP103 in different molecular subtypes of breast cancer 
DP103 staining in (A) a normal ductal tissue and (B) an invasive ductal carcinoma. (C) 
The gene expression value of DP103 (y-axis) is plotted for each breast cancer subtype. 
DP103 staining in (D) a normal ductal tissue, (E) in a Luminal A subtype, (F) in a 
Luminal B subtype, (G) in a HER2 subtype and (H) in a Basal subtype from cohort in 
Table S1A. DP103 staining in (I) a normal ductal tissue, (J) in a Luminal A subtype, (K) 
in a Luminal B subtype, (L) in a HER2 subtype and (M) in a Basal subtype from cohort 
in Table S1C. (N) Box and whisker plots of DP103 expression level distributions in 
tumors defined by histologic grade (Nottingham grading system). Shaded rectangles 
represent interquartile range; central line represents median value. 
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Figure S2: Expression of DP103 in different histological grades of breast cancer and 
its positive correlation with metastasis-associated genes. 
DP103 staining (A) in normal non-malignant ductal tissue, (B) in low grade invasive 
ductal carcinoma, (C) in invasive ductal carcinoma of tumor grade 2 and 3 and (D) in 
high grade invasive ductal carcinoma from cohort in Table S1A. Cell nuclei were 
counterstained with haematoxylin. DP103 staining in (E) in grade I invasive ductal 
carcinoma, (F) in invasive ductal carcinoma of grade II tumor and (G) in grade III 
invasive ductal carcinoma from cohort in Table S1C. DP103 mRNA expression 
positively correlates to expression of metastasis genes (H) HMGB1 and (I) H2AFZ in 85 
human breast patients from cohort in Table S1D showing positive correlation using 
Pearson’s Correlation Coefficient. 
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Figure S3: Suprresion of DP103 decreases migratory ability of breast cancer cells  
(A) Transfection efficiencies of the two different siRNAs and in combination on 
expression of DP103 in MDA-MB-231 and BT549 cells. (B) MDA-MB-231 cells were 
subjected to siRNA knockdown of DP103 and the monolayer edge distances of the cells 
were tracked using live microscopy. (C) 2D plots of individual cell migration tracks with 
starting point of all the cell tracks coincided at the origin. Top and bottom left: control 
siRNA (ctsi) treated MDA-MB-231 show increased migratory distances with 72% of 
cells outside a radius of 101µm that coincides with the centre of mass (positive sign) of 
all the cell coordinates. Top and bottom right: siRNA against DP103 treated MDA-MB-
231 show decreased migratory distances with 46% cell inside a radius of 74µm that 
coincides with the centre of mass of all the cell coordinates, and 56% of cells inside a 
radius of 101µm in comparison to ctsi. X and Y axes represent migration distance in µm. 
(D) Analyses of cell migration tracks. ctsi show a significant increase in the Accumulated 
distance (top left), Euclidean distance (top right), mean cell speed (bottom left) and 
confinement ratios (bottom right) in comparison to siDP103 cells. Box edges represent 
standard deviation; the small square within the box represents the mean and divider at 
50% value. 
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Figure S4: Suppression of DP103 decreases invasive ability of breast cancer cells 
while its ectopic expression enhances cell invasion 
(A) Cell displacement (µm) tracks in 3D collagen gel. The tracks of a population of cells 
(n>50) were adjusted to start from the same origin (0,0,0). (B) The histogram of cells 
speed averaged over each track, track number >50. The height of each column 
corresponds to the percentage of tracks of a certain speed. (C) 3D Z-stack of confocal 
images was projected to X-Y plane, and cell morphology was shown with fluorescence 
from GFP. Left: Cells transfected with control siRNA (ctsi); Right: DP103 knockdown 
cells. Loss of pseudopodial protrusions in cells after siDP103 (white arrows). (D) MDA-
MB-231 cells were transfected with pcDNA3/EV and pcDNA3-FLAG-DP103 (DP103/F-
DP103). Cells extract immunoblotted with anti-DP103 antibodies. (E) MDA-MB-231 
cells were transfected as stated in D and prepared for invasion assay. (F) MDA-MB-231 
cells that invaded through the chambers counted and represented in percentages * denotes 
p<0.05. 
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Figure S5: MMP9 predict survival and strongly correlate with DP103 levels in 
breast cancer. Also, suppression of DP103 expression decreases MMP9 gene 
expression 
 (A-B) Different expression levels of MMP9 between (A) normal ductal tissue and (B) 
invasive ductal carcinoma tissue. (C) DP103 and MMP9 mRNA expression levels in 85 
human breast patients were determined and showed positive correlation using Pearson’s 
Correlation Coefficient (r2=0.5686). (D) DP103 mRNA expression levels correlates 
positively with MMP9 mRNA expression in basal and claudin-low subtypes. (E) 
Pearson’s Correlation Coefficient was determined between the mRNA expression of 
DP103 and MMP9 in various breast cell lines. DP103 knockdown in another invasive 
breast cancer cell line, HS578t, showed drop in (F) mRNA levels of MMP9 and (G) 
MMP9 protein levels * denotes p<0.05. (H) MDA-MB-231 and (I) BT549 cells 
transfected with either control siRNA or siDP103. Cell viability determined by crystal 
violet assay. 
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Figure S6: MMP9 mediates effects of DP103 in invasiveness 
(A) MDA-MB-231 and MCF10A cells were transfected with pcDNA3 (EV) and 
pcDNA3-FLAG-DP103 (DP103). Cells extract immunoblotted with anti-DP103 and anti-
MMP9 antibodies. (B) MDA-MB-231 cells assayed for invasion capability with either 
MMP2/9 inhibitor (SB-3CT, 10µM) or pan-MMPs inhibitor (GM6001, 50µM) (10X 
magnification). Insert shows zoomed pictures (40X magnification). (C) The number of 
cells invaded through the transwell invasion chambers from (B) counted and represented 
* denotes p<0.05. (D) MDA-MB-231 cells transfected with either empty vector 
(pcDNA3) or DP103 (DP103) assayed for transwell invasion with or without MMP9 
Inhibitor I (1µM). The number of cells that invaded through the transwell invasion 
chambers counted and represented * denotes p<0.05. 
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Figure S7: DP103 regulates NFκB-dependent gene expression 
 Control siRNA and siDP103 treated BT549 cells transfected with Renilla and luciferase 
reporter plasmid containing NFκB. The cells were subsequently stimulated with (A) 
10µM VP16, (B) 25µM doxorubicin and (C) 10µM CPT for 0h, 6h, and 12h and then 
harvested for luciferase assay. Results are expressed in fold difference and are the 
average of three separate experiments * denotes p<0.05. Control siRNA and siDP103 
treated BT549 cells were transfected with Renilla and luciferase reporter plasmid 
containing AP-1. The cells were subsequently stimulated with (D) 10µM VP16, (E) 
25µM doxorubicin and (F) 10µM CPT for 0h, 6h, and 12h and then harvested for 
luciferase assay. Results are expressed in fold difference and are the average of three 
separate experiments * denotes p<0.05. (G) MDA-MB-231 cells transfected with control 
siRNA or siDP103. Cells were left untreated or treated with CPT (10µM) for indicated 
times. Protein extracts were examined with (top) EMSA and (bottom) Western blotting of 
nuclear and cytoplasmic protein fractions using antibody human-anti-p65, human-anti-
DP103 and human-anti-GAPDH. (H) MDA-MB-231 cells were transfected with either 
control siRNA or DP103 siRNA and treated with or without (H) 10µM CPT or (I) 25µM 
doxorubicin for 48h. Graph showing percentage of cell viability (bottom) from three 
separate experiments * denotes p<0.05. (J) MDA-MB-231 cells transfected with control 
siRNA or siDP103. Cells were either left untreated or treated with CPT as indicated. 
Protein extracts were examined with EMSA and Western blotting using human-anti-
DP103 and human-anti-GAPDH antibodies. 
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Figure S8: The helicase dead mutant GNT of DP103 retained its ability to induce 
invasion in MDA-MB-231 cells  
(A) Map showing the FLAG-tagged wild-type (WT) and GNT mutant with single amino 
acid mutated in the helicase domain of DP103. (B) MDA-MB-231 cells transfected with 
either empty vector (EV), wild-type DP103 (WT) or GNT mutant (GNT) and assayed in 
transwell invasion chamber for 48h. Insert shows zoomed pictures. (C) The number of 
cells that invaded through the transwell invasion chambers in (B) counted and 
represented * denotes p<0.05. (D) MDA-MB-231 cells transfected with pGNT mutant 
were stimulated with TNFα for 10min. 0.5mg of protein lysate were immunoprecipitated 
with TAK1 and IgG antibodies and IP material and lysates were analysed by 
immunoblotting with the indicated antibodies. Western blot analysis of the input lysate is 
shown in the panel below. 
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Figure S9: DP103 enhances TAK1-mediated IKK2 phosphorylation and hence 
NFκB activation  
(A) MDA-MB-231 cells were stimulated with TNFα for 10min. 0.5mg of protein lysate 
were immunoprecipitated with TAB2 and IgG antibodies and IP material and lysates 
were analysed by immunoblotting with the indicated antibodies. (B) MDA-MB-231 cells 
were stimulated with TNFα for 10min. 0.5mg of protein lysate were immunoprecipitated 
with TAB3 and IgG antibodies and IP material and lysates were analysed by 
immunoblotting with the indicated antibodies. (C) Purified recombinant full-length GST-
TAK1 and His-DP103 proteins were stained using Coomassie blue staining. (D) 
Coomassie blue staining of purified GST-IKK2- WT and GST-IKK2-Mut proteins. The 
sequences are shown in the bottom panel and the amino acids in red indicate the wild 
type and mutant TAK1 phosphorylation sites in the activation loop of IKK2. (E) MDA-
MB-231 cells transfected with siRNA control or siRNA against DP103 were stimulated 
with TNFα for 10min. 0.5mg of protein lysate were immunoprecipitated with TAK1 and 
IgG antibodies and IP material and lysates were analysed by immunoblotting with the 
indicated antibodies. Western blot analysis of the input lysate is shown in the panel 
below. (F) MDA-MB-231 cells infected with empty vector (EV) or pBOBI-DP103 were 
stimulated with TNFα for 10min. IP material and lysates were analysed by 
immunoblotting with the indicated antibodies as described in (E). 
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SUPPLEMENTAL TABLES 
 
Table S1: A) & B) Clinicopathological features (Singapore) 
 
A)                                                                      B) 
Clinicopathological 
features 
Number of cases  Clinicopathological 
features 
Number of 
cases 
Age (years) Histological tumor grade 
Mean 53 1 66 
Median 51 2 151 
Minimum 19 3 170 
Maximum 86 NA 12 
Ethnicity Tumor type 
Chinese 336 Luminal A 175 
Malay 35 Luminal B 38 
Indian 17 Basal 60 
Others 11 HER2 46 
  NA 80 
NA= not available  
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Table S1: C) Clinicopathological features (Canada) 
 
Clinicopathological features Number of cases 
Age (35-92 years) 411 
Grade 
I 
II 
III 
 
38 
70 
303 
Histological subtypes 
Invasive ductal carcinoma 
Invasive lobular carcinoma 
Typical medullary carcinoma 
Atypical medullary carcinoma 
Colloid carcinoma 
 
326 
10 
49 
19 
7 
Estrogen receptor 
Positive 
Negative 
 
94 
225 
Progestron receptor 
Positive 
Negative 
 
94 
225 
HER2 receptor 
Positive 
Negative 
 
63 
256 
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Table S1: D) Clinicopathological features (China) 
 
Clinicopathological features Number of cases 
Age (years) 
= 35 
35-55 
> 55 
 
5 
42 
16 
Tumor size (=cm) 
= 2 
2-5 
> 5 
 
26 
34 
3 
Lymph node metastasis 
Absent 
Present  
 
33 
30 
Grade 
I 
II 
III 
 
14 
37 
12 
Histological subtypes 
Ductal  
Lobular  
Others 
 
60 
1 
2 
Estrogen receptor 
- 
+ 
 
19 
44 
Progestron receptor 
- 
+ 
 
22 
41 
c-erbB-2 receptor  
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Low 
High 
30 
33 
Ki-67 
+ 
++ 
+++ 
++++ 
 
43 
16 
2 
2 
 
 
 
Table S1. (A) Clinicopathological features of number of cases from Singapore cohort. 
Collated expression analysis of DP103 epitope in the epithelial compartments of 
indicated number of ductal specimens from (B) Singapore cohort and (C) Canada cohort. 
(D) Clinicopathological features of number of cases from China cohort. 
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Table S2: A 
 
 DP103 expression 
Low High P value 
Diagnosis 
Normal 
Malignant 
 
38 
63 
 
0 
267 
 
< 0.001 
 
 
Table S2: B 
 DP103 expression 
Low High P value 
Diagnosis 
Basal 
Other tumor subtypes 
 
3 
50 
 
47 
164 
 
0.0053 
 
 
Table S2: C 
 DP103 expression 
Low High P value 
Diagnosis 
Normal 
1 
2 
3 
 
38 
51 
5 
0 
 
0 
5 
128 
133 
 
< 0.001 
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Table S2: D 
 DP103 expression 
Low High P value 
Diagnosis 
Normal 
Malignant 
 
15 
0 
 
0 
385 
 
< 0.001 
 
 
Table S2: E 
 DP103 expression 
Low High P value 
Triple negative 
Other tumor subtypes 
8 
24 
144 
157 
 
0.0001 
 
 
Table S2: F 
 DP103 expression 
Low High P value 
Normal 
Grade I 
Grade II 
Grade III 
15 
2 
0 
27 
0 
24 
47 
242 
 
< 0.001 
 
Table S2. Collated expression analysis of DP103 epitope in basal and non-basal breast 
tumor subtypes in specimens from (A) Singapore cohort and (B) Canada cohort. 
Association analyses on expression of DP103 in the various tumor grades were 
determined using Fisher’s Exact and Kendall-Tau tests in specimens from (C) Singapore 
cohort and (D) Canada cohort. Analysis of the tissue microarrays showed that the staining 
intensity of DP103 in the epithelial compartment was highly significantly associated with 
histological tumor grade. 
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Table S3: 
 
Cell line No. of mouse with 
metastasis 
Metastasis (p/s) 
Lung Liver 
MDA-MB-231-
DP103 
4/11 7.9×107 
1.0×106 
1.3×106 
3.8×106 
5.4×107 
8.2×107 
7.0×106 
1.3×108 
MDA-MB-231-EV 1/12 1.9×107 2.3×107 
 
Table S3. Spontaneous metastases from orthotopic mammary fat pad implant. Two 
million cells empty vector transfected MDA-MB-231 cells (MDA-MB-231-EV) or 
DP103 transfected cells (MDA- MB-231-DP103) are injected orthotopically into the 
abdominal m.f.p. of female nude mice. The incidence of pulmonary and liver metastases 
at necropsy from primary tumors formed by these two cancer cell lines was evaluated by 
bioluminescence imaging as described in methods and tabulated. 
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Table S4: A 
 MMP9 expression 
Low High P value 
Diagnosis 
Normal 
Malignant 
 
53 
71 
 
0 
286 
 
< 0.001 
 
 
Table S4: B 
 MMP9 expression 
Low High P value 
Diagnosis 
Normal 
Malignant 
 
15 
46 
 
0 
339 
 
< 0.001 
 
 
Table S4: C 
 DP103 expression 
Low High P value 
MMP9 expression 
Low 
High 
 
56 
6 
 
10 
253 
 
< 0.001 
 
 
Table S4: D 
 DP103 expression 
Low High P value 
MMP9 expression 
Low 
High 
 
4 
19 
 
74 
196 
 
< 0.001 
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Table S4. Collated expression pattern analysis of MMP9 epitope in epithelial 
compartments of ductal specimens from (A) Singapore cohort and (B) Canada cohort. 
Normal non-malignant ductal tissues had reduced staining in comparison to the malignant 
invasive ductal carcinoma tissues. Association analysis between expression of DP103 and 
MMP9 were determined using Fisher’s Exact and Kendall-Tau tests in specimens from 
(C) Singapore cohort and (D) Canada cohort. Results suggested that high DP103 
expression is highly significantly correlated with high MMP9 levels. 
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Table S5: A 
 Phospho-p65 expression 
Low High P value 
Diagnosis 
Normal 
Malignant 
 
49 
69 
 
0 
269 
 
< 0.001 
 
 
Table S5: B 
 Phospho-p65 expression 
Low High P value 
Diagnosis 
Basal 
Other tumor subtypes 
 
5 
50 
 
47 
141 
 
0.0141 
 
 
 
Table S5: C 
 Phospho-p65 expression 
Low High P value 
Histological tumor grades 
Normal 
1 
2 
3 
 
49 
54 
4 
4 
 
0 
4 
130 
134 
 
< 0.001 
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Table S5: D 
 DP103 expression 
Low High P value 
Phospho-p65 expression 
Low 
High 
 
55 
7 
 
10 
246 
 
< 0.001 
	  	  	  	  
Table S5. (A) Collated expression analysis of phospho-p65 S276 epitope in the epithelial 
compartments of ductal specimens. Normal non-malignant ductal tissues had reduced 
staining in comparison to the malignant invasive ductal carcinoma tissues. (B) Collated 
expression analysis of phospho-p65 S276 epitope and its association with tumor subtype. 
High expression of phospho-p65 S276 was significantly associated with basal breast 
tumor subtype. (C) Collated expression analysis of phospho-p65 S276 epitope and its 
association with histological tumor grades. Analysis of the tissue microarrays showed 
that the staining intensity of phospho-p65 in the epithelial compartment was highly 
significantly associated with histological tumor grade. (D) Association analysis between 
expression of DP103 and phospho-p65 (Ser276) were determined using Fisher’s Exact 
and Kendall-Tau tests. Results suggest that high DP103 expression is highly significantly 
correlated with high phospho-p65 levels 
 
 
 
 	  	  	  	  	  	  
	  	  	  
	  	  
246	  
Appendix IV: Identification of genes that could distinguish 
between luminal A and luminal B molecular subtypes of breast 
cancer using in silico analysis 	  
Our objective was to find out new biomarkers that could facilitate our ability to 
distinguish between luminal A and luminal B subtypes of breast cancer. In silico analysis 
was carried out using RNA sequencing data of 756 patients to identify genes whose 
expression pattern varied differentially between these two subsets of tumors. As shown in 
Figure 1, there were 20532 genes that significantly (< 0.05) have different expression 
between luminal A and luminal B breast cancer (with higher expression in luminal B 
tumors). Only, 1966 genes could reach to the < 0.01 significant level, with higher 
expression in luminal B tumors. From these genes, there are 162 genes whose expression 
has no overlap between boxes in the boxplots (Table 1). However, the number of those 
genes is not applicable to be studied using IHC and TMA of human tissue. We tried to 
apply certain criteria to select the best candidates for our study that includes; selection of 
proteins that are highly expressed in luminal B than in luminal A based on the web 
application bc-GenExMiner [415], positive correlation with Ki-67, inclusion in the 
proliferation peak according to MiSTIC, established role in proliferation and localization 
only to the nuclei (Literature, Human Protein Atlas and genecard website). Based on this 
short list, only 19 genes fulfilled the abovementionned criteria (Table 2) and are 
supposedly putative targets to readily distinguish between luminal A and luminal B breast 
cancers (Figure 2). 
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Figure 1: steps of selection of target genes that can distinguish between luminal A 
and luminal B breast cancer 
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Figure	  2:	  Proliferation	  cluster	  according	  to	  MiSTIC	  that	  include	  some	  of	  the	  genes	  of	  interest.	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Table 1: List of genes that are significantly highly expressed in luminal B than in 
luminal A breast cancer 
 
No. Gene Description Gene ID BaseMean 
LumB 
BaseMean 
LumA P value 
1 MYBL2 v-myb myeloblastosis 
viral oncogene homolog 
(avian)-like 2 
4605 
22.5612802 5.45347035 2.03E-47 
2 UBE2C Ubiquitin-conjugating 
enzyme E2C 
11065 
54.0548116 16.3211930 1.15E-61 
3 BIRC5 Baculoviral IAP repeat 
containing 5 
332 
57.4202590 17.7166410 1.56E-40 
4 TOP2A Topoisomerase (DNA) II 
alpha 170kDa 
7153 
83.4312383 25.9139120 1.93E-28 
5 CDC6 Cell division cycle 6 
homolog (S. cerevisiae) 
990 
12.2336271 4.15630539 4.20E-12 
6 TROAP Trophinin associated 
protein (tastin) 
10024 
9.51400063 3.26005655 1.73E-36 
7 AURKA Aurora kinase A 6790 15.3307455 5.41037698 2.48E-47 
8 TPX2 TPX2, microtubule-
associated, homolog 
(Xenopus laevis) 
22974 
25.2692678 8.93857292 2.32E-62 
9 CCNB2 Cyclin B2 9133 21.0276064 7.57380166 4.67E-56 
10 FOXM1 Forkhead box M1 2305 15.8692775 5.73305857 1.74E-41 
11 CCNE2 Cyclin E2 9134 12.2881905 4.47509131 1.86E-33 
12 EPR1 Effector cell peptidase 
receptor 1 (non-protein 
coding) 
8475 
5.59553581 2.03984849 3.24E-23 
13 SPAG5 Sperm associated antigen 
5 
10615 
13.4969697 4.97266578 1.19E-39 
14 UBE2T Ubiquitin-conjugating 
enzyme E2T (putative) 
29089 
30.7293649 11.4604247 4.94E-60 
15 KIF2C Kinesin family member 11004 10.5085973 3.92776939 3.71E-36 
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2C 
16 CCNA2 Cyclin A2 890 11.1416815 4.16783656 3.85E-36 
17 RRM2 Ribonucleotide reductase 
M2 
6241 
21.1899761 7.95771322 1.12E-39 
18 AURKB Aurora kinase B 9212 9.42374092 3.54873814 6.47E-34 
19 PLK1 Polo-like kinase 1 5347 14.07631319 5.301641822 5.96E-42 
20 MELK Maternal embryonic 
leucine zipper kinase 
9833 
10.70792702 4.06248384 2.17E-35 
21 CEP55 Centrosomal protein 
55kDa 
55165 
11.13325208 4.231002183 9.11E-36 
22 CDK1 Cyclin-dependent kinase 
1 
983 
31.36632574 12.14120845 1.10E-40 
23 PRC1 Protein regulator of 
cytokinesis 1 
9055 
25.33267512 9.888556646 1.13E-50 
24 CDKN3 Cyclin-dependent kinase 
inhibitor 3 
1033 
19.73354066 7.71829765 1.99E-45 
25 MAD2L1 MAD2 mitotic arrest 
deficient-like 1 (yeast) 
4085 
20.79272789 8.153700774 1.33E-45 
26 PBK PDZ binding kinase 55872 10.44410264 4.096301906 6.77E-30 
27 E2F8 E2F transcription factor 8 79733 3.514804923 1.380413666 1.91E-13 
28 SGOL1 Shugoshin-like 1 (S. 
pombe) 
151648 
4.763050728 1.877912897 8.75E-18 
29 CDC20 Cell division cycle 20 
homolog (S. cerevisiae) 
991 
18.71899424 7.393666306 4.02E-41 
30 CDC45 Cell division cycle 45 
homolog (S. cerevisiae) 
8318 
5.953133949 2.351757406 4.41E-22 
31 ASPM asp (abnormal spindle) 
homolog, microcephaly 
associated (Drosophila) 
259266 
7.322075181 2.909558614 2.70E-24 
32 MCM10 Minichromosome 
maintenance complex 
component 10 
55388 
3.760270946 1.499660267 1.14E-15 
33 E2F1 E2F transcription factor 1 1869 8.971866952 3.588748062 3.61E-27 
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34 PTTG1 Pituitary tumor-
transforming 1 
9232 
31.36775093 12.55534751 7.78E-46 
35 CENPA Centromere protein A 1058 5.887119358 2.360024949 2.95E-22 
36 NUSAP1 Nucleolar and spindle 
associated protein 1 
51203 
26.46628428 10.61239344 1.05E-48 
37 NDC80 NDC80 kinetochore 
complex component 
homolog (S. cerevisiae) 
10403 
8.536390669 3.426616685 1.51E-27 
38 BUB1 Budding uninhibited by 
benzimidazoles 1 
homolog (yeast) 
699 
9.605833444 3.861973889 2.92E-29 
39 NCAPG Non-SMC condensin I 
complex, subunit G 
64151 
6.685396906 2.68791162 5.18E-22 
40 UHRF1 Ubiquitin-like with PHD 
and ring finger domains 1 
29128 
14.37347409 5.789620827 5.23E-35 
41 MKI67 Antigen identified by 
monoclonal antibody Ki-
67 
4288 
13.03307084 5.254331813 9.23E-35 
42 KIF4A Kinesin family member 
4A 
24137 
8.296237485 3.345751033 1.72E-25 
43 DLGAP5 Discs, large (Drosophila) 
homolog-associated 
protein 5 
9787 
7.691272319 3.122815093 2.11E-24 
44 CKAP2L Cytoskeleton associated 
protein 2-like 
150468 
5.00579807 2.032800472 4.13E-17 
45 ANLN Anillin, actin binding 
protein 
54443 
11.2754635 4.615518027 1.72E-32 
46 BUB1B Budding uninhibited by 
benzimidazoles 1 
homolog beta (yeast) 
701 
10.62362119 4.356970525 1.13E-28 
47 NEK2 NIMA (never in mitosis 
gene a)-related kinase 2 
4751 
18.36402133 7.568874618 5.94E-38 
48 DSCC1 Defective in sister 79075 6.546108431 2.699219059 1.22E-20 
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chromatid cohesion 1 
homolog (S. cerevisiae) 
49 ESPL1 Extra spindle pole bodies 
homolog 1 (S. cerevisiae) 
9700 
3.928328133 1.622730444 3.33E-13 
50 MND1 Meiotic nuclear divisions 
1 homolog (S. cerevisiae) 
84057 
5.134850579 2.122949804 8.13E-18 
51 TRIP13 Thyroid hormone receptor 
interactor 13 
9319 
12.26161151 5.102962031 1.13E-31 
52 CDCA5 Cell division cycle 
associated 5 
113130 
11.59976315 4.848443452 6.46E-30 
53 CDCA3 Cell division cycle 
associated 3 
83461 
7.015025423 2.932708801 1.41E-22 
54 EXO1 Exonuclease 1 9156 5.503272414 2.302433579 1.29E-18 
55 MLF1IP MLF1 interacting protein 79682 16.50960816 6.931655656 2.37E-34 
56 TTK TTK protein kinase 7272 6.368888467 2.680333217 4.16E-21 
57 NUF2 NUF2, NDC80 
kinetochore complex 
component, homolog (S. 
cerevisiae) 
83540 
11.39017715 4.805649425 3.37E-29 
58 CCNB1 Cyclin B1 891 32.63932898 13.77564215 4.79E-48 
59 ATAD2 ATPase family, AAA 
domain containing 2 
29028 
23.52900372 9.933064828 1.13E-40 
60 FAM83D Family with sequence 
similarity 83, member D 
81610 
7.283453576 3.08062417 5.26E-22 
61 CENPE Centromere protein E, 
312kDa 
1062 
4.066544804 1.727809448 2.36E-13 
62 KPNA2 Karyopherin alpha 2 
(RAG cohort 1, importin 
alpha 1) 
3838 
95.81742474 40.77903671 3.47E-43 
63 TYMS Thymidylate synthetase 7298 26.76991293 11.39933121 1.99E-32 
64 CDCA8 Cell division cycle 
associated 8 
55143 
10.20273559 4.352052726 4.89E-28 
65 NCAPH Non-SMC condensin I 23397 5.070918115 2.183032477 4.36E-16 
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complex, subunit H 
66 DEPDC1 DEP domain containing 1 55635 4.153440889 1.80544395 2.44E-14 
67 KIF23 Kinesin family member 
23 
9493 
11.06854727 4.8225495 2.46E-26 
68 ZWINT ZW10 interactor 11130 31.77903524 13.90331721 7.47E-44 
69 KIF15 Kinesin family member 
15 
56992 
4.735634414 2.073602085 1.56E-14 
70 KIF20A Kinesin family member 
20A 
10112 
10.06915908 4.432234997 4.19E-25 
71 KIF18A Kinesin family member 
18A 
81930 
5.926833373 2.611963871 7.56E-17 
72 IQGAP3 IQ motif containing 
GTPase activating protein 
3 
128239 
10.84228695 4.78452376 8.16E-26 
73 RACGAP
1 
Rac GTPase activating 
protein 1 
29127 
20.52655907 9.07106785 1.01E-34 
74 DEPDC1
B 
DEP domain containing 
1B 
55789 
3.77042553 1.667463791 4.42E-12 
75 HJURP Holliday junction 
recognition protein 
55355 
6.222561501 2.75454221 2.81E-18 
76 KIF11 Kinesin family member 
11 
3832 
15.15731627 6.714665773 4.45E-30 
77 CENPF Centromere protein F, 
350/400kDa (mitosin) 
1063 
13.90916199 6.163152483 1.16E-29 
78 LMNB1 Lamin B1 4001 30.4946221 13.51946745 1.44E-42 
79 KIFC1 Kinesin family member 
C1 
3833 
12.47527417 5.5340709 1.12E-28 
80 GTSE1 G-2 and S-phase 
expressed 1 
51512 
9.986669508 4.43574954 4.95E-25 
81 KIF18B Kinesin family member 
18B 
146909 
5.538756658 2.463040247 5.24E-16 
82 GINS1 GINS complex subunit 1 
(Psf1 homolog) 
9837 
7.609546683 3.386084893 1.42E-19 
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83 ARHGAP
11A 
Rho GTPase activating 
protein 11A 
9824 
7.23887503 3.233067779 1.82E-18 
84 FAM72D Family with sequence 
similarity 72, member D 
728833 
3.344285675 1.497213937 3.84E-11 
85 FAM72B Family with sequence 
similarity 72, member B 
653820 
3.167482734 1.421347072 9.49E-11 
86 RAD51 RAD51 homolog (S. 
cerevisiae) 
5888 
5.919803196 2.673817983 6.22E-16 
87 RECQL4 RecQ protein-like 4 9401 7.538265069 3.406595705 1.55E-18 
88 DIAPH3 Diaphanous homolog 3 
(Drosophila) 
81624 
9.520660474 4.308330623 3.72E-20 
89 FAM64A Family with sequence 
similarity 64, member A 
54478 
4.792426209 2.183308365 1.38E-14 
90 DTL Denticleless E3 ubiquitin 
protein ligase homolog 
(Drosophila) 
51514 
10.27333209 4.681351781 1.50E-21 
91 CDC25C Cell division cycle 25 
homolog C (S. pombe) 
995 
4.415865467 2.016897262 5.59E-12 
92 HMMR Hyaluronan-mediated 
motility receptor 
(RHAMM) 
3161 
6.941401232 3.176887115 4.00E-17 
93 SHCBP1 SHC SH2-domain binding 
protein 1 
79801 
5.06372862 2.321716222 4.52E-14 
94 FAM54A Family with sequence 
similarity 54, member A 
113115 
3.098604 1.424061641 2.69E-10 
95 MYBL1 v-myb myeloblastosis 
viral oncogene homolog 
(avian)-like 1 
4603 
5.505701383 2.530823817 2.40E-11 
96 FAM72A Family with sequence 
similarity 72, member A 
729533 
2.77178156 1.277734735 4.03E-09 
97 RAD51A
P1 
RAD51 associated protein 
1 
10635 
6.800423623 3.138928644 1.12E-17 
98 RAD54L RAD54-like (S. 8438 3.923622577 1.821366416 6.29E-12 
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cerevisiae) 
99 KIF14 Kinesin family member 
14 
9928 
2.818038653 1.309073217 6.60E-09 
100 NEIL3 Nei endonuclease VIII-
like 3 (E. coli) 
55247 
2.920613807 1.358010886 6.39E-09 
101 KIAA010
1 
KIAA0101 9768 
17.02374109 7.930428251 1.25E-27 
102 GINS2 GINS complex subunit 2 
(Psf2 homolog) 
51659 
25.27644279 11.85970134 2.36E-30 
103 C15orf42 Chromosome 15 open 
reading frame 42 
90381 
2.434535576 1.144459147 4.71E-08 
104 HMGB2 High mobility group box 
2 
3148 
104.6331187 49.36988843 8.74E-43 
105 SKA3 Spindle and kinetochore 
associated complex 
subunit 3 
221150 
4.456471849 2.116230181 2.68E-12 
106 ASF1B ASF1 anti-silencing 
function 1 homolog B (S. 
cerevisiae) 
55723 
17.22805226 8.252568134 2.16E-27 
107 TACC3 Transforming, acidic 
coiled-coil containing 
protein 3 
10460 
20.09643355 9.630079451 3.96E-30 
108 FANCA Fanconi anemia, 
complementation group A 
2175 
8.235418606 3.947952427 5.87E-19 
109 SPC24 SPC24, NDC80 
kinetochore complex 
component, homolog (S. 
cerevisiae) 
147841 
4.032725109 1.936938501 1.10E-10 
110 CENPK Centromere protein K 64105 4.754524154 2.305517872 6.63E-11 
111 FANCI Fanconi anemia, 
complementation group I 
55215 
16.4236062 7.988116512 7.94E-25 
112 RAD54B RAD54 homolog B (S. 
cerevisiae) 
25788 
6.832992035 3.326538029 2.26E-14 
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113 CDC25A Cell division cycle 25 
homolog A (S. pombe) 
993 
2.754510583 1.344223745 2.06E-08 
114 KIAA152
4 
KIAA1524 57650 
10.68085201 5.256659245 1.09E-19 
115 OIP5 Opa interacting protein 5 11339 4.093006024 2.028394927 4.46E-10 
116 ZNF367 Zinc finger protein 367 195828 5.752741057 2.858417297 2.24E-12 
117 CENPI Centromere protein I 2491 2.828417282 1.407844865 1.24E-07 
118 PLK4 Polo-like kinase 4 10733 4.461248713 2.243658574 4.72E-10 
119 CKS2 CDC28 protein kinase 
regulatory subunit 2 
1164 
60.66507266 30.88699141 3.64E-24 
120 BLM Bloom syndrome, RecQ 
helicase-like 
641 
3.2371873 1.648671892 2.94E-08 
121 PARPBP PARP1 binding protein 55010 4.916851301 2.512549436 2.32E-10 
122 FBXO5 F-box protein 5 26271 6.854115735 3.514321431 2.12E-13 
123 CLSPN Claspin 63967 2.665958101 1.371922225 4.58E-07 
124 EZH2 Enhancer of zeste 
homolog 2 (Drosophila) 
2146 
9.854077401 5.084649728 2.44E-17 
125 DSN1 DSN1, MIND 
kinetochore complex 
component, homolog (S. 
cerevisiae) 
79980 
15.94115954 8.246638055 1.08E-20 
126 TCF19 Transcription factor 19 6941 10.27841898 5.322891804 1.45E-17 
127 MCM2 Minichromosome 
maintenance complex 
component 2 
4171 
19.43072012 10.17303828 1.31E-23 
128 E2F2 E2F transcription factor 2 1870 2.496417704 1.323581843 2.18E-06 
129 ORC1 Origin recognition 
complex, subunit 1 
4998 
2.651307078 1.407000886 9.58E-07 
130 MCM4 Minichromosome 
maintenance complex 
component 4 
4173 
37.95550079 20.15210467 2.65E-22 
131 STIL SCL/TAL1 interrupting 
locus 
6491 
4.625227924 2.474386004 1.61E-09 
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132 TIMELE
SS 
Timeless homolog 
(Drosophila) 
8914 
19.18263837 10.27150493 1.36E-20 
133 SKA1 Spindle and kinetochore 
associated complex 
subunit 1 
220134 
5.0268672 2.693818237 7.87E-10 
134 ERCC6L Excision repair cross-
complementing rodent 
repair deficiency, 
complementation group 6-
like 
54821 
2.502786742 1.34626481 6.01E-06 
135 E2F7 E2F transcription factor 7 144455 2.443698322 1.316106371 1.06E-05 
136 BRIP1 BRCA1 interacting 
protein C-terminal 
helicase 1 
83990 
4.231152964 2.285930939 4.56E-08 
137 PCNA Proliferating cell nuclear 
antigen 
5111 
106.8253702 57.7425208 3.24E-35 
138 C15orf23 Chromosome 15 open 
reading frame 23 
90417 
12.55941208 6.83444985 1.93E-16 
139 SPC25 SPC25, NDC80 
kinetochore complex 
component, homolog (S. 
cerevisiae) 
57405 
9.525868939 5.232527087 2.57E-13 
140 WDR62 WD repeat domain 62 284403 4.194362818 2.307357532 6.57E-08 
141 CENPW Centromere protein W 387103 4.102187927 2.271809473 2.91E-06 
142 SKA2 Spindle and kinetochore 
associated complex 
subunit 2 
348235 
20.11785755 11.2532852 6.96E-17 
143 H2AFZ H2A histone family, 
member Z 
3015 
145.3840557 81.8195626 1.62E-32 
144 CENPN Centromere protein N 55839 4.773237403 2.694364663 1.12E-08 
145 KNTC1 Kinetochore associated 1 9735 7.951400732 4.497711888 1.11E-10 
146 CKS1B CDC28 protein kinase 
regulatory subunit 1B 
1163 
70.44432378 39.96437789 4.41E-27 
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147 POLQ Polymerase (DNA 
directed), theta 
10721 
1.843672144 1.079144425 
0.000610
439 
148 WDHD1 WD repeat and HMG-box 
DNA binding protein 1 
11169 
4.755206652 2.789665385 3.84E-07 
149 SGOL2 Shugoshin-like 2 (S. 
pombe) 
151246 
4.483234895 2.638450014 7.04E-07 
150 DNMT3B DNA (cytosine-5-)-
methyltransferase 3 beta 
1789 
2.400776324 1.413168229 5.81E-05 
151 CHEK1 Checkpoint kinase 1 1111 7.080511724 4.178165997 1.09E-09 
152 MCM6 Minichromosome 
maintenance complex 
component 6 
4175 
19.23246548 11.36947179 1.70E-16 
153 C17orf53 Chromosome 17 open 
reading frame 53 
78995 
2.677502498 1.588275804 
0.000103
146 
154 FANCD2 Fanconi anemia, 
complementation group 
D2 
2177 
6.675775812 3.974084516 1.77E-08 
155 C1orf135 Chromosome 1 open 
reading frame 135 
79000 
2.775367679 1.661307235 4.87E-05 
156 RFC4 Replication factor C 
(activator 1) 4, 37kDa 
5984 
15.2969524 9.214279648 5.27E-14 
157 LRR1 Leucine rich repeat 
protein 1 
122769 
7.48124308 4.822033333 4.78E-07 
168 TUBA1C Tubulin, alpha 1c 84790 152.748762 98.72965128 8.91E-20 
159 DNAJC9 DnaJ (Hsp40) homolog, 
subfamily C, member 9 
23234 
22.43209052 14.52839977 3.23E-12 
160 CCDC99 Coiled-coil domain 
containing 99 
54908 
6.785710359 4.418837584 1.75E-06 
161 TUBA1B Tubulin, alpha 1b 10376 485.5340805 317.2500722 2.31E-20 
162 GMPS Guanine monphosphate 
synthetase 
8833 
35.93670996 25.49866346 6.96E-10 
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Table 2: list of 19 genes that are supposed to be excellent targets to distinguish 
between luminal A and luminal B breast cancer 
 
No Gene Description Role in 
proliferation 
Proliferation 
peak (MiSTIC) 
Cellular 
localization	  	  
1 MCM2 Minichromosome 
maintenance complex 
component 2 
Yes	   Yes	   Nucleus	  
2 CENPA Centromere protein A Yes	   Yes	   Nucleus	  
3 NDC80 NDC80 kinetochore 
complex component 
homolog (S. cerevisiae) 
Yes	   Yes	   Nucleus	  
4 MYBL2 v-myb myeloblastosis viral 
oncogene homolog (avian)-
like 2 
Yes	   Yes	   Nucleus	  
5 FOXM1 Forkhead box M1 Yes	   Yes	   Nucleus	  
6 E2F8 E2F transcription factor 8 Yes	   Yes	   Nucleus	  
7 E2F1 E2F transcription factor 1 Yes	   Yes	   Nucleus	  
8 UHRF1 Ubiquitin-like with PHD and 
ring finger domains 1 
Yes	   Yes	   Nucleus	  
9 ATAD2 ATPase family, AAA 
domain containing 2 
Yes	   Yes	   Nucleus	  
10 HMGB2 High mobility group box 2 Yes	   Yes	   Nucleus	  
11 ASF1B ASF1 anti-silencing function 
1 homolog B (S. cerevisiae) 
Yes	   Yes	   Nucleus	  
12 EZH2 Enhancer of zeste homolog 2 
(Drosophila) 
Yes	   Yes	   Nucleus	  
13 TCF19 Transcription factor 19 Yes	   Yes	   Nucleus	  
14 E2F2 E2F transcription factor 2 Yes	   Yes	   Nucleus	  
15 MCM4 Minichromosome 
maintenance complex 
component 4 
Yes	   Yes	   Nucleus	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16 TIMELESS Timeless homolog 
(Drosophila) 
Yes	   Yes	   Nucleus	  
17 E2F7 E2F transcription factor 7 Yes	   Yes	   Nucleus	  
18 WDHD1 WD repeat and HMG-box 
DNA binding protein 1 
Yes	   Yes	   Nucleus	  
19 MCM6 Minichromosome 
maintenance complex 
component 6 
Yes	   Yes	   Nucleus	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